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Chronic neuropathic pain, resulting from dysfunction of the nervous system, 
is a clinical concern in both humans and animal patients. Neuropathic pain is 
characterised by spontaneous pain, hypersensitivity, manifested as hyperalgesia 
and allodynia, and refractoriness to conventional analgesics such as non-steroidal 
anti-inflammatory drugs, thus representing an unmet therapeutic need.  
Equine laminitis is a disease that involves the disruption of the dermo-
epidermal junction within the hoof, leading to severe pain and lameness, with 
poor responsiveness to anti-inflammatory therapy. We developed a Quantitative 
Sensory Testing method, using a novel hydraulically-powered feedback-
controlled hoof tester, in order to provide an objective tool for the assessment of 
mechanical hyperalgesia in laminitic horses.  Hoof Compression Thresholds of 
laminitic horses were significantly lower than those of normal horses and 
variance component analysis of the data confirmed the reliability of the method. 
In order to investigate mechanisms underlying laminitis pain, we performed 
histological studies of peripheral nerves innervating the hoof. Electron 
micrographic analysis of the digital nerve of laminitic horses revealed a 
significant reduction in the number of unmyelinated and myelinated fibres 
together with abnormal morphology. Additionally, cell bodies of sensory neurons 
innervating the hoof in cervical C8 dorsal root ganglia showed an upregulated 
expression of the nerve injury marker activating transcription factor-3 (ATF3), 
neuropeptide Y (NPY), and the TRPM8 channel; each of which has been 
associated with laboratory models of neuropathic pain.  
Previous work has shown that, in a rodent model of neuropathic pain, the 
TRPM8 channel is upregulated in sensory neurons and its activation by cool 
temperature, menthol or icilin leads to reversal of the hypersensitive pain state. 
Further investigation of TRPM8-channel mediated analgesia was aimed at 
uncovering the molecular mechanisms involved in the activation of this system 
in sensitised states. It was hypothesised that serotonin, released following 
inflammation and nerve damage, can enhance TRPM8 channel activity through 
peripheral 5-HT1B receptors. Calcium fluorometry carried out in HEK293 cells 
xiii 
 
transfected with the TRPM8 channel and the 5-HT1B receptor revealed that co-
administration of a 5-HT1B receptor agonist facilitated the activation of the 
TRPM8 channel by icilin. Moreover, it appears that this effect is mediated 
through phospholipase D1 (PLD1), possibly leading to increased production of 
phosphatidylinositol (4,5-) bisphosphate (PIP2),  a known positive modulator of 
TRPM8 channel activity. In vitro co-immunoprecipitation studies suggested that 
the TRPM8 channel, the 5-HT1B receptor and PLD1 physically interact with each 
other, further providing a molecular basis for their functional co-operation. 
Calcium imaging carried out in cultured rat DRG cells showed that the 5-HT1B 
receptor-mediated enhancement of icilin responses at the TRPM8 channel also 
occurs in sensory cells and is reversed by inhibition of PLD1. Moreover, TRPM8 
and the 5-HT1B receptor appear to be physically associated in vivo as shown by 
their co-immunoprecipitation from spinal cord homogenates. Assessment of 
nociceptive behavioural reflexes following intrathecal injection of selective 
pharmacological agents provided further support for the idea of 5-HT1B receptor 
facilitation of TRPM8 channel responses in vivo.  In addition to providing novel 
evidence of a neuropathic component to equine laminitis and validation of a 
novel QST method for pain assessment in horses, this study reveals for the first 
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Chapter 1: INTRODUCTION 
 
1.1 Pain definition 
 
The ability to respond to aversive environmental stimuli is a defining attribute 
of animals. The detection of a noxious, i.e. a damaging or potentially damaging 
stimulus and the generation of a motor response to avoid it is known as 
nociception. This term was coined by Sherrington (1903) in order to describe the 
responses observed in decorticate animals, unable to feel pain. However, 
nociception can (and generally does) result in the experience of pain, which 
relies upon higher CNS processing. Pain has been defined as “an unpleasant 
sensory and emotional experience associated with actual or potential tissue 
damage, or described in terms of such damage” (I.A.S.P., 1979). A number of 
limitations have been identified with regard to this definition and its application 
to non-verbal humans and animals. Anand and Craig (1996) highlighted that the 
IASP definition relies heavily on language and self-report. They argued that self-
report is just one of the “efferent” responses to pain and that the “inability to 
communicate does not presuppose inability to feel pain”. Molony (1997) has 
provided a working definition of animal pain that focuses on efferent responses 
other than verbal self-report:  “Animal pain is an aversive sensory and emotional 
experience representing an awareness by the animal of damage or threat to the 
integrity of its tissues; it changes the animal’s physiology and behaviour to 
reduce or avoid the damage, to reduce the likelihood of recurrence and to 
promote recovery”. Additionally, Molony’s definition acknowledges that pain 
comprises not only a sensory-discriminative component (relating to stimulus 
location, intensity and type) but also an emotional component, thereby involving 
some form of awareness by the animal. Pain is thus associated with stress and 
suffering and has an obvious impact on animal welfare. In addition, sustained 
pain may have detrimental effects on physical health, for example by causing 
metabolic changes that retard and impair wound healing or result in immuno-
suppression (Hellebrekers, 2000). Hypersensitive and often persistent (chronic) 
pain states, which develop following nerve damage or inflammation, are a 
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particularly important veterinary concern as they occur not only in association 
with disease states such as lameness but also when adequate analgesia for 
surgery or routine procedures such as castration and tail docking is not provided 
(Kent et al., 2000; Lomax et al., 2010; Slingsby et al., 2006). 
 
1.2 Types of pain 
 
Pain has clearly evolved to serve a protective function, signalling actual or 
potential damage to the organism in order to enhance its chances of survival. 
Nociceptive pain, also known as physiological pain, is pain that is elicited by a 
noxious stimulus which generates a response (reflex withdrawal, arousal and 
autonomic responses). This type of pain is transient and serves as a warning 
system to escape if possible from impending bodily damage (Scholz and Woolf, 
2002). Acute pain is elicited by injury of body tissue and activation of 
nociceptive transducers at the site of tissue damage. Acute pain is seen after 
trauma, surgery and in the course of some diseases. This type of pain is short 
lived (from days to weeks), responds to treatment and does not persist beyond 
healing. Chronic pain, on the other hand, is also triggered by injury or disease but 
it is maladaptive, i.e. it does not serve a protective role, it lasts for months or 
longer and it is less responsive to treatment.  
 
1.3 Pain plasticity  
 
There is not a direct relationship between the intensity of noxious stimuli and 
the perceived intensity of pain. Melzack and Wall in 1965 proposed the Gate 
Control Theory of pain which acknowledged the complex relationship between 
external stimuli and the perceived sensation they evoke. This theory suggested 
that the central nervous system (CNS) modulates pain signalling, as the spinal 
cord and the brain act as filtering and processing sites, rather than as passive 
transmitters and perceivers (Melzack et al., 2001; Melzack and Wall, 1965). 
Thus, the role of the CNS has been proved crucial for the establishment and 
maintenance of sensitised pain states (discussed in later sections), and also, in 
3 
 
phenomena that involve pain suppression, such as the so-called stress-induced 
analgesia (Butler and Finn, 2009). 
Studies on the cellular and molecular neurobiology of sensory afferents have 
also described plasticity of the peripheral nervous system, revealing a wide range 
of functional phenotypes that are elicited by different tissue conditions, 
suggesting a complexity that rivals that of the dorsal horn of the spinal cord for 
processing afferent information (Price and Geranton, 2009; Reichling and 
Levine, 2009). 
Pathophysiological (chronic) pain states that arise following injury and 
disease are characterised by abnormal pain hypersensitivity, typically manifested 
as hyperalgesia and allodynia. Allodynia is defined as pain resulting from 
normally innocuous stimuli, e.g. light touch following sunburn, while 
hyperalgesia is defined as a heighted response to painful stimuli (Basbaum and 
Jessell, 2000) (Figure 1.1).  A frequent complaint from human patients suffering 
from chronic pain is spontaneous pain, which is stimulus-independent and 
clinically manifested as sensations of pins and needles, burning, stabbing, 
shooting, and paroxysmal pain (Attal and Bouhassira, 2004).   
 
 
Figure 1.1: Diagram illustrating the phenomena of allodynia and hyperalgesia. 
Light-gray area relates to physiological pain whereby the intensity of the pain 
perceived is proportional to the stimulus intensity. Following injury, this 
relationship is shifted to the left and thus previously innocuous stimuli now elicit 
pain (allodynia) and noxious stimuli evoke an increased pain sensation 
(hyperalgesia). Adapted from Cervero and Laird (1996). 
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1.4 Neuropathic pain 
 
Neuropathic pain has been defined by the IASP as a type of chronic pain that 
is “initiated or caused by a primary lesion or dysfunction in the nervous system” 
(Merskey and Bogduk, 1994). In categorisation according to the location, 
neuropathic pain can be central (for example caused by a stroke, spinal cord 
injury or conditions like multiple sclerosis) or peripheral (as in diabetic 
neuropathy, post-herpetic neuralgia or phantom-limb pain). In human patients, 
neuropathic pain is clinically characterised by spontaneous pain (often described 
as shooting, burning or stabbing) and amplified evoked responses to noxious and 
non-noxious stimuli (i.e. hyperalgesia and allodynia). Traditional analgesics such 
as non-steroidal anti-inflammatory drugs (NSAIDs) or opiates are not effective 
in most neuropathic pain human patients (Namaka et al., 2004). Current 
treatments for neuropathic pain such as anticonvulsant or tricyclic 
antidepressants vary in efficacy, may have undesirable side-effects and their 
mechanisms of action are not completely understood (Baron et al., 2010).  
 
1.5 Laboratory models of neuropathic pain 
 
Current understanding of the mechanisms involved in neuropathic pain has 
advanced considerably due to the development of laboratory animal models of 
chronic pain. One of the most frequently used neuropathic pain models is the 
chronic constriction injury (CCI) model developed by Bennett and Xie (1988). 
This model involves the loose ligation of the rat sciatic nerve with chromic cat 
gut ligature which results in the partial occlusion of the epineurial vasculature. 
Following CCI surgery, rats develop hyperalgesia and allodynia and exhibit 
nocifensive behaviours indicative of spontaneous pain. Other commonly used 
models of neuropathic pain are partial sciatic nerve ligation (PSL) which 
involves tight ligation of about half of the sciatic nerve (Seltzer et al., 1990), 
spinal nerve ligation (SNL) which involves the tight ligation of the L5 and L6 
spinal nerves (Kim and Chung, 1992) and spared nerve injury (SNI) (Decosterd 
and Woolf, 2000) in which the tibial and the common peroneal nerve, two of the 
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three distal nerve branches of the sciatic nerve are axotomised, leaving the third 
branch, the sural nerve, intact.  
 
Additionally, models have been developed to mimic particular disease states 
that bring about peripheral nerve injury such as, for example, the streptozotocin 
model of peripheral diabetic neuropathy (Malcangio and Tomlinson, 1998), 
peripheral demyelination (Wallace et al., 2003), a model of post-herpetic 
neuralgia induced with varicella-zoster virus (Fleetwood-Walker et al., 1999) or 
HIV-induced neuropathy  (Herzberg and Sagen, 2001).  
 
Laboratory animal models of neuropathic pain have certain limitations. For 
example, some degree of variation has been described in the nociceptive 
hypersensitivity exhibited by CCI rats, probably due to the tightness or the type 
of ligature (Maves et al., 1993; Ro and Jacobs, 1993), making standardisation 
difficult and limiting comparisons across laboratories.  In the PSL model, the 
magnitude and duration of the pain hypersensitivity varies depending both on the 
suture material and the strains of rats used (Yoon et al., 1999). Another 
methodological limitation is that sciatic nerve injury often results in a postural 
deformity of the ipsilateral paw that is clearly noticeable and renders blind 
testing impossible. Caudal trunk resection models have been suggested as an 
alternative to overcome this limitation as testing on the tail can be carried out 
blindly and consistently (Jaggi et al., 2011). 
The validity of animal models of neuropathic pain has also been questioned as 
they might not mirror some features that are common clinical complaints in 
human patients suffering from neuropathic pain syndromes (e.g. sleep 
disturbance, Kontinen et al., 2003). Criticisms have also been focused on the 
perceived lack of predictive value of animal models of neuropathic pain in drug 
discovery (Blackburn-Munro, 2004; Rice and Hill, 2006).  
Despite their limitations, laboratory animal models of neuropathic pain have 
greatly contributed to our understanding of the mechanisms involved in 
neuropathic pain, as described below, and it is considered that they will remain 
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essential tools in the repertoire of drug discovery programmes (Whiteside et al., 
2008).     
 
1.6 Chronic and neuropathic pain in domestic animals 
 
The management of chronic pain in domestic animals remains a largely unmet 
clinical need in veterinary medicine. The potential for the development of 
chronic pain as a consequence of disease and surgical procedures raises animal 
welfare concerns (Lascelles and Main, 2002).  Limitations in current strategies to 
recognise and treat chronic pain contribute to this situation. 
Little is known about the incidence of chronic pain in domestic animals. 
Studies investigating the epidemiology of pain in domestic animals are limited. 
However, recent studies in dogs and cats have found that, although the most 
frequently identified type of pain is acute and inflammatory, an incidence of 
secondary hyperalgesia of 12–18% suggests that central plasticity and sustained 
pain may be key clinical concerns that should be explored and targeted (Muir, III 
et al., 2004; Wiese et al., 2005). 
Similarly, there is evidence that lame cattle and sheep are in a chronic state of 
hyperalgesia beyond healing of lesions (Ley et al., 1989; Whay et al., 1998). 
Beak trimming in poultry has also been associated with long-term physiological 
and behavioural changes associated with increased pain sensitivity (Breward and 
Gentle, 1985; Duncan et al., 1989).     
In this regard, pre-emptive analgesia may be important in the prevention of 
chronic pain as it not only aims to reduce nociception but also sensitisation 
induced by tissue damage. Some evidence for this phenomenon has been 
successfully observed in animals following administration of opioids, NSAIDs 
and NMDA receptor antagonists (Lascelles, 2000; Wilson et al., 2005), although 
its benefits are still debated in human patients (Furlan et al., 2006; Moiniche et 
al., 2002).  
 
Neuropathic pain is poorly recognized in domestic animals mainly due to 
difficulties associated with its diagnosis and characterisation (Cashmore et al., 
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2009). Suspected neuropathic pain disorders described in domestic animals are 
associated with sensory abnormalities (especially allodynia and dysaesthesia), 
abnormal behaviour or locomotion associated with sensory hypersensitivity and 
unresponsiveness to conventional analgesic therapy, including non-steroidal anti-
inflammatory drugs (NSAIDs) and opioids (Cashmore et al., 2009). Examples of 
disorders reflecting neuropathic pain in domestic animals include orofacial pain 
syndrome in cats (Rusbridge et al., 2010), syringomyelia in dogs (Rusbridge and 
Jeffery, 2008) and headshaking in horses (Newton et al., 2000). In many cases, 
diagnosis has been made from responses to pharmacotherapy that targets 
neuropathic pain (Davis et al., 2007; Robertson and Lascelles, 2010). 
 
Naturally occurring diseases in domestic animals can be used as models of 
human pain. Recent reports have suggested that conditions such as osteosarcoma 
and osteoarthritis in dogs or several musculoskeletal disorders in horses can 
provide useful comparative data on the aetiopathogenesis of human diseases and 
can also be used to assess new therapeutic approaches with a potential 
application in humans (Brown et al., 2005; Innes and Clegg, 2010). 
In particular, naturally occurring neuropathic disorders in domestic animals 
also have the potential to provide clinically relevant models that closely mimic 
human neuropathic pain conditions. For example, feline diabetes mellitus 
resembles the disease in humans, both in terms of the observed peripheral nerve 
pathology and the clinical symptoms, and is considered a useful model for 
human diabetic neuropathy (Henson and O'Brien, 2006; Mizisin et al., 2007). 
  
1.7 Neural circuits of pain 
1.7.1 Primary afferent neurons and nociceptors 
Sensory information from the environment is transduced and relayed to the 
CNS by primary afferent neurons.  Primary afferent neurons have their cell body 
in dorsal root ganglia (DRG) of spinal nerves or in the cranial nerve ganglia in 
the head. Primary afferent neurons are pseudo-unipolar neurons which have an 
axonal stalk from which originate both a peripheral axon, whose nerve endings 
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innervate the skin, muscle, bones and viscera, and a central axon with terminals 
that synapse with the CNS. This means that peripheral and central terminals are 
similar biochemically and, thus, primary afferents can send and receive messages 
from either end, having been described as “a bidirectional signalling machine” 
(Basbaum et al., 2009). Although this “bidirectionallity” of primary afferents is 
apparent, for example, through the phenomenon of presynaptic inhibition, it 
remains to be elucidated whether activation of central terminals can backfire the 
whole afferent to release neurotransmitters from peripheral terminals.  
For the sake of clarity, only cutaneous primary afferents will be discussed 
here.  
According to axon calibre and myelination, parameters that determine 
conduction velocity, there are two types of cutaneous sensory afferents: large 
diameter, myelinated A-fibres, which are fast-conducting; and small diameter, 
unmyelinated C-fibres, which are slow-conducting. 
Aβ fibres are large diameter, fast-conducting (> 10 m/s) myelinated fibres and 
they have been traditionally associated with the detection and conduction of 
innocuous stimuli (Lewin and Moshourab, 2004).  However, there is substantial 
evidence that a subset of Aβ fibres are nociceptors, i.e. are specifically activated 
by noxious (damaging or potentially damaging) stimuli (for a review see Djouhri 
and Lawson, 2004). 
However, most nociceptors are primary afferent neurons which give rise to 
either thinly-myelinated Aδ fibres or unmyelinated C fibres and terminate in 
naked, unmyelinated nerve endings in the periphery. Aδ afferent fibres have 
conduction velocities of 2.2-8 m/s in the rat (Harper and Lawson, 1985) and 
mediate well localised, “first” or “sharp” pain. Small diameter, unmyelinated C 
fibres, with conduction velocities of < 1.4 m/s in the rat (Harper and Lawson, 
1985) mediate dull, poorly localised, “second” or “slow” pain.  
Aδ nociceptors are further divided into two types, according to their 
electrophysiological responses to noxious mechanical and thermal stimuli. Type 
I Aδ nociceptors have high temperature thresholds (> 50ºC), whereas type II Aδ 
nociceptors have a much lower heat threshold but a very high mechanical 
threshold (Beydoun et al., 1996; Simone and Kajander, 1997). Thus, type I fibres 
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are likely to convey the first pain provoked by noxious mechanical stimuli, while 
type II are likely to mediate the first pain response to noxious heat.  
Most C fibres are polymodal, responding to noxious mechanical, thermal and 
chemical stimuli (Bessou and Perl, 1969). A subgroup of C fibres, the so-called 
“silent” nociceptors, are mechanically insensitive but become gradually sensitive 
during inflammation, probably due to their higher sensitivity to chemical stimuli 
than other C fibre mechano-heat receptors (Schmidt et al., 1995).  
Not all Aδ and C fibres are nociceptors. Aδ fibres are also involved in the 
detection of innocuous mechanical and thermal stimuli (Iggo, 1969; Lynn and 
Carpenter, 1982). Similarly, a subpopulation of C fibres responds to innocuous 
cooling (Iggo, 1969) and another subset is activated by innocuous stroking of the 
hairy skin (Vallbo et al., 1999). A group of unmyelinated low threshold 
mechanoreceptors play a particular role in the mechanical hypersensitivity 
caused by injury (Seal et al., 2009). 
Nociceptors can also be classified in terms of the proteins they contain and 
release (Figure 1.2). Two different populations of C fibres have been described 
according to their molecular make-up. Peptidergic neurons release substance P, 
calcitonin-gene related peptide (CGRP) and express the TrkA and p75 receptors, 
which detect the neurotrophin, nerve growth factor (NGF) (Snider and 
McMahon, 1998). Non-peptidergic C fibres, on the other hand, bind the lectin 
Bandeiraea simplicifolia IB4 isolectin, express the enzyme thiamine 
monophosphatase (TMP) and express the c-Ret neurotrophin receptor and a 
ligand-binding component, a receptor called GDNF family receptor α (GFRα), 
which is activated by glial-derived neurotrophic factor (GDNF) (Airaksinen and 
Saarma, 2002; Bennett et al., 1998; Snider and McMahon, 1998). Most of the 
IB4-positive fibres also express G protein-coupled receptors of the Mrg family 
(Dong et al., 2001) as well as specific purinergic receptor subtypes, such as the 
P2X3 receptor (Ramer et al., 2001).   
Nociceptors can also be characterised according to their differential 
expression of particular ion channels that are involved in the transduction of 
specific noxious stimuli, whether they be chemical (e.g. TRPV1, formerly VR1, 
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and TRPA1), thermal heat (e.g. TRPV1) or thermal cold (e.g. TRPA1), which 
will be reviewed in section 1.8.1.  
 
 
Figure 1.2: Diagram showing two different populations of cutaneous 
nociceptors based on their molecular signature. The substance P/CGRP/TrkA 
population represents roughly 40% of DRG neurons in rodents, whereas the IB4 
population represents roughly 30%. Both populations of nociceptors are 
sensitive to capsaicin, presumably expressing the VR1 (TRPV1) receptor. From 
Snider and McMahon (1998). 
 
1.7.2 Nerve injury-related alterations in the properties of primary afferent 
neurons 
A characteristic feature of neuropathic pain disorders is the generation of pain 
in the absence of an identifiable stimulus that has been linked to the generation 
of action potentials in primary afferent neurons (Costigan et al., 2009). Indeed, 
nerve injury can alter the functional properties of primary afferent neurons. Early 
studies investigating the firing properties of nerves following transection 
revealed that both neuroma sprouts and DRG neurons can generate spontaneous 
ectopic discharges (Wall and Devor, 1983; Wall and Gutnick, 1974). Further 
studies carried out in partial nerve injury animal models of neuropathic pain have 
shown that abnormal firing occurs both in injured and intact nerve fibres (Ali et 
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al., 1999; Wu et al., 2002) that might be linked to pain behaviour and changes in 
gene expression (Obata et al., 2003). Moreover, spontaneous pain can be initiated 
by ectopic activity in both nociceptors (Bostock et al., 2005) and in low-
threshold myelinated fibres (Campbell et al., 1988).  
Another phenomenon observed following nerve injury is that of ephaptic 
transmission whereby nerve fibres and/or cell bodies start to cross-excite each 
other (Amir and Devor, 1992; Amir and Devor, 2000).  
The molecular basis underlying these changes in the excitatory properties and 
the activity of primary afferent in neuropathic pain will be discussed in section 
1.8.3. 
1.7.3 Organization of the dorsal horn of the spinal cord 
Central terminals of primary afferent neurons synapse with second order 
neurons in the dorsal horn of the spinal cord. The dorsal horn has been divided 
into six layers (laminae I-VI) based on the cytoarchitectural organization of its 
neurons (Rexed, 1954). Most Aδ and C fibres, conveying noxious and thermal 
information, terminate primarily in laminae I and II of the superficial dorsal 
horn, with a small number of Aδ fibres terminating in lamina V. Aβ fibres, which 
convey innocuous information from the periphery, terminate predominately on 
dorsal horn neurons in laminae III-VI (Todd, 2002).  
Peptidergic and non-peptidergic primary afferents also differ in the regions of 
the dorsal horn in which they terminate (Figure 1.2). CGRP/TrkA–expressing 
DRG neurons project mainly to lamina I (where the substance P receptor NK1 is 
heavily expressed) and outer lamina II (IIo), whereas IB4-binding DRG neurons 
project mainly to the inner lamina II (IIi), characterised by a subpopulation of 
neurons that express the γ isoform of protein kinase C (PKCγ) (Figure 1.2) 
(Snider and McMahon, 1998). Although it is not clear if these different 
projection patterns represent a corresponding functional dichotomy, it has been 
suggested that laminae I and lamina IIi might play distinct roles in the generation 
of the hypersensitivity associated with inflammatory and neuropathic pain, 




Three main classes of dorsal horn neurons have been described according to 
their excitatory responses (Cervero et al., 1976; Handwerker et al., 1975). Low-
threshold (LT) neurons (also called class I neurons) are only activated by 
innocuous stimuli and are primarily found in laminae I, III and IV, receiving 
inputs from innocuous mechanosensitive Aβ fibres or innocuous temperature 
information from Aδ/C fibres (Willis and Coggeshall, 1991). Class II neurons, 
also called wide-dynamic range neurons (WDR), are activated by innocuous and 
noxious stimuli (Menetrey et al., 1977) and are found predominantly in lamina 
V, as well as in IV and VI. Finally, nociceptive-specific neurons (NS, also called 
class III) respond only to noxious stimuli and are mainly located in laminae I and 
II.  
 
Most lamina I neurons are projection neurons, and they relay noxious 
information, mainly contralaterally via the spinothalamic tract and subdivisions 
such as the spinomesenchephalic tract, to various areas in the brain, including the 
thalamus, periaqueductal grey matter (PAG), the lateral parabrachial area and 
several parts of the medulla (Burstein et al., 1990; Cechetto et al., 1985; Giesler, 
Jr. et al., 1979; Lima and Coimbra, 1988; Menetrey and Basbaum, 1987; 
Menetrey et al., 1982; Spike et al., 2003; Todd et al., 2000).  
 
Lamina II, originally called the substantia gelatinosa (SG) due to its 
appearance, contains both inhibitory and excitatory interneurons that modulate 
the activity of neurons in other laminae. Both NS and WDR cells have been 
identified in IIo, whereas only WDR cells and low-threshold mechanical neurons 
have been reported in IIi  (Dubner and Bennett, 1983). 
 
Lamina III and IV neurons are mainly responsive to low-threshold stimuli but 
some are also WDR cells. Some neurons from this area send dendrites to the 
superficial dorsal horn. Sprouting of low threshold primary afferent terminals 
from lamina III into more superficial areas of the dorsal horn has been suggested 
as a mechanism for the development of neuropathic pain (Mannion et al., 1998). 
However, further studies have provided a legitimate reason for believing that this 
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may not be the case because validity of using cholera toxin B subunit (CTb) as a 
selective tracer for sprouting myelinated fibres following peripheral nerve injury 
(Shehab et al., 2003).   Cells from laminae III-IV from the origins of the 
spinocervical and postsynaptic dorsal column tracts (Brown, 1983) also 
contribute to ascending pathways such as the spinothalamic tract (Al-Khater et 
al., 2008; Willis et al., 1979). 
 
Lamina V has a major role in pain processing since the majority of its neurons 
are WDR cells that respond to innocuous and noxious input. Moreover, axons 
from cells in this lamina contribute to ascending pathways, such as the 
spinothalamic and spinomesencephalic tracts (Dubner and Bennett, 1983). 
1.7.4 Effect of nerve injury on the behaviour of spinal cord neurons 
Sustained nociceptor activation caused by peripheral nerve injury leads to 
central sensitisation, a phenomenon which results in enhanced responsiveness of 
neurons in the spinal dorsal horn (Chapman et al., 1998; Laird and Bennett, 
1993; Takaishi et al., 1996; Woolf, 1983). Central sensitisation typically involves 
an increase in ongoing activity in dorsal horn neurons, an increased excitability 
resulting in enhanced responsiveness to peripheral stimuli and the enlargement of 
receptive fields size beyond the injured area, changes which are clinically 
manifested as allodynia and secondary hyperalgesia (Ji et al., 2003; Suzuki et al., 
2000).  Central sensitisation is dependent on post-synaptic changes involving N-
methyl-D-aspartate (NMDA) receptors, which are similar to those underlying 
long-term potentiation (LTP), a mechanism involved in memory formation in the 
hippocampus (Ji et al., 2003). The molecular basis of central sensitisation will be 
further discussed in section 1.9.3. 
Some authors have differentiated between central sensitisation and 
centralisation of pain, whereby pain is generated by the CNS independently of 
ongoing peripheral activity (Devor, 2006). Central changes leading to 
centralisation of pain may include increased excitability, structural changes in 
synaptic connectivity, loss of inhibitory interneurons and alteration in descending 
modulatory systems (Costigan et al., 2009).  
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1.7.5 Ascending pathways 
Projection neurons from the dorsal horn of the spinal cord transmit 
somatosensory information to supraspinal structures through a number of 
pathways. The spinothalamic tract (STT) is a major ascending pathway for 
nociceptive and temperature information. STT neurons originate mainly from 
lamina I and laminae IV-VI and in their majority project to the contralateral 
ventrobasal and posterior thalamus, where they synapse with cells that project to 
the somatosensory cortex, which is involved in the sensory discriminative 
component of pain (Treede et al., 1999; Willis et al., 1979).  
Another relevant ascending pathway is the spinoparabrachial pathway, which 
is mainly comprised of noci-specific neurons with very few neurons responding 
exclusively to innocuous stimuli (Bester et al., 2000). This pathway mainly 
originates from cells in lamina I that express the SP receptor NK1 (Bester et al., 
2000; Todd, 2002) and are thought to encode the intensity of noxious stimuli 
(Doyle and Hunt, 1999). The parabrachial area is involved in autonomic 
regulatory functions and projects to the central nucleus of the amygdala and the 
hypothalamus, and is thus thought to be involved in autonomic and affective 
reactions to painful stimuli (Bester et al., 2000).  
Other pathways that relay nociceptive information to the brain include the 
ventral spinothalamic tract, the spinomesencephalic tract and the spinocervical 
tract. These will be not discussed further.  
1.7.6 Descending modulation of pain 
The transmission of nociceptive inputs is modulated at all levels of the 
neuroaxis. Descending modulation of pain was proposed by Sherrington (1906), 
who believed that the transmission of sensory information critically involved the 
interaction of inhibitory and excitatory systems. Hagbarth and Kerr (1954) 
provided the first evidence of modulation of spinal afferent conduction following 
repetitive stimulation of various areas of the brain. The influence of descending 
modulation on the processing of nociceptive inputs in the dorsal horn was a 
prominent feature of the Gate Control Theory, proposed by Melzack and Wall 
(1965), and was further supported by reports that showed induction of analgesia 
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through electrical stimulation of the periacqueductal gray (PAG) in the 
mesencephalon, a phenomenon called stimulation-produced analgesia (SPA) 
(Akil and Liebeskind, 1975; Reynolds, 1969). Further elucidation of the anatomy 
and neurochemistry underlying this phenomenon revealed the involvement of 
endogenous opioids and a serotonergic system originating at the nucleus raphe 
magnus (NRM), a medullary structure innervated by the PAG that sends 
projections to the spinal and medullary dorsal horn (Basbaum et al., 1976; Mayer 
and Price, 1976). 
The existence of descending modulatory systems devoted to modifying 
nociceptive transmission suggests an adaptive mechanism whereby responses to 
pain are modulated according to their relevance for increasing the organism’s 
chances of survival. Although pain is vital as a warning mechanism for life 
preservation, there are certain circumstances, for example in situations of 
extreme danger, in which the inhibition of pain might be more adaptive than its 
perception. A key phenomenon in this regard is what has been termed stress-
induced analgesia (SIA), a suppression of pain sensation in the presence of 
stressful stimuli (reviewed by Butler and Finn, 2009). The evolutionary 
advantage conferred by stress-induced analgesia has been suggested, for 
example, in studies showing that SIA is induced in rats, mice and voles in 
response to the presence of predators (Kavaliers and Choleris, 1997; Saksida et 
al., 1993; Sudhakar and Venkatesh, 2001). 
 
Descending modulation of spinal nociceptive transmission can also be 
facilitatory. A key area involved in descending facilitation is the rostral medial 
medulla (RMM) and this pathway appears to course through an anatomical 
pathway independent from the dorsolateral funiculus, which is involved in 
descending inhibitory pathways (Zhuo and Gebhart, 2002).  The RMM has been 
suggested to play a prominent role in the development of secondary hyperalgesia 
in a variety of chronic pain states (Urban and Gebhart, 1999). Additionally, 
selective ablation of RMM cells expressing the μ-opioid receptor prevented the 
development or reversed the establishment of allodynia in a rat model of 
neuropathic pain (Porreca et al., 2001). Descending facilitation is initiated by 
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injury to primary afferents and tissue inflammation (Gardell et al., 2003; Wei et 
al., 1999) and projection neurons from lamina I have been shown to regulate a 
descending serotoninergic facilitatory pathway that is mediated by 5-HT3 
receptors in superficial dorsal horn (Suzuki et al., 2002). 
 
1.8 Molecular mechanisms of nociception 
 
Nociceptors form late during neurogenesis and develop from neural crest stem 
cells, migrating from the dorsal part of the neural tube (Woolf and Ma, 2007). 
All embryonic nociceptors are NGF dependent and express the TrkA receptor 
(Marmigere and Ernfors, 2007). Mutations in the TrkA receptor, for example as 
in the hereditary sensory and autonomic neuropathy type IV, might result in loss 
of nociceptor neurons and congenital pain hyposensitivity (Verpoorten et al., 
2006). Nociceptor differentiation occurs through complex temporal patterns of 
protein expression. During the perinatal and postnatal period TrkA is 
downregulated in half of the developing nociceptors which instead start 
expressing the GDNF receptor Ret and become the nonpeptidergic population of 
nociceptors (Molliver et al., 1997). 
   
Sensory transduction is carried out by specific molecules located in the 
membrane of the peripheral terminals of primary afferent neurons. A particularly 
relevant group of channels in this regard is the transient receptor potential family 
(TRP), a diverse family of non-selective cation channels. TRP channels were 
discovered in Drosophila melanogaster for their role in phototransduction 
(Montell and Rubin, 1989). TRP channels are ubiquitously expressed across all 
kingdoms of life, having been identified in species ranging from yeast to 
mammals (Ramsey et al., 2006). TRP ion channels appear to subserve a main 
function as cell sensors, with prominent roles in vision, olfaction, taste, 
mechanosensation, osmoregulation and thermosensation (Clapham, 2003).  
Mammalian TRP channels are classified into subfamilies based on sequence 
homology: TRPC (canonical); TRPV (vanilloid, so named because the first 
identified member is activated by the vanilloid, capsaicin, the pungent ingredient 
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of chilli peppers); TRPM (melastatin, named for the role of the first member of 
this family in melanoma metastasis); TRPA (ankyrin, named for the ankyrin 
repeats in the N-terminal tail of this subfamily member); TRPP (polycystin, 
named for its involvement in polycystic kidney disease); and TRPML 
(mucolipin, so called due to mutations in this channel are associated with 
mucolipidosis) (Clapham, 2003; Moran et al., 2004; Ramsey et al., 2006). The 
genetic sequences and structures of TRP are very diverse although they all share 
a structure based on six transmembrane (TM) domains, with cytoplasmic amino 
and carboxy termini. TRP channels appear to function as tetramers, and mostly 
as homomers (Clapham, 2003; Ramsey et al., 2006).  
The emergence of transient receptor potential (TRP) channels during 
development occurs in a time-dependent manner, with TRPV1, TRPV2, TRPM8 
and TRPA1 expression first becoming detectable in embryonic mice at E12.5, 
E10.5, E16.5 and P0, respectively (Hjerling-Leffler et al., 2007; Shibasaki et al., 
2010). Although the role of TRP channels during development has not been 
elucidated it appears that it might go beyond their sensory function. A recent 
study has suggested that TRPV2 is involved in the regulation of axon outgrowth 
in both sensory and motor neurons (Shibasaki et al., 2010).  
1.8.1 Molecular transduction of noxious stimuli 
The molecular basis of noxious stimulus transduction, with a particular 
emphasis on TRP channels, is briefly reviewed below for each stimulus 
modality. 
 
Noxious heat transduction 
 
Temperatures over 43ºC are typically perceived as painful, in agreement with 
firing thresholds of C and type II Aδ fibres. Cloning and functional 
characterization of the capsaicin (vanilloid) receptor (TRPV1) has provided a 
molecular basis for noxious heat detection (Caterina et al., 1997). This receptor is 
highly expressed in sensory neurons, preferentially in Aδ and C fibres that 
typically express molecular markers of nociceptors (Caterina et al., 1997; 
Tominaga et al., 1998). Indeed, TRPV1 is activated not only by capsaicin but 
also noxious heat and protons (low pH is a feature of inflammation) (Caterina 
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and Julius, 2001). TRPV1 has also been shown to be activated by other chemical 
agonists, including endogenous lipids, such as the endocannabinoid anandamide, 
N-arachidonoyl-dopamine, and various metabolic products of lipoxygenases, 
spider toxins and artificial sweeteners (Riera et al., 2007; Siemens et al., 2006; 
Suh and Oh, 2005). Thus, TRPV1 acts as a polymodal transducer that integrates 
a variety of stimuli.  The integrative role of TRPV1 is most apparent in 
hypersensitive pain states associated with tissue damage which will be further 
discussed in section 1.8.3.  
TRPV1 has been considered a promising target for pain relief. For example, 
TRPV1-containing neurons can be rendered insensitive to further noxious 
stimulation through desensitisation following the prolonged application of 
agonist drugs, such as capsaicin (Dray et al., 1990). 
 
The molecular domain conferring thermal sensing to TRPV1 appears to be 
localised to the C-terminal domain. Indeed, interchange of the C-terminus of 
TRPV1 and that of TRPM8 (which detects cool temperatures, see below) results 
in a shift in temperature activation to that typical of the donor, i.e. TRPV1 with a 
TRPM8 C-terminus activates at low temperatures (around 25°C) and TRPM8 
with a TRPV1 C-terminus activates at temperatures around 45°C (Brauchi et al., 
2006). 
 
Knock-out studies haves shown that acute noxious thermal detection is not 
mediated solely by TRPV1 (Davis et al., 2000; Woodbury et al., 2004). Other 
TRP receptors have been suggested to play a role in heat sensation. TRPV2 
shows a temperature activation threshold of around 52ºC and is expressed in a 
subpopulation of Aδ fibres that respond to high-threshold noxious heat (Leffler 
et al., 2007; Lewinter et al., 2004; Rau et al., 2007). TRPV3 and TRPV4 are 
activated at temperatures between 25ºC and 35ºC and mice lacking these 
receptors displayed altered thermal preference on a platform with graded 
temperatures, suggesting a role in temperature detection in vivo (Chung et al., 





Noxious cold transduction 
 
The identification of molecular transducers of cold temperature in sensory 
neurons has been aided by research on receptors for natural cooling compounds, 
such as menthol. Cloning and characterization of the transient receptor potential 
TRPM8 has shown that this receptor is activated by cooling chemical compounds 
and also innocuous cold temperatures below 25ºC (McKemy et al., 2002; Peier et 
al., 2002). A role has also been suggested for TRPM8 as a noxious cold detector, 
and although the mechanisms underlying these opposing functions are unclear, it 
has been hypothesised that TRPM8 could be expressed in two distinct 
populations of sensory afferents, one conveying nociceptive inputs and the other 
one innocuous cold information (Fleetwood-Walker et al., 2007; Knowlton et al., 
2010; Takashima et al., 2010). Although TRPM8 is preferentially expressed in 
small afferents that are TRPV1-negative but TrkA-positive (Kobayashi et al., 
2005; Peier et al., 2002; Story et al., 2003), some studies have reported levels of 
co-expression of TRPM8 and TRPV1 ranging from 10% to 29% (Obata et al., 
2005; Okazawa et al., 2004). Additionally, there are several reports of a subset of 
trigeminal and DRG cells that respond to both menthol and capsaicin and show 
some degree of histochemical co-localisation of TRPM8 and TRPV1 (McKemy 
et al., 2002; Okazawa et al., 2004; Reid et al., 2002; Viana et al., 2002). Since 
TRPV1 is typically expressed in nociceptors, it could be inferred that activation 
of TRPM8 in the same cells would be perceived as noxious, thus contributing to 
cold pain.  However, the variable times that cells were maintained in vitro in 
these studies (during which phenotypic changes may occur), mean they may not 
necessarily provide an accurate reflection of in vivo function.  
Further insights into the physiological roles of TRPM8 in cool sensation and 
pain processing have been gained from TRPM8 knockout studies, which have 
confirmed a major role of TRPM8 in cool sensation. Experiments carried out 
using in vitro skin-nerve preparations showed that subpopulations of C and Aδ 
fibres were activated by cooling from 32ºC to 28ºC in wild type mice, but not in 
TRPM8 knockouts (Bautista et al., 2007). Similarly, sensory ganglion cells from 
knockout mice showed significantly reduced elevation of intracellular Ca2+ in 
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response to cooling (range 20ºC–10ºC) as well as to application of menthol and 
icilin (Bautista et al., 2007; Colburn et al., 2007; Dhaka et al., 2007).   
With regard to their behaviour, TRPM8 knockout mice do not exhibit the 
preference for temperatures around 30ºC (over those in the range downwards to 
15ºC) that is observed in wild type mice (Bautista et al., 2007; Colburn et al., 
2007; Dhaka et al., 2007), suggesting  that TRPM8 is implicated in this 
avoidance behaviour. Similarly, the licking and/or flinching responses to skin 
cooling by acetone were consistently reduced in TRPM8-knockout mice 
(Bautista et al., 2007; Colburn et al., 2007; Dhaka et al., 2007). However, it was 
noted that knockout mice avoided temperatures below 10ºC, suggesting that 
other receptors must, of necessity, be involved in noxious cold transduction 
(Daniels and McKemy, 2007).  
 
 It seems clear that the majority of TRPM8-expressing cells are not classical 
nociceptors and might be able to exert a quite different functional influence on 
pain processing (Fleetwood-Walker et al., 2007). Indeed, TRPM8 has been 
implicated in an endogenous analgesic system apparent in hypersensitive pain 
states (Proudfoot et al., 2006). Cool temperatures and chemical cooling-
compounds such as menthol have been traditionally used to treat pain. The 
mechanisms of cooling analgesia will be further discussed in section 1.10.  
 
Another TRP channel, TRPA1 has been shown to be activated by cold 
temperatures, with an average threshold between 12-24°C in heterologous 
expression systems, with a maximal activation at temperatures below 20°C 
(Babes et al., 2004; Story et al., 2003). TRPA1 appears to be a major contributor 
of cold sensing in vagal afferent fibres and trigeminal ganglion neurons (Fajardo 
et al., 2008; Karashima et al., 2009). 
However, knockout studies have provided opposing results and its role in 
noxious cold-transduction is still being debated (Bautista et al., 2006; Karashima 
et al., 2009; Kwan et al., 2006).   
Importantly, it has been suggested that discrepancies shown between 
knockout studies could reflect the diversity of behavioural tests used by different 
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groups, the use of only male or both male and female mice and the strategies 
used to generate the knockout animals (Story and Gereau, 2006). Furthermore, 
knockout animals might exhibit functional compensation by related channels and 
receptors, so they might not necessarily be useful predictors of a gene’s role in 
disease states (Patapoutian et al., 2009).  
A recent TRPM8/TRPA1 double knockout has provided further evidence 
against TRPA1 mediating noxious cold (Knowlton et al., 2010). TRPM8, 
however, was confirmed as a key receptor in thermal preference for temperatures 
ranging between 30ºC and 15ºC (Knowlton et al., 2010). The evidence regarding 
the role of TRPM8 in noxious cold transduction is less conclusive. Even though 
knockout mice appeared to have less aversive responses to 5ºC than wild type 
mice, they could clearly discriminate between this noxious temperature and 
30ºC, choosing to spend over 80% of the time on the 30ºC plate (Knowlton et al., 
2010). 
It is likely that other channels contributing to noxious cold detection are 
present in the peripheral nervous system. For example, Kv1 potassium channels 
have been shown to be involved in cold detection in TRMP8-expressing neurons. 
The proposed model argues for two distinct populations of cold thermosensory 
neurons based on the levels of expression of TRPM8 and Kv1 and their 
antagonistic effects on neuronal excitability: one population could express high 
TRPM8 levels, low or absent Kv1 expression and would be involved in 
innocuous cold sensing and the other population would be involved in noxious 
cold detection, expressing low TRPM8 levels and high expression of Kv1 
(Madrid et al., 2009).  
Voltage-gated sodium channel Nav1.8 has also been implicated in the 
perception of cold pain (Zimmermann et al., 2007) and a recent knock-out study 
has suggested a role for Nav1.8 and Nav1.9 in the development of cold allodynia 
in neuropathic pain models (Leo et al., 2010). 
Other candidates come from data from double knock-out mice, lacking 
TREK-1 and TRAAK, which suggests a role in noxious cold detection for these 
channels, although their mode of operation has not been fully elucidated (Noel et 






Nociceptors respond to noxious chemical substances that are either 
encountered as irritants in the environment or are released endogenously, for 
example following tissue damage. 
TRP channels have a prominent role in sensory chemo-detection and are 
activated by plant-derived substances such as capsaicin (TRPV1), menthol 
(TRPM8) and allyl isothiocyanate (mustard oil) and cinnamaldehyde (present in 
cinnamon oil) (TRPA1). Mice lacking TRPA1 show greatly reduced sensitivity 
to “tear gases” and isocyanates that produce pain and inflammation, suggesting a 
role for TRPA1 as a noxious chemo-transducer in vivo (Bessac et al., 2009). 
Moreover, co-localisation of TRPA1 and TRPV1 in a subgroup of DRG and 
trigeminal nociceptors, also suggests a role for TRPA1 in nociception (Story et 
al., 2003). 
Sensory neuron terminals also respond to proalgesic agents released 
endogenously in response to tissue damage or physiological stress. 
For example, extracellular ATP induces the depolarisation of sensory neurons, 
and may play a role in nociceptor activation when released from damaged tissue. 
ATP activates purinergic receptors, including the members of the P2X family of 
ligand-gated ion channels (Florenzano et al., 2002; Prasad et al., 2001). The 
P2X3 receptor is uniquely expressed in sensory neurons, particularly in 
nociceptors (Chen et al., 1995). Indeed, topical or intradermal application of ATP 
induces pain (Bleehen, 1978; Coutts et al., 1981).  
Another chemical mediator, serotonin is released from mast cells, platelets 
and endothelial cells following tissue damage (Millan, 1999). Peripherally 
applied serotonin has been shown to induce pain in humans and to evoke 
nociceptive behaviours in the rat (Jensen et al., 1990; Taiwo and Levine, 1992). 
However, the role of serotonin and serotonin receptors (5-HT receptors) in pain 
processing is complex as serotonin may inhibit and/or facilitate nociceptive 
inputs depending on the type of nociceptive stimuli and, crucially, the type of 5-
HT receptors involved, both peripherally and centrally (Millan, 1999). The role 






The identification of the molecular transducers that detect tactile stimuli has 
proven rather difficult. The variety of mechanical stimuli that organisms are able 
to sense (ranging from vibration or light touch to noxious pressure) and the many 
subtypes of neurons responding to them have been factors hindering progress in 
this area of research (Tsunozaki and Bautista, 2009). However, recent studies 
have provided new insights into mammalian sensory mechano-transduction, 
suggesting a possible role for three classes of ion channels. 
Studies carried out in the nematode C.elegans, have identified protein 
members of the degenerin/epithelial Na channel (DEG/ENaC) family, mec-4 and 
mec-10 and associated proteins mec-2 and mec-6 as a mechano-transducing 
complex in neurons (Chalfie and Sulston, 1981). Far less conclusive results have 
been obtained in studies investigating DEG/ENaC channel mammalian 
orthologs, ASIC 1, 2 and 3, present in sensory neurons, as their role as mechano-
transducers has not been confirmed by knock-out studies (Drew et al., 2004; 
Page et al., 2005; Price et al., 2000; Price et al., 2001; Roza et al., 2004). 
TRP channels have also been suggested as candidates for mechanical 
transducers in sensory neurons (Christensen and Corey, 2007) but whether they 
act directly as transducers or are involved in the modulation of mechano-
transduction is not clear (Tsunozaki and Bautista, 2009). Knock-out studies of 
TRPA1 have provided conflicting results with some reporting no changes in 
mechanical thresholds and others reporting deficits in mechano-sensation 
(Bautista et al., 2006; Kwan et al., 2006; Petrus et al., 2007). These studies also 
investigated the role of TRPA1 in sensitised states, which will be discussed in 
section 1.8.3. 
Lastly, two-pore potassium (KCNK) channels have also been proposed as 
possible mechano-transducers in mammals. Indeed, several KCNK subunits are 
expressed in sensory neurons (Medhurst et al., 2001). KCNK2 (also known as 
TREK1) is expressed in a subset of C fibre nociceptors and is activated by heat, 
osmotic stretch, and pressure (Alloui et al., 2006). Paradoxically, KCNK2-
deficient mice display enhanced sensitivity to heat and mild mechanical stimuli, 
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but normal responses to noxious mechanical pressure (Alloui et al., 2006). The 
authors of that study suggest that KCNK2 could counteract the effects of an 
unidentified transduction channel located in skin sensory cells. Another 
candidate, KCNK18 is expressed in a subset of peptidergic C fibres and low 
threshold (Aβ) mechanoreceptors, but its role in mechano-transduction is not 
clear and might be limited to regulating action potential duration and excitability 
(Bautista et al., 2008; Dobler et al., 2007).  
Since a clear mechano-transducer molecule in sensory neurons has not been 
explicitly identified so far, it is likely that multiple functionally overlapping 
transduction complexes are involved in sensing touch and that this might be 
clarified by further research on mouse strains in which multiple genes have been 
knocked out (Chalfie, 2009). 
1.8.2 Voltage-gated ion channels in nociceptive conduction 
The transduction of noxious stimuli results in the generation of receptor 
potentials that activate a variety of a voltage-gated ion channels involved in the 
conduction of the activity giving rise to pain. Voltage-gated sodium and 
potassium channels are crucial for the generation of action potentials which 
convey nociceptive inputs to synapses in the dorsal horn, whereas voltage-gated 
calcium channels are critical to the release of neurotransmitters from nociceptor 
terminals (Basbaum et al., 2009). 
  
Sodium channels  
 
Voltage-gated sodium channels (Nav) open in response to a change in 
membrane potential and are responsible for the rapid depolarisation required for 
the generation of an action potential. Several voltage-gated sodium channels 
have been shown to be expressed in nociceptors. These channels are classified 
according to their sensitivity to the sodium channel blocker tetrodotoxin (TTX), 
Nav1.3 and Nav1.7 (amongst others) are sensitive to TTX (TTX-S) whilst Nav1.8 
and Nav1.9 are resistant (TTX-R) (for a review see Krafte and Bannon, 2008). 






Calcium channels  
 
A number of voltage-gated calcium channels (Cav) are expressed in 
nociceptors where they evoke an increase in intracellular calcium in response to 
depolarization. In nociceptors, Cavs are involved in the release of 
neurotransmitters such as substance P and CGRP (Lee et al., 2005). Calcium 
channels are heteromeric proteins composed of α1 pore forming subunits and the 
modulatory subunits α2δ (which regulates the kinetics of activation and 
inactivation), α2β or α2γ (Basbaum et al., 2009). Calcium channels can be 
broadly divided into two groups based on their activation thresholds. High 
threshold voltage-gated calcium channels include the L (Cav1), type and the N, R 
and P/Q (Cav2) types; low threshold voltage-gated calcium channels are the T 
(Cav3) type calcium channels (for a review see Gribkoff, 2006). The high 
threshold N type, Cav2.2 channel is highly expressed in nociceptors and is 
considered one of the most important voltage-dependent calcium channels in 
pain processing (Gribkoff, 2006). Additionally, knockouts of the α1B subunit 
specific to this channel showed reduced reflex responses to noxious mechanical 
and thermal stimuli and reduced pain behaviour in the second phase of the 
formalin response, suggesting a central role where this channel is abundant on 
presynaptic terminals (Kim et al., 2001). 
1.8.3 Peripheral molecular mechanisms of neuropathic pain 
Following tissue damage and injury a peripheral hypersensitive state develops 
which involves reduced thresholds for firing and increased excitability of 
nociceptors. The molecular mechanisms underlying peripheral hypersensitivity 
include the sensitisation of nociceptors and activation of silent nociceptors in the 
presence of inflammatory mediators, altered expression of neuropeptides and 
their receptors, expression of new receptors and changes in the expression, 











Peripheral sensitisation is dependent on inflammatory mediators such as 
prostaglandin E2 (PGE2), bradykinin, ATP, protons, nerve growth factor (NGF) 
and cytokines such as tumor necrosis factor alpha (TNF-α) and interleukin-1β 
that are released from non-neuronal cells (fibroblasts, mast cells, neutrophils, 
monocytes and platelets) as well as from nerve terminals (Basbaum et al., 2009).  
If nerve injury is involved, mediators can also be released by Schwann cells and 
damaged axons (Campana, 2007). These inflammatory mediators are detected by 
specific receptors in the primary sensory neurons including: G protein-coupled 
receptors for PGE2 and bradykinin, ionotropic receptors for ATP and protons, 
and tyrosine kinase receptors for NGF and cytokines (Ji and Strichartz, 2004; 
Woolf and Costigan, 1999).  
Peripheral sensitisation can result from the direct action of the inflammatory 
mediators on particular ion channels involved in nociception or by initiating 
transcriptional changes that result in changes in protein expression. For example, 
NGF induces hypersensitivity to heat and mechanical stimuli. NGF acts directly 
on peptidergic C fibre nociceptors, which express the high-affinity NGF receptor 
tyrosine kinase TrkA and the lower affinity NGF-binding protein, p75. 
Interaction of NGF with its receptors induces the activation of downstream 
signalling pathways (including phospholipase C (PLC), mitogen-activated 
protein kinase (MAPK) and phosphoinositide 3- kinase (PI 3-K) that lead to the 
functional potentiation of target proteins, for example TRPV1, resulting in an 
enhancement of heat sensitivity (Chuang et al., 2001 ; Zhang et al., 2005). NGF 
also induces upregulation of pronociceptive neuropeptides such as substance P 
and CGRP (Donnerer et al., 1992; Woolf et al., 1994). In addition, transport of 
the NGF-TrkA complex to the nucleus of the nociceptive neuron results in 
increased expression of a number of ion channels that contribute to the 
excitability of nociceptive neurons, including TRPV1 and the Nav1.8 voltage-







TRP channels in neuropathic pain 
 
TRP channels have not only been revealed as the major group of sensory 
neuron transducers but also as crucial elements in the development of 
hypersensitive pain states following injury.  As described above, following injury 
there are changes in TRPV1 expression and function. The role of TRPV1 as an 
integrator of inflammatory mediators has been confirmed by the failure of knock-
out mice to develop thermal hyperalgesia in inflammatory pain models (Caterina 
et al., 2000; Davis et al., 2000). Indeed, TRPV1 antagonists have been shown to 
provide pain relief in models of inflammatory pain (Krause et al., 2005). 
TRPV1 antagonists have also been reported to reduce pain sensitivity in 
models of neuropathic pain (Culshaw et al., 2006). However, there are not 
conclusive data on the expression levels of TRPV1 following nerve injury, with 
some studies reporting an increase and others reporting a decrease (Kim et al., 
2008; Michael and Priestley, 1999). Interestingly, a recent study has indicated 
that the regulation of TRPV1 mRNA levels following nerve injury might be 
dependent on genotype, as increased, decreased or unaltered levels were 
observed in different mouse strains (Persson et al., 2010). In models of diabetes-
induced neuropathic pain, TRPV1 expression is increased during the 
hyperalgesic phase and mice lacking TRPV1 fail to develop streptozotocin-
induced thermal hyperalgesia (Pabbidi et al., 2008). However, TRPV1 did not 
appear to be required for the development of hypersensitivity in the PSL model 
of neuropathic pain (Caterina et al., 2000).  
 It has been suggested that the role of TRPV1 in neuropathic pain may include 
sensitization of intact peripheral terminals (through the pathways described 
above), ectopic activity in injured axons (through activation of axonal TRPV1 
receptors) or a contribution to the modulation of transmitter release (Patapoutian 
et al., 2009). Indeed, a recent study has suggested a role for TRPV1 channels in 
the modulation of synaptic transmission through its activation by 
endocannabinoids, such as anandamide (Sagar et al., 2010). 
TRPA1 also appears to play a role in hypersensitive states associated with 
chronic pain. Nerve injury, Complete Freund’s adjuvant (an inflammatory 
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model) and NGF increase TRPA1 expression and activity in sensory neurons  
(Diogenes et al., 2007; Ji et al., 2008; Obata et al., 2005). Moreover, antisense 
knockdown of TRPA1 results in a reduction of cold hyperalgesia in both 
inflammatory and neuropathic pain models (Katsura et al., 2006; Obata et al., 
2005). It has been suggested that increased sensitivity to cold in the SNL model 
could be related to an increased expression of TRPA1 in Aδ fibres (Ji et al., 
2008; Ji et al., 2007). 
TRPM8 expression increases in DRG neurons ipsilateral to injury in the CCI 
model of neuropathic pain and there is an enhancement in expression in small 
myelinated fibres (Frederick et al., 2007; Proudfoot et al., 2006). However, no 
alterations in TRPM8 expression were reported in the SNL model of nerve 
injury, nor in a model of inflammation (Katsura et al., 2006; Obata et al., 2005). 
Similarly, there are reports showing either no change or a reduction on the levels 
of mRNA transcripts for both TRPM8 and TRPA1 in neuropathic pain (Caspani 
et al., 2009; Persson et al., 2010; Staaf et al., 2009). Although a role has been 
suggested for TRPM8 as a candidate mediating cold hypersensitivity in 
neuropathic pain (Colburn et al., 2007; Xing et al., 2007), other reports suggest 
that neither TRPM8 nor TRPA1 are involved in cold allodynia (Caspani et al., 
2009; Namer et al., 2008). 
The role of TRPM8 in nociceptor sensitisation has been questioned. Indeed, 
inflammatory mediators that induce sensitisation of other TRP channels, result in 
suppression of TRPM8 function. For example, PKC activation and 
phosphatidylinositol 4,5-bisphosphate depletion (which are signalling events 
downstream of bradykinin receptors) and protein kinase A (PKA) activation 
(which occurs downstream of PGE2 receptors) abolish or reduce TRPM8 activity 
(De Petrocellis et al., 2007; Liu and Qin, 2005; Rohacs et al., 2005).  
 
Voltage-gated ion channels and further peripheral mediators in neuropathic pain   
 
Following nerve damage there are changes in primary afferent neurons in 
terms of their neurotransmitter content and altered gene expression that result in 
alteration in their properties and activity leading to hyperexcitability. Alterations 
in the level of expression, cellular localization and distribution of sodium 
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channels are strongly associated with neuropathic pain (Attal and Bouhassira, 
2006). Damaged axons may start to generate ongoing ectopic activity due to the 
accumulation of sodium channels around the site of injury (Devor et al., 1993); 
however, so far, no specific sodium channel has been positively associated with 
hyperexcitability in damaged nerves (Nassar et al., 2006). Pharmacological 
treatment using sodium channel blockers, such as some antiepileptic drugs or 
local-anaesthetics, has been shown to provide anti-hyperalgesic effects in 
patients suffering from neuropathic pain (Attal and Bouhassira, 2006). 
Voltage-gated calcium channels have also been implicated in neuropathic pain 
states. Cav2.2 and α2δ subunits are upregulated in DRG neurons following nerve 
injury, suggesting a role in the pathological signal transmission that characterises 
neuropathic pain states (McGivern, 2006). 
Another phenomenon observed following nerve injury is that of ephaptic 
transmission whereby nerve fibres and/or cell bodies start to cross-excite each 
other (Amir and Devor, 1992; Amir and Devor, 2000). It has been suggested that 
cross-excitation might be mediated by neuropeptides, particularly neuropeptide 
Y (NPY) (Hokfelt et al., 2007). Cross excitation between A and C fibres is 
correlated with increased NPY in large DRG neurons and the increase in NPY 
receptor Y2 in small cells following nerve injury (Noguchi et al., 1993; 
Wakisaka et al., 1991; Wakisaka et al., 1992; Zhang et al., 1997).  
1.8.4 Role of the sympathetic nervous system in neuropathic pain 
In addition to changes within sensory nerves, sympathetic efferents are able to 
activate sensory afferents when the latter start to express α2-adrenoceptors 
following nerve injury (Devor et al., 1994; Xie et al., 1995). Noradrenergic axon 
sprouting into DRG and functional coupling with the somata of primary sensory 
neurons has been shown to occur following peripheral nerve injury (McLachlan 
et al., 1993; Shinder et al., 1999). Recent studies using chemical and surgical 
sympathectomy in the SNI model suggest that sympathetic input is not involved 
in the establishment of neuropathic pain but is involved in the maintenance of 




1.9 Spinal molecular mediators of nociception and chronic pain 
1.9.1 Glutamate neurotransmission in the dorsal horn 
Glutamate is the main excitatory neurotransmitter in the dorsal horn released 
from the terminals of primary afferents. Spinal cord neurones responsive to 
glutamate are predominantly located in LI and LII of the dorsal horn (Schneider 
and Perl, 1988) and their response is mediated by post-synaptic ionotropic 
glutamate receptors which include NMDA (N-methyl-D-aspartate), AMPA (α-
amino-3-hydroxyl-5-methyl-4-isoxazole-propionate) and kainate receptors as 
well as by metabotropic glutamate receptors (Bleakman et al., 2006). Glutamate 
is also released by excitatory interneurons (Sorkin and McAdoo, 1993).  
AMPA and kainate receptors mediate fast excitatory transmission in the 
dorsal horn, while the NMDA receptor is functionally blocked by Mg2+ in a 
voltage-dependent manner and this inhibition is removed upon sufficient 
depolarisation of the postsynaptic membrane (Mayer et al., 1984). As the main 
excitatory neurotransmitter involved in nociceptive transmission, much research 
has been focused on the role of glutamate, its receptors and the signalling 
pathways downstream of receptor activation, together with their contribution to 
the development and maintenance of chronic pain states.  
Metabotropic glutamate receptors (mGluRs) are G protein-coupled receptors, 
comprising 8 subtypes (mGluR 1-8), which are categorised into 3 groups 
depending on their subsequent signalling pathways and their structural and 
pharmacological characteristics (Neugebauer, 2002). Activation of group I 
(mGluR 1 and 5) receptors leads to the activation of PLC, and subsequent release 
of Ca2+ from intracellular stores, whereas group II (mGluR 2 and 3) and group III 
(mGluR 4/6-8) are negatively coupled to adenylate cyclase, and thus inhibit 
cAMP (cyclic adenosine monophosphate) formation and PKA activation 
(Neugebauer, 2002). Generally, activation of group I mGluRs increases neuronal 
excitability and can enhance ionotropic glutamate receptor activity (Bleakman et 
al., 1992) by mechanisms such as receptor phosphorylation, whereas groups II 
and III are generally inhibitory (Bleakman et al., 2006).  
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1.9.2 GABA and glycine influences in the dorsal horn 
Gamma-aminobutyric acid (GABA) and glycine are neurotransmitters with 
generally inhibitory actions that are released by interneurons within the spinal 
cord. GABA acts on ionotropic GABAA receptors and metabotropic GABAB 
receptors located pre-synaptically on primary afferent terminals as well as on 
spinal neurons especially within the superficial dorsal horn (Todd and Sullivan, 
1990; Todd et al., 1996). In normal conditions, GABA and glycine inhibit the 
transmission of nociceptive signals from primary afferent nociceptors to 
postsynaptic projection neurons (pre-synaptic inhibition) and reduce the 
excitability of projection dorsal horn neurons (post-synaptic inhibition), thus 
acting as modulators or “gate-keepers” of nociceptive transmission. Thus, 
pharmacological blockade of GABAergic and glycinergic influences results in 
tactile allodynia and increased synaptic transmission from Aβ fibres to 
nociceptive lamina I neurons (Baba et al., 2003; Torsney and MacDermott, 
2006).  
Pre-synaptic inhibition appears to be mediated solely by GABAergic 
synapses, whereas both GABA and glycine are involved in post-synaptic 
inhibition (Zeilhofer et al., 2009). GABAA receptors are ligand-gated chloride 
channels and their activation increases membrane Cl- conductance resulting in 
hyperpolarisation of the cell, whilst GABAB receptors are linked to Ca
2+ and K+ 
channels. Their activation results in a decrease in Ca2+ currents and an increase in 
K+ currents that hyperpolarise the cell and reduces transmitter release (Malcangio 
and Bowery, 1996). Glycine receptors contain a chloride-permeable ion channel 
and activation of these receptors hyperpolarises neurones (Hamill et al., 1983). 
But glycine does not only serve an inhibitory role. Glycine is an obligatory co-
agonist of typical NR1 and NR2 subunit-containing NMDA receptors and in 
addition, NMDA receptors containing the NR3 subunit can be activated by 
glycine, independently of glutamate (Chatterton et al., 2002). 
Inhibitory dorsal horn neurons are activated by input from both nociceptive 
and non-nociceptive primary afferent nerve fibres and through descending 
antinociceptive pathways (Willis and Coggeshall, 1991). There is also evidence 
for the existence of direct inhibitory GABAergic and glycinergic pathways 
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descending from the rostral ventromedial medulla (Antal et al., 1996; Kato et al., 
2006). 
1.9.3 Central sensitisation in chronic pain states 
Sustained nociceptor activation caused by peripheral nerve injury and 
inflammation leads to central sensitisation, where enhanced responsiveness of 
neurons in the spinal dorsal horn is thought to underlie chronic hyperalgesia and 
allodynia (Chapman et al., 1998; Kidd and Urban, 2001; Laird and Bennett, 
1993; Takaishi et al., 1996; Woolf, 1983). Long-term hyper-excitability of dorsal 
horn neurons has been attributed to an increased release of excitatory 
neurotransmitters and alterations in their receptors and also to a decrease or 
disruption of afferent and descending inhibitory mechanisms in the spinal cord 
(Saade and Jabbur, 2008).  
NMDA receptors play a major role in the development and maintenance of 
central sensitisation (Coderre and Melzack, 1992; Leem et al., 1996; Sotgiu and 
Biella, 2002; Woolf and Thompson, 1991). NMDA receptors are abundantly 
expressed in the dorsal horn of the spinal cord and NMDA receptor subunits 
NR1 and NR2B are preferentially concentrated in the superficial dorsal horn. 
NMDA receptor channels are ordinarily blocked by Mg2+ and require 
depolarisation-induced removal of this block as well as glutamate binding in 
order to open. Depolarisation by increased input from hyperexcitable afferents 
following injury removes the Mg2+ block resulting in the opening of the channel 
and the entrance of Na+ and Ca 2+, which will lead to further depolarisation and 
the activation of intracellular signalling cascades, causing the development of 
long-term changes in neuronal plasticity. NMDA receptors also interact with 
specific synaptic proteins that have scaffolding, cytoskeletal, adapter and 
signalling functions (Husi et al., 2000). 
Of particular interest is the suggestion that distinct NMDA receptor–adaptor 
proteins of the membrane-associated guanylate kinase (MAGUK) family may 
play different roles in neuropathic and inflammatory pain (Garry et al., 2004; 
Garry et al., 2003). Although both AMPA and NMDA receptor antagonists have 
anti-nociceptive properties, the ubiquity of these receptors across the CNS and 
the associated psychotropic side effects of NMDA antagonists such as ketamine, 
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severely hamper their use as analgesics. The development of specific NMDA 
antagonists targeting specific receptor subunits holds promise but is still far from 
clinical application (Chizh et al., 2001). Continuing studies on glutamate receptor 
interacting proteins in the CNS in chronic pain states may provide novel and 
selective analgesic targets. 
1.9.4 Spinal disinhibition in chronic pain states 
It has been proposed that peripheral nerve injury may lead to a loss of local 
inhibitory control (disinhibition). This may be due to the death of inhibitory 
interneurons and/or decreased expression of both the inhibitory neurotransmitter 
GABA, and of the GABA and opioid receptors, resulting in increased dorsal 
horn neuron excitability (Sugimoto et al., 1990; Woolf and Mannion, 1999). 
However, there is some evidence against the role of inhibitory neurons in 
neuropathic pain, as neuronal loss has been shown not to be necessary for its 
development (Polgar et al., 2003). 
An alternative mechanism has been suggested based on the involvement of 
the K+ Cl– co-transporter KCC2 that regulates chloride homeostasis. A reduction 
in expression levels of KCC2 would alter the transmembrane anion gradient, 
shifting GABA-mediated signalling from hyperpolarising to depolarising. 
Indeed, downregulation of KCC2 has been reported in dorsal horn neurons 
ipsilateral to peripheral nerve injury, providing a potential mechanism underlying 
hyperexcitability of lamina I neurons (Coull et al., 2003). This downregulation 
appears to be mediated by BDNF released from the microglia (Coull et al., 
2003).  
The importance of glial cells in chronic neuropathic pain has recently been 
highlighted (Watkins et al., 2007), with microglial activation observed in the 
dorsal horn after peripheral nerve injury appearing to contribute to the allodynia 
associated with chronic neuropathic pain (Tsuda et al., 2003). 
Following nerve injury there are also changes in the descending modulatory 
pathways. For example, dorsal horn neurons are less sensitive to inhibition by μ-
opioid agonists (Kohno et al., 2005) and there is a shift of descending 
serotonergic inputs towards facilitation (Vera-Portocarrero et al., 2006). The role 
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of serotonin receptors in nociceptive processing will be further discussed in 
chapter 4.  
 
1.10 Mechanisms of cooling-induced analgesia 
 
The application of cold temperature as analgesic therapy has been historically 
acknowledged by classical medical literature with reports from, for example, 
Hippocrates, Galen and Avicenna (cited in Aziz et al., 2000; Meeusen and 
Lievens, 1986). The application of cold temperatures remains a therapeutic 
option nowadays, with clinical trials showing cooling to provide relief for 
chronic back pain, dental pain, post-operative pain, orthopaedic pain and for 
paediatric pain (Belli et al., 2009; Greenstein, 2007; Henning and Firoz, 2010; 
Levy and Marmar, 1993; Ross and Soltes, 1995; Sauls, 1999).  
Cold therapy is also commonly used in the treatment of inflammation and soft 
tissue injuries in the horse.  More specifically, the application of cold has been 
recommended in the treatment of acute tendon injuries and suspensory desmitis 
(Hunt, 2001) and laminitis (van Eps and Pollitt, 2004). 
Plant-derived compounds that evoke a cooling sensation, such as menthol, 
have also been used as analgesic therapies. Topical mint oil is used to relieve 
neuralgia in both traditional Chinese and European herbal medicine (Patel et al., 
2007). Menthol has been reported to provide relief in human patients suffering 
from migraines (Borhani et al., 2007). Additionally, a role for using menthol in 
neuropathic treatment has recently emerged. Application of topical peppermint 
oil (containing 10% menthol) has been reported to be effective in a case of 
postherpetic neuralgia (Davies et al., 2002). In case reports, this compound has 
also been shown to be effective for the treatment of chemotherapy-induced 
neuropathic pain (Colvin et al., 2008) and enabling continuation of carboplatin 
chemotherapy otherwise limited by its neuropathic side effects (Storey et al., 
2010). Finally, menthol has been reported to alleviate cold allodynia in patients 
with neuropathic pain (Wasner et al., 2008).  
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A number of menthol-containing liniments are used for treating horses, for 
example for muscle sprains, but there is a lack of systematic analysis of their 
effectiveness in the veterinary literature.     
1.10.1 Neural circuits mediating cold temperature sensation 
Two distinct populations of primary afferent fibres that are responsive to cold 
temperatures have been described. One population is activated by low-threshold 
‘cool’ temperatures (of around 20ºC–35ºC) (Dubner et al., 1975; Kenshalo and 
Duclaux, 1977), whereas another population is activated by high-threshold 
noxious cold temperatures of <15ºC, which are generally perceived as painful 
(Georgopoulos, 1976; LaMotte, 1988). Similarly, experiments carried out in 
sensory neurons in culture have identified two distinct populations of cold-
sensitive neurons, one responding to low-threshold cool temperatures (with an 
activation threshold of around 29ºC) and one responding to high-threshold cold 
temperatures (with an activation threshold of around 20ºC) (Nealen et al., 2003; 
Reid et al., 2002; Thut et al., 2003).  
At the spinal cord level, processing of innocuous and noxious cold 
temperatures is also differentiated. A subset of neurons in the superficial dorsal 
horn responds specifically to innocuous cold temperatures and receive input 
mainly from Aδ fibres (Burton, 1975; Iggo and Ramsey, 1974). Noxious cold, on 
the other hand, activates a subset of dorsal horn neurons that also respond to heat 
and noxious pinch (Christensen and Perl, 1970). The ascending axons of cooling-
specific cells and those from noxious cold-activated multireceptive cells have 
different conduction velocities and different thalamic terminations (Craig and 
Dostrovsky, 2001). Moreover, distinct subpopulations of thalamic neurons have 
also been identified that respond to cool, but not noxious cold, or alternatively to 
noxious cold but not to cool temperatures (Bushnell et al., 1993) providing a 
physiological basis for findings from psychophysical studies in humans and 
monkeys that show perceptual differentiation between cool and noxious cold 
stimuli (Chen et al., 1996b; Rainville et al., 1999). 
Further evidence of independent processing of innocuous versus noxious cold 
has recently been provided in relation to how these inputs can be differentially 
modulated by the periaqueductal gray (Leith et al., 2010). In that study, 
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stimulation of the ventrolateral-PAG inhibited noxious responses to a cold 
stimulus. Moreover, innocuous cold information transmitted by non-nociceptive 
and wide-dynamic-range neurons remained unaltered, whereas noxious cold 
information transmitted by wide-dynamic range and nociceptive-specific neurons 
was significantly depressed.  
1.10.2 TRPM8-mediated cooling-induced analgesia 
Cloning and characterisation of the TRPM8 channel as the transducer of cool 
temperatures and of chemical cooling by natural compounds such as menthol or 
synthetic agents such as icilin and the menthol analogue, WS-12 (Ma et al., 
2008; McKemy et al., 2002; Peier et al., 2002) has provided a molecular target 
for investigating the mechanisms underlying cooling-induced analgesia. As 
described before, TRPM8 is expressed by a subset (10%–15%) of small diameter 
primary afferents in spinal DRG and in trigeminal ganglia and can be activated 
by cooling or by menthol (Madrid et al., 2006; McKemy et al., 2002; Peier et al., 
2002; Proudfoot et al., 2006; Reid et al., 2002). In the spinal cord, TRPM8 
activation by menthol or cooling results in an increased frequency but not 
amplitude of miniature excitatory postsynaptic currents (mEPSCs), suggesting 
that the channel’s location is presynaptic (Baccei et al., 2003; Tsuzuki et al., 
2004). 
TRPM8 activation, using peripherally (topically) or centrally (intrathecally) 
applied TRPM8 agonists menthol and icilin in the CCI model of chronic 
neuropathic pain, results in a reduction of sensitised reflex pain behaviours. 
Moreover, TRPM8 activation reduces the hyper-responsiveness generally 
observed in dorsal horn neurons following CCI surgery (Proudfoot et al., 2006). 
Similar results are observed upon cooling of the skin at the typical range of 
temperatures for TRPM8 activation (Proudfoot et al., 2006). Importantly, reflex 
responses were unchanged in both the uninjured contralateral limb of CCI 
animals and in normal animals without a sensitized pain state.  
Confirmation of the role of TRPM8 in cooling-induced analgesia was 
provided by the failure to observe icilin-induced reversal of sensitisation 
following antisense knockdown of TRPM8 (Proudfoot et al., 2006). 
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Icilin is also capable of producing analgesia in other chronic pain models, 
such as the Complete Freund’s Adjuvant inflammatory pain model and a 
neuropathic pain model of demyelination following the application of 
lysolecithin (Proudfoot et al., 2006). 
Further confirmation of a TRPM8-mediated analgesic effect in inflammatory 
models has been provided by a TRPM8 knockout study (Dhaka et al., 2007). The 
reduction in nocifensive behaviours produced by cooling the plantar\surface of 
the hind-paw (17ºC) in wild-type mice in which the hindpaw had been injected 
with formalin was absent in formalin-injected TRPM8-nulls (Dhaka et al., 2007). 
The effects of TRPM8 activation on central processing of pain have not been 
fully elucidated. However, it appears that TRPM8-mediated analgesia involves 
the activation of inhibitory glutamate receptors. Indeed, blockade of these 
receptors with selective mGluR Group II or III antagonists prevented the icilin-
mediated reversal of reflex behaviour sensitization (Proudfoot et al., 2006). This 
suggests that the central analgesic influence of TRPM8 activation in neuropathic 
pain is mediated by mGlu Group II and III receptors. Moreover, dorsal horn 
application of a mGluR Group II and III antagonist prevented the reduction in 
noxious stimulus-induced firing that was caused by peripheral application of 
icilin (Proudfoot et al., 2006).  Interestingly, application of the opioid receptor 
antagonist, naloxone, had no effect on icilin-mediated analgesia, suggesting that 
this phenomenon is independent of the classical opioid analgesic system 












1.11 Pain assessment in animals 
 
Objective and quantitative evaluation of pain in animals is an essential 
requirement in a variety of contexts ranging from veterinary clinical assessment 
to biomedical research. Pain assessments carried out by veterinarians are mostly 
subjective and therefore dependent on the skills and the expertise of the 
clinicians. In the past few years, there has been a major drive to develop 
objective pain assessment methods. They have mainly been based on 
physiological indices, evoked-responses to standard stimuli through quantitative 
sensory testing (QST) and behavioural quantification.   
1.11.1 Physiological measures of pain 
Pain is a stressor and as such it induces a biological stress response, involving 
the recruitment of the sympatho-adrenal and the hypothalamic-pituitary-adrenal 
systems. Physiological signs generally associated with pain include pupil 
dilatation, increased respiratory rate, changes in blood pressure and heart rate. 
Increases in heart rate can be associated with acute pain in many species 
(Dobromylskyj et al., 2000; Sanford et al., 1986), however, no differences in 
heart rate were found after arthroscopic surgery in horses (Raekallio et al., 1997). 
A reduction in heart rate variability (HRV) has been associated with pain in 
human infants and adults and it has been suggested that alterations in HRV may 
allow grading of the level of distress caused by pain (Cain et al., 2007; Lindh et 
al., 1999). A recent study evaluating the association between HRV and 
behavioural measures of pain in laminitic horses concluded that assessment of 
HRV offers reliable complementary evidence for pain assessment, although it 
may also be affected by other factors, such as movement, eating or mental state 
(Rietmann et al., 2004). Indeed, the main limitation of using physiological 
measures to assess pain is that they can be altered by numerous other factors and 
so they are not specific to pain. 
The physiological (endocrine) responses to painful procedures such as 
dehorning of cattle (McMeekan et al., 1998), castration and tail docking in lambs 
(Molony and Kent, 1997), have also been investigated. Measurement of stress 
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hormones such as cortisol has been useful in farm animal species as an indirect 
indicator of acute pain, although they present some limitations such as their lack 
of specificity to pain and the occurrence of a ‘‘ceiling-effect’’ (Mellor et al., 
2000; Molony and Kent, 1997). Measurement of plasma corticosteroid levels can 
be useful in conjunction with behavioural quantification when assessing the 
relative effects of a range of painful treatments that elicit injury-specific 
behaviours (Lester et al., 1996). Although, as mentioned above, these are indirect 
markers of pain, corticosteroid levels show graded responses to a range of 
procedures in lambs, and they correlate with behavioural markers, providing 
valuable supportive measures for the assessment of the relative pain intensity 
caused by such procedures (Lester et al., 1996).  
1.11.2 Quantitative sensory testing (QST) 
Quantitative Sensory Testing (QST) techniques are routinely used to assess 
particular aspects of sensory function in the evaluation of human neurological 
function. QST methods are psychophysical, non-invasive tests based on the 
application of standard physical stimuli and the end-point of the test is 
determined by the patient’s report of stimulus detection or perception of a change 
in its intensity.  
In animals, QST techniques have been adapted by using evoked nociceptive 
responses as a means of assessing changes in the sensitivity of tissues to 
potentially painful stimulation. In this context, QST involves the controlled 
application of standard noxious stimuli (mechanical or thermal) at particular 
anatomical locations in order to elicit a withdrawal or avoidance reaction, which 
determines the endpoint of the test. Common parameters measured in QST are 
reaction time (time elapsed from the onset of the stimulus to the withdrawal 
response) and the nociceptive threshold (the minimum magnitude of the stimulus 
required to elicit an avoidance reaction).  
QST techniques are commonly used to detect nociceptive thresholds in 
laboratory animals, with von Frey filaments and the Hargreaves’ hot plate being 
some of the instruments most frequently used to measure mechanical and thermal 
thresholds, respectively (Chaplan et al., 1994; Hargreaves et al., 1988). 
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For a particular QST technique or protocol to be reliable it needs to meet 
standards of repeatability and sensitivity. Repeatability can be defined as the 
level of agreement between measurements from a particular animal obtained by 
tests separated by short periods of time. Repeatability can be adversely affected 
by the animal learning to react to the stimulus before it becomes noxious 
(Chambers et al., 1990) and can depend on the precise location of the site that is 
stimulated (Haussler et al., 2007). Sensitivity refers to the ability of the method 
to detect changes in the measured quantity. Several studies have shown 
decreased mechanical nociceptive thresholds in animals following surgery or in 
animals with chronic pain, while other studies have shown increased nociceptive 
thresholds after analgesic treatment (KuKanich et al., 2005; Lascelles et al., 
1997; Lascelles et al., 1998; Ley et al., 1995; Slingsby et al., 2001). Another 
important aspect regarding the development of QST methods is that they have to 
be tailored to the behavioural characteristics of the species they are intended for. 
For example, a QST device that was attached to the animal’s limb using a cuff 
was successfully used in sheep, cattle and horses, but proved to be not suitable 
for juvenile pigs, requiring the development of an alternative method 
(Sandercock et al., 2009). 
It remains to be determined if any QST techniques are sensitive and robust 
enough to be clinically useful in animals as a means of monitoring disease 
progression or treatment efficacy. A number of factors can influence QST 
measurements. Mechanical nociceptive thresholds differ between tissues and 
body regions. For example, horses showed lower thresholds when measured on 
soft tissue than those measured on bony landmarks and thresholds were also 
lower over spines of cervical vertebrae than over those of the lumbo-sacral 
region (Haussler and Erb, 2006). Additional factors potentially affecting QST 
measurements are sex, height, weight and age, which is particularly relevant 
when QST measurements from clinical cases are compared with reference 
measurements made from control animals (i.e. those not in pain). It is important 
to appreciate that QST techniques provide measures of activation of nociceptor 
pathways, but not conscious perception of pain. However, they are important 
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tools, since demonstration of such activation is good evidence that pain may be 
experienced. 
1.11.3 Behavioural quantification 
Pain evokes changes in the behaviour of animals and behavioural assessment 
is crucial in the evaluation of pain in the veterinary patient (Hansen, 1997).  
Behavioural pain responses are aimed at enhancing the animal’s chances of 
survival. The simplest type of behavioural response to a painful stimulus is an 
automatic response or withdrawal reflex. Other responses are aimed at protecting 
the site of injury (e.g. guarding behaviour), minimising the pain, and promoting 
healing. Often, pain can be manifested as aggression, even in animals that have 
not displayed aggressive behaviour previously. The recognition of pain 
behaviours in animals will depend on a number of factors relating to the animal 
assessed, the observer making the assessment and the environment where the 
assessment is taking place. Animal-dependent variables include species, or even 
strain, sex, weight, age, social dominance, previous conditioning and overall 
health  (Hardie, 2000). Observer-dependent variables include knowledge of the 
species (or even the individual’s) behaviour, observational skills and attitudes 
towards pain in animals or in that particular species (Hardie, 2000).  
The effects of chronic pain on animals’ behaviour are more subtle and are 
difficult to both identify and quantify. Questionnaire based owner-reported 
changes in behaviour have been shown to provide a reliable tool for measuring 
chronic pain in dogs (Wiseman-Orr et al., 2006) but this approach might not be 
suitable for other species.  
In laboratory animal models of chronic pain, there appears to be activation of 
the HPA axis and ‘depressive-like’ symptoms similar to the responses produced 
by an inescapable stressor (Blackburn-Munro and Blackburn-Munro, 2001). A 
recent study in mouse models found that chronic pain caused long-term anxiety 
that persisted beyond the reversal of the hypersensitive period associated with the 
pain (Narita et al., 2006), and owner-reported behavioural changes have already 
shown that dogs suffering from chronic pain exhibit altered attitude and 




The affective component of the pain experience is acknowledged in a wide 
variety of animal species in terms of the neurobiology and the responses 
observed, but its measurement still remains a problematic. A novel approach that 
might prove useful for assessing the affective component of pain in animals 
could be through measurement of cognitive biases. In humans, emotions are 
associated with biases in information processing and research has revealed a 
relationship between negative affective states and pessimism and risk-aversion 
(e.g. Eysenck et al., 1987). Similar cognitive biases have been identified in rats 
and starlings, showing that stressed animals behave “pessimistically” when 
presented with an ambiguous stimulus (Brilot et al., 2010; Enkel et al., 2010; 
Harding et al., 2004). Although cognitive bias testing has not yet been shown to 
provide a reliable and sensitive method for assessment of chronic pain in 
animals, this methodology may well hold potential to investigate the affective 
component of chronic pain in animals. 
 
1.12 Overview of experimental work described in this thesis 
This PhD research project has two components. Firstly, a translational 
research component that aims to validate a novel QST method for assessing 
mechanical nociceptive thresholds in horses and establish whether neuropathic 
changes contribute to the chronic pain state observed in equine laminitis. The 
second component reports the discovery and investigation of an endogenous 
mechanism involving 5-HT1B receptors that facilitates the activation of TRPM8 
receptors and is predicted to enhance the analgesic influence they have been 















All experiments were carried out in accordance with the UK Animals 
(Scientific Procedures) Act 1986 and associated guidelines, and had received 
ethical approval from the University of Edinburgh ethical committee.  
With regard to the use of quantitative sensory testing in horses, it was agreed 
with the UK Home Office Inspectorate that any pain inflicted was of limited 
severity and of short duration, that the results were of potential benefit to the 
horses being tested, and that the studies did not need to be licensed as scientific 
procedures under the Animals (SP) Act (1986). 
2.1.1 Horses (laminitic and control) 
Seven horses suffering from refractory (chronic) laminitis for more than 2 
months were selected, with their owners’ consent, from patients referred to the 
Royal (Dick) School of Veterinary Studies, and from horses under the care of the 
International League for the Protection of Horses (now World Horse Welfare), in 
Aberdeenshire.  As the laminitic cases were drawn from a clinical caseload, 
therapy was not discontinued during the measurement period.  
Seven normal (control) horses, each one matched as far as possible with one 
of the laminitic horses for size, age, breed and sex, were selected, with their 
owners consent, from amongst horses in local riding schools or belonging to 
members of staff of the Royal (Dick) School of Veterinary Studies.  
2.1.2 Rats (chronic constriction injury (CCI) model of neuropathic pain) 
Wistar rats (Harlan, UK), weight between 180-250 g, were used in all 
experiments and were given access to food and water ad libitum and housed in 
accordance with Home Office guidelines. The chronic constriction injury (CCI) 
developed by Bennett and Xie (1988) was used as a model of neuropathic pain. 
Prior to surgery, animals were anaesthetised in about a 3% isoflurane/oxygen 
mixture for the entire procedure (Zeneca, Cheshire, UK); following exposure of 
the sciatic nerve, proximal to the trifurcation at mid-thigh level, four loose 
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ligatures of chromic cat gut (SMI AG, Hunningen, Belgium) were tied around 
the nerve, separated by 1 mm from each other. Following suturing, animals were 
allowed to recover in a protected and warm environment. CCI rats consistently 
developed mechanical and thermal reflex sensitisation, which peaked between 
days 9 and 16 post-surgery, when drug-testing or tissue collection were carried 
out. Development of sensitisation was always quantified behaviourally before 
carrying out further experiments.  
 
2.2 Quantitative sensory testing 
 
   Behavioural reflex responses to noxious mechanical stimuli were measured 
in horses using a newly developed hoof tester, as described below. In laboratory 
rats, behavioural reflex responses to punctate mechanical and noxious thermal 
stimuli were measured. Animals were habituated to the testing conditions before 
performing tests from which results were recorded. In laboratory rats, a 
minimum of 3 tests was performed for each type of method, in order to establish 
a consistent baseline before drug application or to measure development of 
sensitisation prior to tissue collection.  
2.2.1 Hoof testing 
A feedback-controlled, hydraulic hoof-tester was designed and built by Robert 
Clark (Consultant Engineer, Roslin, Midlothian) in order to measure hoof 
compression thresholds (HCTs) in horses. This instrument (Figure 2.1) is 
powered by a hydraulic motor that pumps fluid at high pressure through flexible 
lines to a piston and a stimulating probe connected to a load cell. For stimulation, 
the circular flat surface of the probe (14.0 mm diameter) was applied to the sole 
of the hoof and its position secured by applying the non-slip “anvil” of the hoof 
tester on the dorsal hoof wall.   A process controller (Eurotherm 3508, 
Eurotherm, UK) used the output from the load cell to set a maximum (safety cut-




Figure 2.1:  Hydraulically-powered and feedback controlled Hoof Tester. The 
diagram shows the hand piece, its connections to the control system and to a 
laptop computer. A hoof with surface marks on the sole is shown to indicate the 
location of the three sites (Toe, Medial and Lateral) used for testing. 
 
Testing was carried out in a quiet environment and, prior to testing, the horses 
were allowed 10 mins to become accustomed to the environment and habituated 
to the noise produced by the hoof tester. The horses were tested while standing 
squarely on a firm level surface and were restrained, using a head collar, by an 
experienced horse handler. All testing was performed after lifting the horse’s 
forelimb and holding it between the observer’s thighs, with the sole of the hoof 
facing up, as is standard practice in farriery. 
After cleaning the sole with a wire brush or hoof knife, the flat, circular, 
surface of the probe was applied to three sites; labelled Toe (half way between 
the apex of the frog and the white line),  Medial (to the apex of the frog) and 
Lateral (to the apex of the frog)  (Figure 2.1).  
Application of gradually increasing pressure was started and stopped by a 
single ‘on-off’ thumb-switch on the handle of the instrument. HCTs were 
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detected by the operator at the onset of a withdrawal response of the limb and 
pressure on the probe was immediately released. This response was generally 
detected as a sudden change in tone of the flexor muscles of the limb being 
tested. If the horse did not respond, pressure was automatically released through 
a relief valve, set to open at 85 kg/cm² to avoid damage. The rate of application 
and the setting for the pressure relief valve (maximum) were chosen after pilot 
studies in which the rate, duration and maximum pressure applied to ‘normal’ 
horses were gradually increased. Pre- and post-test lameness assessments, at a 
walk and trot, did not detect any adverse effects.  
The pressure exerted by the probe (kg/cm²) was calculated from the force 
measured by the, in-line, calibrated load cell and the contact area of the probe 
(1.54 cm²). Pressure during each test was monitored graphically and recorded to 
an Excel file on a laptop computer.  
Horses were tested in three test sessions separated by one week. Within each 
session, the forefeet of horses were tested twice at the three sites (Toe, Medial 
and Lateral). Thus, 12 tests were obtained per horse on each session and a total 
of 36 tests per horse.  Eight (8) readings were not successfully recorded due 
either to operator error or failure to get the horse to cooperate.  In total there were 
250 measurements from the laminitic group, and 246 from normal animals. 
2.2.2 Mechanical allodynia (von Frey filaments test) 
Sensitivity to mechanical stimuli was assessed in laboratory rats by measuring 
the 50% paw withdrawal threshold (PWT) to calibrated Semmes-Weinstein von 
Frey filaments (Stoelting, Illinois, USA). Animals were placed on a raised mesh 
grid and covered with a clear plastic box in order to contain them without 
impeding their free movement. Von Frey filaments were applied in a series of 
increasing calibres, perpendicularly to the plantar surface of the hind paws until 
they bent. PWTs were recorded as the pressure (mN/mm2) required to elicit a 
withdrawal response to ≥50% of applications.  A minimum of 6 applications of 
each filament to the foot was used to establish the withdrawal threshold. A 
pressure of 1,609.52 mN/mm2 was set as the maximum since this force was 
sufficient to lift the paw. 
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2.2.3 Thermal sensitivity (Hargreaves’ test) 
Sensitivity to a noxious thermal stimulus in laboratory rats was assessed by 
measuring paw withdrawal latency, in seconds (s), in response to an infrared 
beam (55°C, Hargreaves’ thermal stimulator, Linton Instrumentation, Diss, UK) 
directed to the mid-plantar glabrous surface of the hind paw. Withdrawal 
responses were only noted when they indicated clear nocifensive behaviour 
(typically manifested as a “flick” of the paw, sometimes followed by licking) and 
their latencies were recorded to the nearest 0.1 s. A maximum cut-off latency of 
20 seconds and a minimum of 5 mins recovery time between tests were 
established in order to prevent tissue damage and sensitisation.  
 
2.3 Drug administration in laboratory rats  
 
Drug administration in laboratory rats was carried out by the intrathecal route. 
Drug effects were assessed by quantification of threshold to noxious stimuli. A 
minimum of three pre-drug tests were performed to produce a mean baseline 
value. Testing commenced 15 mins after injection to allow recovery from 
anaesthesia and avoid a false analgesic effect and tests were repeated every 10 
mins for 60 mins for thermal and mechanical stimulation. An n of 6 rats was 
used for each drug. 
 
2.3.1 Intrathecal application of drugs 
Drugs were administered by percutaneous puncture into the L5/6 
intervertebral space of briefly anaesthetised (3% isoflurane/oxygen over the 
course of the injection) in CCI rats, at the peak of behavioural reflex 
sensitisation, in a volume of 50 μl, using a 0.5 ml syringe with 29-gauge needle 
(BD Biosciences, Oxford, UK). The vehicle for drug injections was saline with 
up to 0.5% dimethyl formamide, which has been extensively characterised 
previously in the laboratory as having no effect on behavioural reflex responses.  
In order to investigate the possibility of an interaction between the TRPM8 
receptor and the 5-HT1B serotonin receptor, the following drugs were applied 
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intrathecally: the TRPM8 agonist, icilin (3,4-dihydro-3-(2-hydroxyphenyl)-6-(3-
nitrophenyl)-(1H)- pyrimidin-2-one, Bioscience, Bristol, UK 2.5 nmol), the 
potent, selective 5-HT1B agonist CP 94253 (5-propoxy-3-(1,2,3,6-tetrahydro-4-
pyridinyl)-1H-pyrrolo[3,2-b]pyridine hydrochloride, Tocris, 2.5 nmol), the 
selective 5-HT1B antagonist, SB2242289 (hydrochloride (1'-methyl-5-[[2'-
methyl-4'-(5-methyl-1,2,4-oxadiazol-3-yl)biphenyl-4-yl]carbonyl]-2,3,6,7 
tetrahydrospiro[furo [2,3-f]indole-3,4'-piperidine hydrochloride, Tocris, 100 μM) 
and the PLD (and PKC) inhibitor,    calphostin-C ((1R)-2-[12-[(2R)-2-
(benzoyloxy)propyl]-3,10-dihydro-4,9-dihydroxy-2,6,7,11-tetramethoxy-3,10-
dioxo-1-perylenyl]-1 methylethylcarbonic acid 4-hydroxyphenyl ester, Tocris, 
0.65 nmol). 
 
2.4 Electron microcrographic analysis of nerve morphology 
 
Lateral digital nerves (3 cm long segments) from five horses euthanized on 
welfare grounds due to refractory laminitis were dissected from the forelimb at 
the level of the proximal sesamoid bone and fixed for 4 h in 2.5% glutaraldehyde 
and 2% paraformaldehyde in 0.1 M sodium cacodylate buffer (pH 7.3) post-fixed 
in OsO4 and embedded in Araldite. Control tissue was collected and treated as 
above from four horses which had no previous history of forelimb lameness and 
were euthanised for clinical reasons other than forelimb pathology. 1 μm resin 
sections of the nerve were stained with Toluidine Blue and three fascicles were 
chosen at random by bright field microscopy. Ultra-thin (80 nm) sections were 
stained with uranyl acetate and lead citrate for examination and image capture 
(done by Steven Mitchell) using a Phillips BioTwin electron microscope (FEI, 
UK Ltd, Cambridge, UK). Identity-concealed images of randomly selected 
fascicles (areas ranging between 6,732 and 47,215 μm2) were analysed using 
Image Tool 3.0 (UTHSCSA, USA).  
In order to investigate any differences between normal and laminitic digital 
nerves that might reflect oedema and therefore affect the quantification of axon 
density, the total area of the nerve sections and the percentage of the nerve area 
occupied by nerve fascicles were calculated. The number and axon diameter of 
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intact myelinated fibres was calculated as well as the percentage of damaged 
myelinated fibres, defined as those with a severe disruption of the myelin sheath 
and/or axonal degeneration. Myelin sheath thickness was measured and G-ratio 
of axons was calculated by dividing the axonal diameter by the total diameter of 
axon plus myelin sheath. The proportion of A-fibres with continuous Schwann 
cell cytoplasm (a nerve morphology abnormality previously described by Court 
et al. (2004) was also calculated. 
C-fibres were identified as small diameter unmyelinated fibres, often 
surrounded when in bundles by Schwann cell cytoplasm. The total number of C-
fibres was calculated as well as the percentage of solitary unmyelinated fibres 
and the number of unmyelinated fibres per Remak bundle.    
 
2.5 Immunohistochemical analysis of protein localisation 
2.5.1 Tissue processing for immunohistochemistry 
DRG from cervical segments seven (involved in forelimb innervation) and 
four (not involved in forelimb innervation) from the same horse were obtained 
post-mortem from five laminitic horses and four control horses for ATF-3 and 
NPY immunohistochemical localisation and four laminitic horses and four 
control horses for TRPM8 immunohistochemical localisation. The tissue was 
embedded in OCT embedding matrix (CellPath plc., Powys, Wales, UK) and 
fast-frozen in isopentane suspended in liquid nitrogen or dry ice before storing at 
–80ºC.  
2.5.2 Immunohistochemistry procedure 
Cryostat sections of DRGs (15 μm) were thaw-mounted on poly-L-lysine 
slides (BDH Merck Ltd., Poole, UK). Only every sixth section was selected, in 
order to ensure that measurements were taken only once for each cell. DRG 
sections were pre-incubated for 1 h (2 h for TRPM8 immunohistochemistry) at 
room temperature in 0.1 M PBS buffer, pH 7.4, containing 0.2% Triton X-100, 
2-4% fish skin gelatin and 10% normal goat serum; and then incubated overnight 
at 4 °C (or at room temperature for TRPM8 immunohistochemistry) with 
primary antibodies diluted in the same buffer. For co-localisation of the peptide 
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NPY, the activating transcription factor ATF-3 or the TRPM8 receptor with the 
myelinated cell marker neurofilament 200 kDa (NF-200), or either of the 
unmyelinated cell markers, peripherin or isolectin B4 (IB4) binding target, 
antisera/lectin were used at the following concentrations: rabbit anti-NPY (1:250; 
Peninsula Laboratories Inc, Belmont, CA, USA); rabbit anti-ATF-3 (1:300; 
Santa Cruz Biotechnology, Santa Cruz, CA, USA); rabbit anti-TRPM8 (1:200; 
Alomone, Jerusalem, Israel); mouse monoclonal anti-NF-200 (1:400 or 1:1000 
for co-localisation with TRPM8; clone N52; Sigma); mouse monoclonal anti-
peripherin (1:250 or 1:500 for co-localisation with TRPM8; Chemicon 
International, Harlow, UK); IB4 from Bandeiraea simplicifolia (1:400; Sigma). 
Sections were then washed in buffer and incubated at room temperature for 2 h 
(3h for TRPM8 immunohistochemistry) in in 0.1 M PBS, pH 7.4, buffer 
containing  4% fish skin gelatin and 10% normal goat serum with appropriate 
secondary antibodies: Alexa Fluor 488-labelled goat anti-mouse IgG (1:500), 
Alexa Fluor 568-labelled goat anti-rabbit IgG (1:1000), Alexa Fluor 488-labelled 
streptavidin (1:200), Alexa Fluor 488-labelled goat anti-rabbit IgG (1:750) and 
Alexa Fluor 568-labelled goat anti-mouse IgG (1:750) (all from Molecular 
Probes Europe BV, The Netherlands). 
Finally, sections were washed three times in 0.1 M PBS before cover-slipping 
with Vecta-Shield (Vector Laboratories, Burlingame, CA, USA). Control 
sections were processed as above omitting the primary reagents. Observations 
were made and sections photographed on an Olympus microscope equiped for 
epifluorescence. For ATF-3 and NPY immunohistochemical localisation, 
sections were visualised and photographed under a Leica TCSNT confocal 
microscope (Leica Microsystems GMBH, Germany). All counts of profiles 
labelled for immunopositive cells were (following blinding) on five or randomly 
selected sections of DRG from each of the animals in each group.  Image 
analysis was performed with Image Tool and ImageJ (RSB-NIH, Maryland, 
USA). Results were expressed as the proportion of labelled profiles per total 
number of single or double-labelled profiles from all sections, 95% confidence 




2.6 Western blot analysis of proteins 
2.6.1 Tissue removal and processing for Western blot 
DRG and spinal cord tissue from L4-L6 was collected from live animals 
under deep anaesthesia in 3% isoflurane/oxygen. A laminectomy was performed 
to expose the spinal cord, and tissue was dissected out. Spinal cord from CCI rats 
was hemisected into ipsilateral and contralateral sections. Ipsilateral and 
contralateral DRGs were also collected separately. Naïve tissues were collected 
from the same anatomical region but without hemisecting the spinal cord and 
with the left and right DRGs being pooled together. In order to minimise 
degradation of tissues, these were collected onto ice-cold foil, weighed, and 
promptly homogenised in 20 volumes of ice-cold Laemmli lysis buffer (e.g. 1 ml 
of buffer to 0.05 mg of tissue)  (85 % Tris buffer (tris-
hydroxymethylaminoethane, 50 mM, pH 7.4, Sigma Chemical Co., UK), 5 % 
mercaptoethanol (Sigma), and 2 % sodium dodecyl sulphate (SDS, Sigma)). 
Following homogenisation, whole cell lysates were heated to 100 ºC for 5 mins 
and then centrifuged for 10 mins at 12,000 g and 4 ºC. Supernatants were 
aliquoted and stored at –20ºC.  
2.6.2 Western blot procedure  
Western blotting was used to detect changes in protein levels in DRG or 
spinal cord tissue from CCI and naïve rats.  
Proteins were separated by SDS-PAGE (sodium dodecyl sulphate-
polyacrylamide gel electrophoresis) using the NuPage XCell SureLockTM 
Minicell gel electrophoresis system (Invitrogen, Paisley, UK). Samples (5-8 μl) 
were mixed with 1-2 μl loading buffer (0.04 % w/v Bromophenol Blue in 
glycerol) and loaded into wells on 4 – 12 % Bis-Tris NuPage gels (Invitrogen). 
Pre-stained standard molecular weight proteins (SeeBlue Plus, Invitrogen) were 
run alongside as a guide. Samples were electrophoresed using appropriate MOPS 
running buffer (NuPage, Invitrogen) under a 200 V potential difference. Proteins 
were transferred to a polyvinylidene difluoride Immobilon-PSQ membrane 
(Millipore, Watford, UK) at 30 V in transfer buffer (5 % NuPage transfer buffer, 
10% methanol) for 90 mins. Efficacy of transfer and protein loading was 
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assessed by staining membranes with Coomassie blue (0.1 % in 30 % methanol, 
10 % acetic acid, GE Healthcare Ltd., UK). Following de-staining of the 
Coomassie blue with 30 % methanol/10 % acetic acid in distilled water, 
membranes were incubated in appropriate blocking buffers to block non-specific 
activity (Table 2.1). Membranes were then washed and incubated with 
appropriate primary antibodies as described in Table 2.1. Blots were also probed 
with antibody for the ubiquitous housekeeping enzyme glyceraldehyde-3-
phosphate dehydrogenase (GAPDH, Chemicon) to enable protein level 
normalization. Following primary antibody incubation, membranes were washed 
and incubated with peroxidase-linked secondary antibodies: goat anti-rabbit (Cat 
No. AP182P, 1:7,500; Chemicon), goat anti-mouse (Cat No. AP192P, 1:10,000; 
Chemicon) or donkey anti-goat/sheep (Cat No. AB324P, 1:10,000; Chemicon) 
made up in blocking buffer, for 50 mins at room. Staining was detected by 
peroxidase-linked chemiluminescent substrate and film development (ECL; Cell 
Signalling, MA, USA, Hyperfilm; GE Healthcare UK Ltd., Bucks, UK). 
Following quantitative densitometry, using Adobe Photoshop, arbitrary grey 
scale values for protein bands of interest were calculated as a percentage of that 
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2.7 Cell culture 
2.7.1 Dorsal root ganglion neuron culture 
Dorsal root ganglion neuron culture was carried out by Andrew Allchorne as 
follows. Coverslips were coated with poly-D-lysine (Sigma). DRG from adult 
rats (normally 10-14 per animal) were harvested and dissected into Dulbecco’s 
modified Eagle Medium (DMEM) supplemented with 10% FBS and 
Penicillin/Streptomycin (Invitrogen). After centrifuging for 3 mins at 1,000 g, 
medium was removed and collagenase (5 mg/ml) and dispase (1 mg/ml) (Roche) 
added and incubated at 37ºC for 2 h. Following centrifugation at 1000 g for 5 
mins, the supernatant was discarded and the precipitate was digested in 0.25% 
trypsin (Invitrogen) at 37ºC for 8 mins.  Then, 0.25% trypsin inhibitor 
(Invitrogen) was added and preparation was centrifuged at 1,000 g for 5 mins. 
The supernatant was removed and the pellet was washed with DMEM/10% FBS 
and re-centrifuged at 1,000 g for 5 mins. After removing the supernatant, DRGs 
were re-suspended in DMEM/10% FBS. Following the addition of DNAse I 
(Sigma), DRG preparations were triturated to dissociate to a single cell 
suspension.  This suspension was then filtered through a 15% BSA (Sigma) 
solution by centrifugation at 1,000 g for 10 mins and then re-suspended in 
DMEM/10% FBS. The cell suspension was then purified by passage through a 
percoll solution (1ml HBSS (x10), 1ml 0.35% NaHCO3, 5 ml distilled H20, 30l 
1N HCl and 3ml Percoll (1.13g/ml solution; Sigma) at 1,000 g for 10 mins at 
4oC. 
The lower percoll layer was re-suspended in DMEM/10%FBS and 
centrifuged for 10 mins at 1,000 g. The cell pellet was then re-suspended in 
plating medium (GIBCO Neurobasal (Invitrogen, supplemented with GIBCO B-
27 Penicillin/Streptomycin (1:100), L-glutamine (200mM, Invitrogen) NGF 
(50nm/ml; BMB) and Ara-C (Cytosine β-D-arabinofuranoside hydrochloride, 
1:1000; Sigma C-6645) in an appropriate volume for the number of cells, as 
assessed by using a haemocytometer. Following plating, cells were incubated at 




2.7.2 Stable TRPM8 HEK293 culture 
A line of HEK293 cells stably expressing human TRPM8 was generated by 
other laboratory members. 24-well plates (Greiner) were coated with fibronectin 
(0.01mg/ml; Sigma) in distilled water and allowed to air-dry in the fume-hood 
for 45 minss.  
Stock cultures of TRPM8-expressing HEK293 cells were trypsinised with 
Tryple Express (Invitrogen) for 1 min and incubated at 37°C for 6 mins. 8ml of 
complete DMEM without Phenol Red (Invitrogen), containing 10% foetal calf 
serum (Harlan/Sera Lab, UK) were then added to the flask, and cells were 
counted before plating out and subculture. Final volume was made up using 
complete DMEM without Phenol Red. Cells were plated out at a density of 1.5 x 
105 cells/well (1ml/well) and incubated at 37°C. 60-80% confluency was reached 
after approximately 24 h.  
2.7.3 Transient cell transfection 
In order to investigate the possible in vitro interactions between the TRPM8 
receptor, the 5-HT1B receptor and PLD1, stable TRPM8 HEK293 cells were 
transfected with FLAG-tagged 5-HT1B receptor and HA-tagged PLD1 cDNA  
(constructed by Eve Lutz and Mike Frohman, respectively) in pcDNA3.1 
expression plasmid or empty vector. FuGENE6 transfection reagent (Roche) was 
added in a ratio of 3:1 to cDNA and incubated at room temperature for a 
minimum of 5 mins before transfection using the FUGENE 6-cDNA complex 
according to the manufacturer’s recommended protocol.  
Cells were then grown for 48 hours at 37C in a 5% CO2, 95% O2 humidified 




Cells were quiesced for 4 h in 10 ml of DMEM per 175 cm2 flask. Cells were 
then homogenised in IP buffer (20% glycerol, 1% CHAPS, 1% sodium 
deoxycholate, 1mM sodium orthovanadate in HEPES 20 mM/NaCl 150 mM 
buffer, pH 7.4), with 1:100 protease inhibitor cocktail 3 (Calbiochem, UK). 
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Flasks were kept on ice for 30-45 mins and then cells were scraped, removed and 
centrifuged at 10,000 g for 10 mins at 4ºC to pellet insoluble materials. 
Supernatants were then decanted and pre-cleared with Protein G-Sepharose (40 
μl/ 2ml supernatant; Sigma, UK) while rotating at 4ºC for 45 mins, in order to 
remove any proteins that non-specifically bind to the beads. Following a pulse-
spin the supernatant was removed and Protein G-Sepharose beads (40 μl/ml) 
added together with the relevant antibody. For immunoprecipitation of the 
FLAG-tagged 5-HT1B receptor, a mouse monoclonal anti-FLAG M2 antibody 
was used (4.32 μl/ml; Sigma-Aldrich). For TRPM8 immunoprecipitation, an 
anti-TRPM8 rabbit antibody was used (7.5 μl/ml; Alomone). For 
immunoprecipitation of HA-tagged PLD1, a mouse monoclonal anti-HA 
antibody (clone 12CA5) was used (5 μl/ml; Roche).  As controls, non-immune 
IgG of the same species as the antibody were used for immunoprecipitation. 
Primary antibodies and non-immune IgGs were incubated with samples 
overnight at 4ºC. Samples were then centrifuged and the supernatants discarded. 
The beads were then washed three times with ice-cold IP buffer after which all 
liquid was removed and a volume of Laemmli buffer equal to that of beads was 
added to each tube. The samples were then thoroughly mixed and heated at 70ºC 
for 10 mins and then either used immediately or stored at -20 ºC. Binding 
partners within the complex of interest were detected by Western blot, (as 
described in 2.6.2) running 15-20 μl of sample (5-10 μl for totals) and 2 μl of 
loading buffer. 
 
2.9 Calcium fluorometry 
 
Stable TRPM8 HEK293 cells with appropriate cDNA transfections were 
cultured in 1ml medium per well of a Greiner 24-well clear flat-bottomed plate 
for 48-72 h before assay (as described on 2.7.2 and 2.7.3).  On the day of assay 
700 μl medium was removed from each well prior to the addition of 100 μl of 
calcium indicator dye solution (Calcium 4 Dye, Molecular Devices, CA, USA), 
pre-warmed to 37oC, to the remaining 300 μl. Calcium 4 Dye was dissolved in 
concentrated form in dimethylsulphoxide (Sigma D2650) and aliquoted at -20oC. 
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When required an aliquot was made up in 2xSPZ medium according to the 
manufacturer’s instructions at a concentration equivalent to 4 μM. 2x SPZ 
consists of divalent-free Hanks’ Balanced Salt Solution (Gibco 14175) with 1.8 
mM Ca2+ (900 μl of 1M volumetric standard CaCl2; BDH 19046) and 0.8 mM 
Mg2+ (82 μl of 4.9 M volumetric standard MgCl2 (Sigma Diagnostics 104-20)) 
with 25 mM HEPES pH 7.40 (12.5 ml of 1 M HEPES (Sigma H3375) adjusted 
to pH 7.40 with NaOH) per 500 ml containing 500 mM (±) sulphinpyrazone (1 
ml of 0.25 M solution of sulphinpyrazone, Sigma S9509) in N,N-
dimethylformamide (Sigma D4551) per 500 ml. 
Plates were incubated at 37oC for 45 mins in the dark in a 95% O2 / 5% CO2 
atmosphere. Plates were then transferred to a shallowly immersed platform in a 
water bath at a holding temperature of 28oC for 5 mins to ensure temperature 
equilibration.  A 50 μl aliquot of 250 mM HEPES pH 8.50 was then added to 
each well (which effectively reversed the acidification of the medium due to 
metabolism and the blockade by sulphinpyrazone of the non-specific anion 
export carrier, restoring a pH of 7.4) and incubation was continued for a further 2 
mins at 28oC.  
With the plates still at 28oC, compounds were added in volumes from 1-4 μl 
per well from generally 100x concentrated solutions in dimethylformamide 
yielding final vehicle concentrations from 0.25 – 1 % (which were documented 
in other studies in the lab to have no effect alone on Ca2+ regulation). 
Intracellular Ca2+ was measured using a Varioskan Flash fluorometric plate 
reader (Thermo Laboratory Instruments). The typical standard plate layout 
contains triplicate determinations of no compound (or control treatment) and five 
measurements following TRPM8 agonist administration with four different 
additional conditions being applied in each case. Ten readings from each well 
were taken 30 sec apart at excitation 488 nm, emission 519 nm in bottom-reading 
mode for the plate reader. Fluorescence reflecting intracellular Ca2+ levels 
(arbitrary units) was recorded using the SkanIt software (Thermo Fisher 
Scientific, Waltham, MA, USA). Data was analysed as percentage-increase over 




The following drugs were used: the TRPM8 agonist icilin (0.25 μM, Tocris), 
the TRPM8 selective channel bolcker AMTB (N-(3-aminopropyl)-2-[[(3-
methylphenyl) methyl]oxy]-N-(2-thienylmethyl)benzamide hydrochloride salt, 
Tocris 3989), the 5-HT1B agonist CP 94253 (2 μM; Tocris) , the 5- HT1B 
selective antagonist SB224289 hydrochloride (1'-methyl-5-[[2'-methyl-4'-(5-
methyl-1,2,4-oxadiazol-3-yl)biphenyl-4-yl]carbonyl]-2,3,6,7tetrahydrospiro[furo 
[2,3-f]indole-3,4'-piperidine hydrochloride, Tocris, 100 μM), the PLD inhibitors 
CAY10593 (also known as VU0155069, 0.5 μM; Cayman Chemicals, Michigan, 
USA), halopemide (4 μM, Cayman), raloxifene (25 μM; Tocris) and calphostin C 
(2.5 μM; EnzoBioscience); the PKC inhibitor BIM1 (2.5 μM; EnzoBioscience); 
the Phosphoinositide-3-kinase (PI 3-K) inhibitor, wortmannin (30 μM; Tocris), 
the synthetic PLC activator m-3M3FBS ( 2.5 μM, Tocris) and the PLC inhibitor 
U-73122 (10 μM; EnzoBioscience). 
 
2.10 Calcium imaging of DRG cells 
 
Ratiometric calcium imaging was performed with FURA-2/AM dye 
(Invitrogen) and analyzed using Simple-PCI software (Compix Inc.). Cells were 
loaded with 3.5 µM Fura-2/AM (Invitrogen, Paisley, UK) in DMEM 
supplemented with 10% pluronic acid (Invitrogen) for 20 mins. Following 
washing, coverslips were placed in a recording chamber containing 2.5 ml of 
DMEM. An Olympus BX50WI microscope was used (20x magnification 
objective lens). Pairs of images were collected every 5 seconds at alternating 
exposures of 340 nM and 380 nM using a Photonics LPS150 monochromator 
and imaged using a Hamamatsu ORCA-ER CCD camera.  
Coverslips were superfused with DMEM buffer at approximately 0.5 ml/min. 
Drugs were applied via a gravity driven perfusion system that allowed rapid 
exchange of solutions. Temperature was maintained at 28.5°C for the duration of 
the experiment. 
Following selection of a suitable field of view, recording was initiated. The 
effects of drugs were compared through paired permutations. After a baseline 
period of 5 mins the first drug treatment was applied for 10 mins, followed by a 
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10 mins wash-out period and the second drug treatment. The following drugs 
were used: icilin (1.25-2.5 µM), CP 94253 (3 µM), calphostin C (2.5 µM) and 
BIM1 (2.5 µM).  
For analyisis, following subtraction of background fluorescence, the ratio of 
fluorescence at 340 nm and 380 nm was calculated. A response was designated 
as an increase in fluorescence ratio from baseline consistent with the timing of 
application. Only icilin-responsive cells were selected for the purposes of 
quantifying responses to further treatments. Area under the curve was determined 




Statistical analyses were carried out as specified in each case below. In all 
cases p < 0.05 was taken to indicate statistical significance, and degrees of 
freedom associated with any tests are denoted by subscripts. 
2.11.1 EM and ATF-3/NPY immunohistochemistry analysis 
Differences in percentages of damaged A-fibres, A-fibres with continuous 
Schwann cell cytoplasm and solitary unmyelinated fibres between laminitic and 
control horses were analysed using simple logistic regressions. Axon diameter of 
myelinated and unmyelinated fibres and myelin sheath thickness data comprised 
repeated measures, therefore, linear mixed effect models were used to determine 
any difference in these parameters between laminitic and control horses. Multiple 
measurements per horse were also taken of the number of fibres per Remak 
bundle but as the data were integers, differences in the number of fibres per 
Remak bundle were analysed using generalised linear mixed-effect models with 
Poisson errors. Differences in the total nerve area occupied by fascicles between 
control and laminitic horses were investigated using a Student’s t-test, and 
differences in the percentage of nerve area occupied by fascicles between normal 
and laminitic horses by general linear models with binomial errors. Mann-
Whitney non-parametric tests were used to analyse fibre density. All analyses 
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were carried out in S-PLUS 6.0 (Insightful, Seattle, USA) and SigmaStat 2.03 
(SPSS Inc., USA). 
2.11.2 Hoof tester data analysis 
Expert advice on this evaluation was taken from Iain McKendrick (BioSS). 
Preliminary statistical analysis to investigate differences in hoof compression 
thresholds between normal and laminitic horses was carried out using a Linear 
Mixed model (Brown and Prescott, 1999), treating Pressure as the response 
variable; Group (laminitic or control) and the other variates: Session (1, 2 or 3), 
Leg (left or right), Site (toe, medial, or lateral) and Test (1st or 2nd) and all 
interactions nested within Group, fitted as fixed effects; and a factor encoding the 
sample matching (Matching), its interaction with Group (which is statistically 
equivalent to fitting an individual horse effect) and all possible interactions of the 
latter term with the other fixed effects, included as random effects.  The fixed 
effects were progressively removed in a stepwise-type process until only 
statistically significant factors remained. 
In order to better appreciate the sources of variation, data for the two groups 
were separately analyzed using Linear Mixed models which treated all relevant 
factors and their interactions as random effects. The estimated variance 
components are used to summarise the sources of variability in the data. The 
sixteen estimated random effects can be found in Table 3.2.  Parsimonious 
models were also produced, by excluding components that were not associated 
with a statistically significant improvement in model fit, as quantified by the 
statistical deviance.  The values of the mean and variance components for each 
group of horses were used, in statistical models, to allow prediction of the 
benefits of reducing different sources of variability (errors) and prediction of the 
numbers of animals and tests that would be required to show treatment effects of 
various sizes. 
To assess the repeatability of the method, intra-class correlation coefficients 
were determined by calculating the ratio of population variability to the total 
variability estimated from the final fitted model.  All mixed modeling was 
carried out using Genstat 10th edition (VSNi, Hemel Hempstead, UK).  Intra-
class correlation coefficients, the sensitivity, specificity and area under the 
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Receiver-Operator Curve were estimated parametrically using these variance 
components; calculations were carried out in Excel 2003. 
2.11.3 QST data analysis 
Behavioural data are stated as mean ± standard error of the mean (SEM) and p 
values <0.05 are considered significant. Parametric statistical tests were used to 
analyse data generated from the Hargreaves’ thermal test. Differences in thermal 
sensitivity between the paw ipsilateral to nerve injury and the contralateral paw 
were analysed using Student’s t-test. Effect of drug treatment was analysed by 
One-Way ANOVA followed by Dunnett’s post-hoc multiple comparisons test. 
The equivalent non-parametric tests for mechanical sensitivity were Wilcoxon 
rank test for ipsilateral: contralateral differences, and Friedman Repeated 
Measures ANOVA followed by Dunn’s test for drug effects.  
2.11.4 Western blot analysis 
Western blot densitometric values were compared by One-Way ANOVA. 
2.11.5 TRPM8 immunohistochemistry  
Double labelling cell counts were analysed by One-Way ANOVA. 
2.11.6 Calcium fluorometry analysis 
Mann-Whitney U tests were carried out to determine differences between 
each drug and their control treatment. Analysis was performed in GraphPad 
Prism, version 5.02 for Windows. Relative fluorescence was plotted as mean ± 
SEM. 
2.11.7 Calcium imaging analysis in DRG cells 
Areas under the curve for paired-drug treatments were calculated compared 








Chapter 3: NEUROPATHIC CHANGES ASSOCIATED 
WITH EQUINE LAMINITIS PAIN 
 
3.1 Introduction 
3.1.1 Impact of laminitis on equine welfare 
Equine laminitis is a common cause of lameness involving one or more feet 
(Dyson, 2003); the forefeet being more frequently affected presumably because 
the forequarters support about 65% of the body weight (Pollitt, 2000). This 
disease is characterised by the disruption of the dermo-epidermal bond between 
the distal phalanx and the inner hoof wall, which may result in the displacement 
and “sinking” of the distal phalanx within the hoof capsule causing structural 
damage, unrelenting pain and a characteristic lameness (Kyaw-Tanner and 
Pollitt, 2004). 
The importance of this disease as a major concern for the equine industry and 
its impact on equine welfare has been historically acknowledged. One of the 
earliest descriptions of equine laminitis was written by the Greek philosopher, 
Aristotle (384-322 BC), although he referred to it as “barley disease” (cited in 
Wagner and Heymering, 1999). In the nineteenth century, William Percivall, the 
British cavalryman and author of the book Hyppopathology-Lameness in the 
Horse (1871) stated that, of all the conditions affecting the horse, “there is no 
one in which his pain, while poignant to the extreme, is apt to be so protracted” 
as equine laminitis.  
Laminitis is a relatively common disease. A study identified a prevalence of 
7.1% in the UK (Hinckley and Henderson, 1996) and a survey carried out in the 
USA found that 13% of horse owners/operations had reported laminitis in their 
horses over the previous year (U.S.D.A., 2000).  
A further factor contributing to the impact of laminitis on equine welfare is 
that no therapeutic regime is able to arrest or prevent its onset and the 
developmental phase of the disease is not clinically recognisable (Bailey et al., 
2004; Pollitt et al., 1998). Finally, pain associated with laminitis can be difficult 
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to control using conventional anti-inflammatory agents and euthanasia on 
welfare grounds is not uncommon (Herthel and Hood, 1999; Swanson, 1999). 
3.1.2 Structure of the laminar structures of the inner-hoof wall  
The innermost layer of the hoof wall and bars of equines, known as the 
stratum lamellatum (layer of leaves), comprises 550-600 primary epidermal 
lamellae (PEL) which project from its surface in parallel rows. Each PEL is 
further divided, increasing its surface area, into 150-200 secondary lamellae 
(Pollitt, 2004). The distal parts of primary and secondary lamellae are orientated 
towards the distal phalanx and interdigitate with the primary and secondary 
dermal lamellae. The dermo-epidermal interface is comprised by the basement 
membrane, a sheet of extracellular matrix, which provides a structural bridge, 
attaching the basal cells of the lamellar epidermis and the connective tissue 
fibrils that arise from the dorsal surface of the distal phalanx (Pollitt, 2004). 
During the developmental and acute phases of laminitis, degradation of the 
basement membrane occurs, with loss of the attachment between epidermal and 
dermal lamellae (Figure 3.1). Subsequent structural damage may take place, 
leading to the rotation and “sinking” of the pedal bone within the hoof capsule. 
Radiographic measurement of this displacement (Figure 3.2) has been reported to 
be a significant prognostic parameter of the disease (Cripps and Eustace, 1999).  
 
 
Figure 3.1: Haematoxylin/Eosin stained histological sections of (a) the intact 
lamellar structures in a normal horse showing the normal interdigitating of 
dermal (arrowhead) and epidermal (arrow) laminae 10x. And (b), showing the 
disruption and separation of the secondary epidermal (arrow) and secondary 
dermal (arrowhead) laminae in acute laminitis 10x. Scale bars= 100 μm. (From 






Figure 3.2: Latero-medial radiograph of equine digit of a laminitic horse 
showing rotation and vertical displacement (‘‘sinking’’) of the third phalanx. 
Radiographic measures include displacement (D) which is the distance (mm) 
between the proximal limit of the dorsal hoof wall and the extensor process of 
the distal phalanx, and the rotation angle (a) which is the angle between the 
dorsal surface of the distal phalanx and the dorsal surface of hoof wall. (From 
Jones et al., 2007). 
3.1.3 Pathophysiology of equine laminitis 
Despite a wealth of investigative effort, the pathophysiology of equine 
laminitis has not been fully elucidated. Most laminitis cases occur in horses and 
ponies kept at pasture and the disease has been linked to the non-structural 
carbohydrates (particularly fructans) that increase in the pasture at particular 
times of the year associated with bright sunshine during the day and cool nights 
(Geor, 2009; Menzies-Gow et al., 2010). Laminitis has also been related to 
predisposing factors in horses, such as insulin resistance and hyperinsulinemia 
(Nourian et al., 2009).  
Digital blood flow disturbances seem to be fundamental in the 
pathophysiology of laminitis, with histopathological changes in the laminar 
structures suggestive of ischaemia-reperfusion injury (Hood et al., 1993). It has 
been proposed that these changes could be induced by toxic compounds 
produced in the hindgut either by bacterial fermentation of carbohydrates or from 
the death or adaptive metabolism of other bacteria, and then released from the 
intestine into the blood stream. Three types of trigger factors, with possible 
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cross-talk between their pathways, have been thus suggested: amines, endotoxin 
and exotoxins (Bailey et al., 2004).   
Bacterial fermentation of carbohydrates in the hindgut results in the 
production of monoamines. Indeed, it has been shown that cecal contents 
collected from horses fed spring/summer grass has 2 to 3-fold higher 
concentrations of some mono- and di-amines than those harvested from animals  
fed with winter grass or hay (Bailey et al., 2003). Additionally, in vitro studies 
have revealed that the digital arteries of horses are 20-30 times more sensitive to 
the vasoconstrictor effects of serotonin than facial or tail arteries (Bailey and 
Elliott, 1998). Tryptamine, a cecum-derived amine, causes vasoconstriction 
through direct activation of serotonin receptors, with a marked selectivity for 
digital veins (Elliott et al., 2003). 
The increase in lactic acid produced by fermentation of carbohydrates in the 
hindgut results in changes in the microbial/bacterial population that could lead to 
the release of exotoxins (Mungall et al., 2001). Also pH reduction could result in 
bacterial death and the release of endotoxins that would then enter the blood 
stream and act on the digital vasculature. However, the role of endotoxins in the 
pathogenesis of equine laminitis has been disputed. Studies have given 
conflicting results in reporting levels of plasma endotoxins in carbohydrate-
overload models of equine laminitis (Hood, 1995; Sprouse et al., 1987). 
Moreover, endotoxin administration has failed to induce laminitis (Hunt et al., 
1990), questioning a direct role of endotoxins in the etiology of laminitis. 
 
Equine laminitis is characterised by disruption of the lamellar basement 
membrane and its attachment to the epidermal basal cells (Pollitt, 1996; Pollitt 
and Daradka, 1998). The lamellar pathology of laminitis has been associated 
with the activation of matrix metalloproteinases (MMPs) (Johnson et al., 1998; 
Pollitt et al., 1998). MMPs are a group of zinc-dependent enzymes that degrade 
extracellular matrix and basement membrane and are involved in the 
physiological remodelling of the lamellae as the hoof grows (Pollitt, 1999). 
Although it has not been fully elucidated what trigger factors are involved in 
naturally occurring laminitis, in vitro studies have shown that bacterial exotoxins 
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can lead to MMP activation (Mungall and Pollitt, 2002). Additionally, 
inflammatory mediators (like interleukin-1β) can lead not only to the release of 
vasoactive mediators but to MMP activation, further giving support to the claim 
that the vascular and enzymatic theories of laminitis pathogenesis are not 
mutually exclusive (Moore et al., 2004). 
3.1.4 Sensory innervation of the equine digit 
Two types of sensory receptors have been identified in the equine foot. 
Lamellated corpuscles, similar to Pacinian corpuscles, found primarily in the 
solar dermis of the heel, are low-threshold mechanoreceptors, which transmit 
their input via rapidly conducting, myelinated A-fibres (Bowker et al., 1993). 
Additionally, naked nerve endings immunoreactive to CGRP and sensory 
neuropeptides such as substance P (SP), neurokinin A (NKA) and peptide 
histidine-isoleucine (PHI) were detected in the dermis of the dorsal hoof wall and 
sole (Bowker et al., 1995). Immunoreactive nerve fibers were observed to extend 
into the primary and secondary dermal laminae and, in the palmar regions, they 
extended through the digital cushion and surrounding connective tissue into the 
dermal tubules of the solar dermis (Bowker et al., 1995). Nerve fibres containing 
CGRP are associated with nociception and they transmit their input via slowly 
conducting C fibres (Schmidt, 1981). Some of these unmyelinated nerves might 
also serve an efferent function in the control of blood flow within the foot 
(Bowker et al., 1995). 
3.1.5 Pain assessment in laminitic horses 
Accurate evaluation of pain and associated lameness in laminitic horses is of 
fundamental importance to equine welfare and effective veterinary management 
of the equine patient.  In a clinical context, lameness is typically assessed 
subjectively by veterinarians through observation of the horse at rest and at 
exercise, and thorough clinical examination. Such subjective assessment is not 
reproducible and is highly influenced by the experience and expertise of the 
clinician. Lameness, particularly in milder forms, can be very difficult to 
evaluate on the basis of clinical examination alone by even highly experienced 
clinicians (Schatzmann, 2000). In an attempt to standardise pain assessments and 
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make them more systematic and less “subjective” a number of scoring systems 
have been put forward. The Obel Score (Obel, 1948) and the Clinical Grading 
System developed by Taylor et al. (Taylor et al., 2002) are two simple 
descriptive scales (SDS) developed specifically for evaluation of equine 
lameness. Simple Descriptive Scales consist of a number of expressions used to 
describe different levels of pain intensity, such as “no pain”, “mild”, “moderate” 
and “severe”. Each descriptor is assigned an index value (generally from 0 - 5), 
which becomes the pain score for the animal. Although Obel score and CGS are 
extensively used to assess lameness in clinical practice and to evaluate response 
to therapy, the performance of these scales has not been thoroughly validated 
(Keegan et al., 1998).  Studies that investigated subjective scales used to assess 
lameness by comparing scores with objective measurements from force plates or 
gait-analysis identified significant inter-observer variability and poor agreement 
with objective assessments (Hood et al., 2001; Keegan et al., 1998; Peloso et al., 
1993; Silver et al., 1983; Taylor et al., 2002). A recent study evaluating 
subjective scales for the assessment of laminitis pain has identified suboptimal 
levels of inter-observer reliability and has highlighted the role of experience 
when using these scales (Vinuela-Fernandez et al., 2010). 
Recognising the inherent limitations of subjective techniques for evaluating 
equine lameness, quantitative evaluation systems (including behavioural 
quantification and the use of calibrated hoof testers) offer potentially superior 
techniques for the assessment of laminitis pain. 
Foot-lifting has been identified as a reliably quantifiable behavioural indicator 
of equine laminitis pain (Jones et al., 2007; Rietmann et al., 2004). Another 
behavioural indicator of laminitis pain, time spent at the back of the box (Jones et 
al., 2007), has also been associated with acute post-surgical limb pain (Price et 
al., 2003).  
Conventional hoof testers are routinely used to assess solar sensitivity and to 
localise more sensitive sites within the foot.  These tools evaluate the presence of 
hyperalgesia and allodynia. However, the application and interpretation of this 
test depends on the skill and experience of the operator and re-evaluation relies 
on the clinician’s memory.  In an attempt to adapt the principles of hoof testing 
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to quantitative sensory testing, Kamerling et al. (1988) produced a calibrated 
electronic hoof tester that allowed recording of hoof compression thresholds. The 
same research group also used this quantitative approach to determine the 
effectiveness of analgesic treatments for chronic laminitis (Owens et al., 1995; 
Owens et al., 1996). However, these studies presented some limitations. The 
hoof-tester used was still applied by hand, with potential for variability in its rate 
of application and in the maximum pressure applied by the hoof tester probe.  
Additionally, they did not provide any data on normal (sound) horses. 
3.1.6 Aims and Hypotheses  
In this study we aimed to further characterise the pain state associated with 
equine laminitis. A first aim was to evaluate a novel QST technique for the 
quantification of hoof compression thresholds in chronic laminitic and normal 
horses. A second aim was to characterise peripheral nerve morphology in the 
lateral digital nerve from laminitic horses and investigate injury-associated 
changes in protein expression in DRG neurons innervating the fore feet of 
laminitic horses.  
 
We hypothesised that: 
 
1. Chronic laminitic horses are in a state of hyperalgesia and their lowered 
hoof compression thresholds can be reliably measured using a novel 
hydraulically powered, calibrated hoof-tester. 
2. The pathological processes affecting the hoof laminae during laminitis 
damage the sensory neurons innervating this region, giving rise to a neuropathic 
pain component that could explain the frequent inefficacy of standard anti-
inflammatory therapy to alleviate laminitis pain. 
 
The quantitative sensory testing, anatomical and biochemical techniques used 





3.2.1 Evaluation of a novel QST technique for the assessment of mechanical 
hyperalgesia in chronic laminitic horses: equine laminitis is associated with 
mechanical hypersensitivity 
Histograms, presented as Figure 3.3a and b, indicate that the threshold 
responses obtained from both Normal (control) and Laminitic horses can be 
described by a normal distribution. A not unexpected and highly statistically 
significant (p<0.001) difference was found between the mean Hoof Compression 
Thresholds (HCTs) of the Normal horses, 59.8  4.3 kg/cm2 (mean  S.E.) and 
the mean HCTs of the Laminitic horses, 29.6  3.5 kg/cm2 (Figure 3.3c, Table 
3.1). None of the fixed effects were found to be statistically significant, except 
for the three way interaction Group.Site.Test (p = 0.03), where the effect was 
centred on a difference of less than 3 kg/cm2 between the first and second HCTs 







































































Figure 3.3: Histograms of the frequency of occurrence of hoof compression 
thresholds (pressure in kg/cm2) obtained from testing of a) Normal (n = 7) and 
b) Laminitic (n = 7) horses. C)  Mean hoof compression thresholds (± S.E.) for 







































Table 3.1:  Summary of QST measurements for Normal and Laminitic horses. 
The values are the mean Hoof Compression Test thresholds ( SEM) for Group, 
Sites and Legs, obtained in three Sessions with two Tests at each site, expressed 
in kg/cm².  
3.2.2 Evaluation of a novel QST technique for the assessment of mechanical 
hyperalgesia in chronic laminitic horses: Variance components analysis 
Variance components, estimated separately for the HCTs of both Normal and 
Laminitic horses, are summarised in Table 3.2.  
In both groups variance components associated with “Session”, “Leg” and 
“Site” were consistently small. Subsequent refitting of the model without these 
terms showed that the properties of the model were not affected, showing that 
these models are consistent with the fixed effects model described earlier.  
However, these terms were statistically significant when they were estimated in 
interaction with the term “Animal” i.e. individual horses showed significant 
variability associated with these components.   
For both Normal and Laminitic horses, the residual variance, estimated from 
the pairs of observations (“Tests” 1 and 2), was the largest of the variance 
components.  This residual variance was significantly greater in the Normal 
group than in the Laminitic group (p<0.01 by z-test).  No statistically significant 
differences were found between Normal and Laminitic horses for the other 
variance components. 
In Normal horses the interaction providing the largest contribution to the total 
variance was that of “Animal by Session”, whereas for Laminitic horses it was 




 Normal Horses Laminitic Horses 
Random term Component S.E. Component S.E. 
“Animal” 19.4 (19.1) 29.5 (29.6) 39.8 (37.8) 35.1 (35.0) 
“Session” 0.0 (-)  - (-) 0.9 (-) 4.5 (-) 
“Leg” 1.3 (-) 10.8 (-) 0.0 (-)  - (-) 
“Site” 0.0 (-)  - (-) 3.0 (-) 4.6 (-) 
“Animal“: “Session” 44.6 (38.7) 23.6 (23.4) 8.3 (10.5) 7.0 (6.9) 
“Animal” : “Leg” 9.9 (10.3) 11.7 (13.6) 26.0 (26.1) 16.7 (16.4) 
“Session” : “Leg” 9.1 (-) 11.2 (-) 1.7 (-) 3.3 (-) 
“Animal” : “Site” 12.6 (12.9) 8.2 (8.2) 1.5 (6.5) 5.2 (5.0) 
“Session” : “Site” 1.0 (-) 3.2 (-) 0.1 (-) 2.3 (-) 
“Leg” : “Site” 0.0 (-)  - (-) 0.0 (-)  - (-) 
”Animal” : “Session” : 
“Leg” 
10.0 (22.0) 11.4 (15.1) 0.4 (0.5) 4.8 (5.4) 
“Animal” : “Session” : 
“Site” 
0.0 (-)  - (-) 4.5  (-) 6.3 (-) 
“Animal” : “Leg” : 
“Site” 
0.0 (-)  - (-) 2.7 (-) 5.3 (-) 
“Session” : “Leg” : 
“Site” 
0.0  (-)  - (-) 0.0 (-)  - (-) 
“Animal” : “Session” : 
“Leg” : “Site” 
0.0 (0.0)  -  (-) 0.0 (5.1)  - (7.6) 
“Residual variance” 102.6 
(103.0) 
10.6 (10.6) 65.1 (65.2) 7.5 (8.3) 
 
Table 3.2: Estimated Variance Components and their Standard Errors for HCTs 
of Normal and Laminitic Horses.  Values in brackets were obtained after re-
fitting of the REML (restricted maximum likelihood) model. Non-statistically 




3.2.3 Evaluation of a novel QST technique for the assessment of mechanical 
hyperalgesia in chronic laminitic horses: Statistical test evaluation: 
variability between animals 
Further statistical analysis was carried out by calculating the intra-class 
correlation coefficients (ICCs) i.e. the ratio of the population variability to the 
total variability in the data. The ICCs were 0.50 (Normal group) and 0.57 
(Laminitic group). Thus, for both groups, around half of the observed variability 
was associated with between-Animal variability.  
The statistical sensitivity, specificity, and area under the Receiver Operating 
Characteristic (ROC) curves were estimated and they were 0.89; 0.86; and 0.94 
respectively.   
The values of the mean and variance components for each group of horses 
were used to determine the benefits of averaging the pairs of tests (Tests 1 and 
2); this showed that the ICCs were 0.67 (Normal group) and 0.73 (Laminitic 
group), with an estimated sensitivity of 0.91, a specificity of 0.89 and an area 
under the ROC curve of 0.96.   
3.2.4 Evaluation of a novel QST technique for the assessment of mechanical 
hyperalgesia in chronic laminitic horses: Statistical test evaluation: within 
Animals and between Sessions 
To assess the repeatability of testing between Sessions, ICCs were determined 
by estimating the ratio of variability associated with “Session” to the total 
variability, while excluding variance components associated with between 
“Animal” variability. The estimated ICCs were 0.32 (Normal group) and 0.14 
(Laminitic group). This indicates that, for both groups, when focusing on a single 
animal, little of the variability was between “Sessions”.   
Since most of the variability is between individual Tests, total variability 
could be reduced by averaging the two HCTs for each Site; the ICCs would then 
be 0.45 (Normal group) and 0.20 (Laminitic group).  
The estimated variance components were also used to model a linear increase 
in the HCTs of Laminitic horses over three Sessions, until they become typical of 
those of Normal animals, as would occur in clinical situations in response to 
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effective treatment and healing. This hypothetical model was used to estimate the 
numbers of horses and/or test repeats (replicates) required to detect an increase 
(using a two-sided t-test) in the mean HCT of Laminitic horses. The increase in 
HCTs between sessions was modeled and quantified as the percentage reduction 
in the initial difference between the mean HCTs of Normal and Laminitic horses; 
this difference disappears as laminitics reach normality.  Assuming 80% power 
and 95% confidence for the statistical test, examples of the numbers of horses 
required are shown in Table 3.3 and it can be seen that if 5 HCTs were obtained 
from a laminitic foot (from a randomly selected Site) in each Session for a group 
of nine (9) horses, there would be an 80% chance of detecting a change in mean 
HCT of 40% towards the mean HCT of Normal horses.  
 
Number of tests 
2 3 4 5 6 
Percentage change, towards 
normal values, in the HCTs of 
a group of Laminitic horses. Number of horses required 
10% 
40 36 34 32 32 
20% 
21 19 18 17 16 
40% 
11 10 10 9 9 
80% 
6 6 6 5 5 
 
Table 3.3:  Power calculations. The table shows the number of repeated tests 
and number of horses in each group required to detect hypothetical 
improvements of 10, 20, 40, and 80% in the HCTs of Laminitic horses towards 
“Normal” values. A 100% improvement constitutes return to normality.  
Estimates were obtained from the results by modelling and a power of 80% with 
a confidence of 95% was assumed for the statistical testing. The table illustrates 
that, to detect an improvement of 40%, a group of at least 9 horses would be 
required and that each hoof would need to be tested at least 5 times before and 








3.2.5 Equine laminitis is associated with morphological abnormalities in 
both myelinated and unmyelinated peripheral nerve fibers innervating the 
hoof 
Lateral digital nerves dissected at the level of the proximal sesamoid bone 
were examined from both normal and laminitic horses. A mean of 11.65% (range 
8.75–14.35) of the total fascicle area from each nerve section was analysed. EM 
analysis of three randomly selected fascicles per lateral digital nerve revealed 
morphological differences in both the myelinated and unmyelinated fibres in 
laminitic compared to non-laminitic horses (Table 3.4).  
The most obvious quantitative feature appeared to be a significant reduction 
in the number of both unmyelinated (−43.2%) and myelinated fibres (−34.6%) 
per unit area in laminitic compared to control horses (p = 0.016). In order to 
eliminate the possibility that the reduced fibre density was an artefact due to 
nerve oedema, morphometric analyses were carried out to measure the 
percentage area of nerve sections occupied by fascicles and total nerve area in 
normal compared to laminitic horses. No significant differences in the mean 
percentages were identified (t4 = − 0.91, p = 0.414) between normals 37% (95% 
CI: 35.7–38.1) and laminitics 41% (39.5–42.0). No significant differences in 
total nerve area were identified between normal and laminitic horses (t4 = − 0.43, 
p = 0.692).  
Further abnormalities were a significant decrease in the number of 
unmyelinated nerve fibres per Remak bundle (F1,7 = 20.7, p = 0.003) together 
with an increase in the percentage of solitary unmyelinated fibres in laminitics 
compared to normal horses (χ21= 35.7, p<0.001, Figure 3.4 and Table 3.4b).  
The percentage of morphologically damaged myelinated fibres was 
significantly higher in laminitic horses when compared to normal horses (χ21= 
31.5, p<0.001, Figure 3.4 and Table 3.4a). Alterations in the shape of surviving 
axons and disruption of the myelin sheath, with accumulation of lipid droplets 
and myelin debris, were the main abnormalities observed.  
Finally, the proportion of myelinated fibres with continuous Schwann cell 
cytoplasm was significantly higher in the laminitic horses (χ2 = 338.4, 
75 
 
p < 0.001). No significant differences in myelin thickness or G-ratios were 
























Table 3.4:  Summary of myelinated and unmyelinated nerve fibre characteristics 
in normal and laminitic horses. Statistical significance is indicated by asterisks 
(* P value of <0.05, ** P<0.01, *** P<0.001; Linear mixed effects models, 
Mann Whitney test). Values are expressed as mean ±SEM. 
 
 
a)  Myelinated fibres 
1.09 (± 0.0) 1.06 (± 0.0) 
Mean thickness of myelin sheath (μm) 
5.08 (± 0.1) 5.38 (± 0.1)  Mean axon diameter (μm) 
72.46 (± 5.9) *** 17.45 (± 1.6) 
Mean percentage of A fibres with 
continuous (>40%) Schwann cell 
cytoplasm 
30.08 (± 5.7) *** 16.40 (± 2.8) Mean percentage of damaged A fibres  
0.34 (± 0.0) * 0.52 (± 0.0) Mean no. of fibres per 100 m2 
Laminitic Horses n=5 Normal Horses n=4 Nerve fibre characteristics 
b) Unmyelinated fibres 
 
1.28 (± 0.0) 1.36 (± 0.0) Mean axon diameter (μm) 
38.06 (± 5.2) ***  30.14 (± 2.3)  Mean percentage of solitary 
unmyelinated fibres 
2.09 (± 0.0) ** 2.75 (± 0.1) Mean no. of fibres per Remak bundle 
3.28 (± 0.3) * 5.77 (± 0.5) Mean no. of fibres per 100m2 




Figure 3.4: Reduced myelinated and unmyelinated fiber density associated with 
laminitis. (a) Electron microscopy images of digital nerve from a normal horse. 
Arrows indicate intact, normal myelinated fibers. Arrowheads indicate clustered 
unmyelinated fibers in Remak bundles.(b) Electron microscopic images of digital 
nerve from a laminitic horse displaying reduced myelinated fiber density 
(arrows), lower numbers of C-fibers per Remak bundle, as well as increased 
numbers of solitary fibers (arrowheads) and increased collagen-filled space, 
compared to normal horse. Scale bars, 5 μm. 
 
3.2.6 The neuronal injury marker ATF3 is selectively expressed in sensory 
neurons innervating the forelimb in laminitic horses 
Using immunohistochemical analysis of the DRG cell population, we assessed 
the presence of ATF-3 in comparison with the expression of NF-200 and either 
IB4 or peripherin. ATF-3 expression was significantly increased in NF-200-
positive C8 DRG cells from laminitic horses (n = 3), where 67% (15 sections, 
304 cells, CI 58.8–69.9) of NF-200-positive DRG cells co-expressed ATF-3, 
while only 10% (15 sections, 345 cells, CI 6.9–13.5) of NF-200-positive DRG 
cells in control horses (n = 3) co-localised ATF-3 (χ21 = 208; p < 0.001) (Figure 
3.5). There was a significantly increased expression of ATF-3 in IB4-positive C8 
DRG cells in laminitic horses (n = 3), where 54% (five sections, 53 cells, CI 
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41.5–67.3) of IB4-positive C8 DRG cells co-localised ATF-3 compared with 9% 
(five sections, 56 cells, CI 3.9–19.3) in control horses (n = 3) (χ21 = 24.5; p < 
0.001). There was also a significantly increased proportion of peripherin-positive 
DRG cells that were positive for ATF-3 in C8 DRG cells from laminitic horses, 
(n = 3), where 57% (nine sections, 115 cells, CI 47.6–65.4) of peripherin-positive 
cells co-expressed ATF-3 compared with 21% (nine sections, 127 cells, CI 13.8–
29.4) showing double-labelling in control horses (n = 3) (χ21 = 30.9; p = 0.001; 
Figure 3.5). Accordingly, immunoblot analysis revealed a significant increase (p 
< 0.05) in ATF-3 expression (expressed as mean percentage of GAPDH 
expression) in C8 DRG (38.9% (28.7–49.1)) in comparison to low levels in the 
control C4 DRG (4.6% (0.5–9.7)) (Figure 3.5 f). The numbers of cells expressing 
NF-200, IB4 or peripherin were unaltered in laminitic DRG compared to normal 
horses (696 compared to 575 NF-200-IR cells, n = 32 sections, 115 compared to 
127 peripherin-IR cells, n = nine sections, 56 compared to 53 IB4-positive cells, 
n = five sections, in normal compared to laminitic horses, respectively). 
3.2.7 Laminitis is associated with a distinctive pattern of expression of 
Neuropeptide Y (NPY) in sensory neurons 
A significant increase in NPY immuno-reactivity was observed in the C8 
DRG of laminitic horses, where 77% (17 sections, 271 cells, CI 72.0–82.3) of 
NF-200-positive cells showed NPY-IR co-localisation, compared to only 10% 
(17 sections, 351 cells, CI 15.7–24.7) in control horses (χ21 = 193; p < 0:001; 





Figure 3.5: (a–e) Immunohistochemical co-localisation of DRG neuronal 
subtype markers (NF-200 and peripherin, green) with neuronal injury marker, 
ATF-3 or neuropeptide Y (NPY) (red) in C8 DRG (which receives forelimb 
innervation) of laminitic (a,d,e), or control horses (b) and co-localisation of NF-
200 (green) with ATF-3 (red) in C4 DRG (not associated with forelimb 
innervation) from the same horse (c). (a) In laminitic horses, there was an 
increased expression of ATF-3 (red) in NF-200-positive DRG cells (green) 
compared to C8 DRG control (non-laminitic) horse (b) and C4 DRG from 
laminitic horse (c). Laminitic horses show expression of ATF-3 (red) in 
peripherin-positive (green) in DRG cells (d), while control horses do not (data 
not shown). Additionally, there was increased co-localisation of NPY (red) and 
NF-200 (green) in C8 DRG cells of laminitic horses (e) compared to control 
horses, where there was normally only sparse NPY expression (data not shown). 
Scale bars, 100 lm. White arrows show co-localised immunopositive cells. Open 
arrows show cell marker (NF-200 or peripherin)-positive cells lacking co-
localisation. (f) Typical immunoblots of whole DRG lysates of laminitic horses (n 
= 3) show clear ATF-3 expression in C8 but not C4 DRG. Levels of the 
housekeeping enzyme, GAPDH (lower blots), were unchanged. 
 
3.2.8 Laminitis is associated with increased expression of the TRPM8 
receptor 
Using immunohistochemical analysis of the DRG cell population, we assessed 
the presence of TRPM8 in comparison with the expression of NF-200 and 
peripherin. The proportions of peripherin-positive neurons found to express 
TRPM8 were significantly higher in C8 DRG from laminitic horses compared to 
C8 from normal horses and C4 from laminitic horses (p < 0.0001). Tukey’s post 
hoc tests indicated that there was no statistical difference between the number of 
double-labelled neurons in C8 DRG from normal horses and C4 DRG from 
laminitic horses. 7.60% ± 0.46 of peripherin-positive cells in the C8 DRG from 
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laminitic horses co-expressed the TRPM8 receptor, compared to 3.95% ± 0.33 in 
C8 DRG from normal horses and 3.20% ± 0.41 in C4 from laminitic horses 
(Figure 3.6a-c). The proportions of NF-200-positive neurons found to express 
TRPM8 were significantly higher in C8 DRG from laminitic horses compared to 
C8 from normal horses and C4 from laminitic horses (p < 0.0001). Tukey’s post 
hoc tests indicated that there was no statistical difference between the number of 
double-labelled neurons in C8 DRG from normal horses and C4 DRG from 
laminitic horses.  5.64% ± 0.57 (mean ± SE) of NF-200-positive neurons from 
the C8 DRG of laminitic horses were immuno-positive for the TRPM8 receptor, 
compared to 2.38% ± 0.1 in C8 DRG from normal horses and 2.23% ± 0.22 in 
C4 DRG from laminitic horses (Figure 3.6d-f).   
 
 
Figure 3.6: Immunohistochemical co-localisation of DRG neuronal subtype 
markers (NF-200 and peripherin, red) the TRPM8 receptor (green) in C8 DRG 
(which receives forelimb innervation) of control horses (a, d) and laminitic 
horses (b,e) and in C4 DRG (not associated with forelimb innervation) from the 
same laminitic horses (c,f).  Laminitic horses (b) show an increased expression 
of TRPM8 (green) in peripherin-positive DRG cells (red) compared to C8 DRG 
control (non-laminitic) horse (a) and C4 DRG from laminitic horse (c). 
Laminitic horses also show increased expression of TRPM8 (green) in NF-200-
positive DRG cells (red) (e), compared to C8 from control horses (d) and C4 
DRG from the same laminitic horses (f). Scale bars, 100 μm. White arrows 





3.3.1 QST assessment of laminitis-associated pain 
Equine laminitis is a relatively frequent disease of horses and ponies which is 
generally perceived by veterinarians to be associated with a variable degree of 
pain according to the severity of its presentation (Price et al., 2002). Clinical 
assessment of pain associated with laminitis continues to be largely subjective 
and relies heavily upon the expertise and skills of the clinician. Although a 
number of subjective pain scales (such as the OBEL score) have been developed 
in an attempt to standardise the assessment of pain in laminitic horses, these 
methods present a number of limitations, mainly regarding their reproducibility 
when used by different observers on the same animal and the role of experience 
in their performance (Vinuela-Fernandez et al., 2010). Therefore, there is a need 
for objective, quantitative methods for the assessment of laminitis pain. 
Quantification of pain behaviours has been shown to provide a reliable method 
of assessing pain in laminitic horses. We have previously shown that behaviours 
such as foot lifting or time spent at the back of the box are significantly increased 
in laminitic horses compared to normal horses (Jones et al., 2007). However, a 
disadvantage of behavioural quantification in a clinical setting is that it requires 
video recording of the animals for long periods of time and data processing and 
analysis is time consuming.  
Quantitative sensory testing protocols are routinely used in human medicine 
to assess sensory nerve function and several QST methods have been developed 
in recent years for pain assessment in animals. In human patients, QST allows for 
the evaluation of qualitative aspects of sensory perception that can be 
communicated through verbal self-report but this is not possible in animals. QST 
tests developed for animals use behavioural responses (e.g. a withdrawal 
response) as an end-point to measure nociceptive thresholds.  
In this study, we have confirmed and extended the measurements of noxious 
mechanical thresholds on the forefeet of lame horses, presented by Kamerling et 
al. (1988). They reported Hoof Compression Thresholds (HCTs) and the number 
of loci which were pain sensitive for 6 horses with lameness from various foot 
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problems (they did not test ‘normal’ horses). The range of HCTs found when 
converted to kg/cm2 was from 18.9  3.4 to 46.4  12.0 with a mean  SEM of 
24.9  3.2 kg/cm2, which is consistent with the mean reported here for laminitic 
horses (29.6  3.5 kg/cm2). The highest HCTs in their range are quite close to the 
mean reported here for normal horses (59.8  4.3 kg/cm2). Kamerling et al. 
(1988) found decreases in HCTs (hyperalgesia) after an undefined number of 
repeated tests. Hyperalgesia was also found as a result of repeated hoof testing 
when using the same calibrated hoof tester to measure the effectiveness of 
detomidine, ketoprofen and phenylbutazone as analgesics for chronic hoof pain 
(Owens et al., 1995; Owens et al., 1996). Owens et al. (1995; 1996) measured 
proportional changes in the HCTs of laminitic horses following treatment, and 
expressed the effectiveness of treatments as the percentage increase in HCTs 
with reference to the baseline. They did not present absolute HCT values for 
either normal or laminitic horses. Kamerling’s et al. (1988) calibrated hoof tester 
was applied manually over a period of about 2 seconds and the maximum 
pressure applied was often determined by the grip strength of the examiner, 
which is clearly not ideal.  Results from the present study suggest that increasing 
probe pressure at the slower rate of about 10 kg/s/cm2 and prevention of 
overstimulation by automatic control of the maximum pressure avoids excessive 
stimulation and prevents development of hyperalgesia. In the horses tested, no 
damage was detected by clinical examination for lameness and no evidence was 
found, from decrease in the HCTs over time, that hyperalgesia developed as a 
result of repeated testing. 
The HCT thresholds for the group of chronically laminitic horses were 
generally less than 50% of those obtained for ‘normal’ control horses and this 
can be related to a widely accepted view of the severity of foot pain suffered by 
horses with chronic laminitis.  
In order for a new QST method to be established for routine assessment its 
reliability needs to be evaluated. This study approached this by analyzing the 
sources of variation and calculating intra-correlations coefficients.  
In both normal and laminitic horses, the “residual variance” component, 
which reflects variability between the first and the second test within a session in 
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individual horses plus any unaccounted for error, was the largest element of the 
variance components, and it was significantly greater in normal than laminitic 
horses (Table 3.2). This higher variance in normal horses compared to laminitics 
may be attributed to the lower HCTs of laminitic horses, which may reduce 
opportunities for interfering variables to produce measurement errors and lower 
the likelihood of coincident voluntary movements of the horse which would 
obscure detection of the threshold. No published quantitative evidence has been 
found with which to compare these differences in the variability of HCTs 
between normal and laminitic horses as most previous studies do not provide 
data on normal animals. 
Variability between different horses was a large source of variability in the 
data, particularly for the group of laminitic horses. This is likely to be due to 
these horses being at different stages of disease progression or to differences in 
their responses to therapy.  
In normal horses, one of the largest contributions to variability was a result of 
“Animal by Session” interaction (i.e. the variability in HCTs of a particular horse 
from one session to another). This was confirmed by calculation of intra-class 
correlation coefficients which showed that, in normal horses, about one third of 
the total variability is associated with between session variability. Such high 
variability in normal horses over time is a limiting factor in further studies using 
HCTs for the measurement of treatment effects or disease progression but such 
reference values are required as it is unlikely that control data from the laminitic 
horses prior to the development of the disease would normally be available.  
The benefits of averaging of various sampling factors were modelled and 
averaging of HCTs from different sites in the same ‘leg’ (foot) seems likely to be 
a useful strategy for improving the effectiveness of the test.  The magnitude of 
the variance associated with an “Animal by Leg” interaction in laminitic horses, 
might correspond to differences in the sensitivity of the left versus right foot of 
individual animals. It is a common clinical finding that one of the feet is 
generally more severely affected than the other and this was also reported by 
Kamerling et al. (1988). Thus averaging of HCTs from both fore-feet together, 
would not be beneficial, for assessment of changes in the severity of laminitis.   
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In neither normal nor laminitic horses was there any strong evidence of 
differences in the statistical properties of HCTs measured at the three different 
sites. A single site, the Toe site (half-way between the apex of the frog and the 
white line), would be easier to use as a consistent anatomical location for testing.   
Differences between the first and second HCT in normal horses at the lateral 
site were statistically significant, although relatively small (<3 kg/cm2), and it 
was not dependent on the right or left foot (leg). We believe this unexpected 
finding should be taken cautiously and it needs to be confirmed before further 
investigation of or speculation on its origin is pursued.   
Owens et al. (1995; 1996) concluded that, because of underlying variability, 
relatively large and consistent changes in HCTs are required to show statistically 
significant improvements in response to treatment. The results presented here are 
consistent with this and provide further insight into the sources of the variability.  
No direct evidence was obtained here to support their proposal that quantitative 
measurement of HCTs provides a better means for detecting analgesic effects 
than subjective assessment of changes in lameness obtained using the Obel 
scoring method. More studies, in which both methods of assessment are used on 
the same horses at the same time, are required to test this proposal.   
In conclusion, this part of the study shows that HCTs can be safely and 
reliably measured, under experimental conditions, using this hoof-tester. The 
variability found in the HCTs indicates that treatments need to produce at least a 
40% improvement in order to be detected in a group of nine laminitic horses 
tested at least five times.  Clinical application of the method, which requires 
measurement of meaningful changes in the HCTs of individual laminitic horses, 
may be achieved after successful investigation and implementation of one or 
more of the following potential improvements: 
 Decreasing the variability between measurements on the same foot of 
an individual horse by rigorous attention (including training) to: the 
horse’s ‘mental state’, its behavioural responses to hoof-testing, 
precise location of the instrument, and improvements in the ability of 
the operator to reliably detect the HCT threshold (end-point) for a 
particular horse.   
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 Finding well-defined and easily applied criteria for the rejection of 
HCT threshold measurements affected by co-incident variables such as 
environmental disturbances or failure of the horse to cooperate.   
 Accommodation of variability by averaging out some of the errors.  
Most variability occurs at the test stratum and we suggest that the 
averaging of five (5) well-controlled HCTs, performed at one site 
(Toe) on the sole of each foot, might be safely achieved without 
cumulative deleterious effects.  
 Because of the complexity and high cost of this hoof tester, 
development and testing of simpler and cheaper calibrated hoof-
testers, would help clinical exploitation of HCTs. We suggest that, in 
order to help ensure the welfare of horses being tested, specifications 
for and use of calibrated hoof testers should be consistent with the 
protocols and safe ‘limits’ described here.  
3.3.2 Abnormal hoof sensory nerve morphology in laminitic horses is 
consistent with that reported in damaged peripheral nerves in neuropathic 
pain states 
Damage to sensory nerves has been associated with spontaneous pain and 
increased nociceptive sensitivity in a variety of clinical and experimental studies. 
In this study, we have quantified a reduction in mechanical nociceptive 
thresholds associated with equine laminitis (compared to normal horses) which is 
indicative of a hypersensitive sensory state.  
Changes in sensory nerve fibres innervating the hoof could potentially 
contribute to the aetiology of the chronic laminitic pain state. To understand the 
mechanisms underlying laminitis pain and the incomplete response to anti-
inflammatory analgesics, it is important to establish whether axonopathic 
changes may contribute. In laminitic horses, EM analysis identified marked 
decreases in myelinated and unmyelinated fibre numbers per unit area of digital 
nerve. This is unlikely to be due to nerve oedema as there were no significant 
differences between nerve section areas and fascicle areas in normal and 
laminitic horses. The marked increase in the number of solitary, unmyelinated 
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fibres may reflect demyelinated A-fibres or an absence of guiding pathways for 
regenerating C-fibres (Bester et al., 1998). The morphological changes observed 
are consistent with those in laboratory neuropathic pain models, such as chronic 
constriction injury (Basbaum et al., 1991; Gabay and Tal, 2004; Gautron et al., 
1990; Micu et al., 2006), crush injury (Lozeron et al., 2004), photochemically-
induced ischemia (Yu et al., 2000) and diabetic neuropathy  (Elias et al., 1998; 
Kalichman et al., 1998; Llewelyn et al., 1991; Sima et al., 1988), thereby 
supporting our hypothesis that peripheral nerve damage may contribute to 
laminitis pain. 
Functional changes in the injured peripheral nerve have also been described in 
neuropathic pain models. 
The loss of large fibres in nerves from laminitic horses is important as part of 
the behavioural changes in neuropathic pain states may result from the loss of 
spinal inhibitory controls exerted indirectly by these afferents (Basbaum et al., 
1991). On the other hand, damage to both A and C-fibres appears to be necessary 
for the establishment of hyperalgesia and allodynia (Gabay and Tal, 2004; Yu et 
al., 2000). Electrophysiological studies further suggest that ectopic discharges in 
both spared C- and A-fibres may be important in maintaining neuropathic pain 
(Ali et al., 1999; Gabay and Tal, 2004; Kajander and Bennett, 1992). 
3.3.3 Sensory neurons of the forelimb in laminitic horses show phenotypic 
changes associated with peripheral nerve injury 
Following peripheral nerve damage, phenotypic changes occur in primary 
sensory neurons that may contribute to mediating central sensitisation (Hokfelt et 
al., 1994; Tsujino et al., 2000). We assessed whether key neurochemical changes 
in sensory neurons of laminitic horses are similar to those in rodent neuropathic 
pain models. The numbers of DRG cells expressing the anatomical markers NF-
200, peripherin or IB4-binding sites were unaltered. Following nerve crush 
injury, peripherin increases transiently in large DRG cells (Wong and Oblinger, 
1990). However, that model is associated with sensory loss (Bester et al., 1998) 
rather than the hypersensitivity seen here, as in other neuropathic and 
inflammatory pain states, where indeed peripherin expression is not upregulated 
(Facer et al., 2007; Renton et al., 2003; Rodriguez et al., 2006). 
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Neuronal expression of ATF-3, a member of the ATF/CREB family of 
transcription factors which is normally minimal, is upregulated following 
peripheral nerve injury and so can act as a marker of frank nerve damage 
(Tsujino et al., 2000). The clear expression of ATF-3 in NF-200, peripherin or 
IB4-positive sensory neurons of laminitic horses compared to normal horses 
indicates neuronal damage to both A and C-fibres matching our observations of 
abnormal nerve morphology. These findings suggest that primary afferent injury 
associated with laminitis arises locally from the damage caused by hoof 
pathology, rather than from systemic disease, since ATF-3 expression is low in 
neurons from DRG not innervating the forelimb. ATF-3 has been demonstrated 
to be induced by a number of stress signals in a wide range of tissues (Chen et 
al., 1996a; Yin et al., 1997). Ischemia and ischemia/reperfusion are established 
causes of ATF-3 expression (Hai et al., 1999), so the ischemia- reperfusion 
injury of the digit thought to underlie acute laminitis (Hood, 1999) may also be 
involved in neuronal damage.  
Immediate early-genes (IEGs) play a role in adaptive plasticity and long-term 
changes in the nervous system. Several IEGs, with which ATF-3 shares many 
characteristics (Wolfgang et al., 1997), have been shown to characterise the 
expression profile after peripheral nerve injury (Herdegen and Zimmermann, 
1995). ATF-3 represses transduction as a homodimer and activates transcription 
as a heterodimer with Jun proteins (Chen et al., 1994; Hai and Curran, 1991). 
ATF-3 is closely related to c-Jun, which is one of the best characterised early 
IEGs and has been shown to be induced in neurons following axotomy and is 
thought to be related to axonal regeneration (Chen et al., 1994; Jenkins and Hunt, 
1991; Leah et al., 1991). Although the function of ATF-3 has not been elucidated 
in detail, it has been suggested that the pattern of ATF-3 and c-Jun co-expression 
post-injury might be involved in determining the fate of DRG neurons following 
axotomy (Tsujino et al., 2000). 
In addition to increased expression of ATF-3 we also found upregulated 
expression of neuropeptide Y (NPY) in large NF-200-positive DRG cells from 
laminitic horses, paralleling observations in other neuropathic pain models 
(Kashiba et al., 1994; Ma and Bisby, 1998; Munglani et al., 1995; Nahin et al., 
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1994; Noguchi et al., 1993; Wakisaka et al., 1991; Wallace et al., 2003). NPY 
has been associated with cross excitation between A and C fibres, through 
correlation of increased NPY in large DRG neurons and the increase in NPY 
receptor Y2 in small cells following nerve injury (Noguchi et al., 1993; 
Wakisaka et al., 1991; Wakisaka et al., 1992; Zhang et al., 1997). 
 
In conclusion, the novel findings reported here suggest that pathological 
changes occurring during laminitis bring about a chronic pain state with a 
neuropathic component. 
Although the mechanisms underlying the pathogenesis of laminitis remain to 
be fully elucidated, it is apparent that the early stages of laminitis are associated 
with vasoconstriction of the digital microvasculature (Peroni et al., 2006) and 
inflammation (Belknap et al., 2007). Indeed, such pathological events can result 
in nerve damage (Moalem and Tracey, 2006; Yu et al., 2000; Zimmermann, 
2001) and may thereby play a role in the pathobiology of laminitis pain through 
the transition from acute inflammatory pain to a chronic syndrome with a 
neuropathic pain component. Additionally, enzymatic events characteristic of the 
developmental phase of laminitis, such matrix-metalloproteinases (particularly 
MMP-2 and MMP-9) might also have a role in the development of neuropathic 
pain component (Kawasaki et al., 2008; Kyaw-Tanner and Pollitt, 2004; Loftus 
et al., 2006).  
Neuropathic changes may be, at least partially, responsible for the limited 
efficacy of currently used anti-inflammatory therapy in the treatment of laminitis 
pain. The administration of anti-neuropathic agents may therefore achieve better 






3.3.4 Equine laminitis is associated with increased expression of TRPM8 in 
sensory neurons innervating the forelimbs 
Immunohistochemical analysis of neuronal bodies from the DRG innervating 
the forelimb (C8) showed an increased expression of the TRPM8 channel, 
compared with those from a cervical DRG not involved in forelimb innervation 
(C4) and also with the C8 DRG from non-laminitic horses. The increase in 
TRPM8 expression was observed in both peripherin and NF200-positive cells. 
TRPM8 expression has been shown to increase in peripherin-positive DRG 
neurons ipsilateral to CCI nerve injury in rats and also to be newly expressed in 
small myelinated (NF-200-positive), presumed-Aδ fibre cells (Frederick et al., 
2007; Proudfoot et al., 2006). However, no alterations in TRPM8 expression 
were reported in the SNL model of nerve injury, nor in a model of inflammation, 
(Katsura et al., 2006; Obata et al., 2005). 
This finding provides, to the author’s knowledge, the first evidence of 
TRPM8 upregulation in a naturally occurring painful disease in a domestic 
animal species. Moreover, in the context of previous studies that identified a role 
for TRPM8 as an analgesic system that can be successfully recruited in chronic 
pain models, (Dhaka et al., 2007; Proudfoot et al., 2006), the findings reported 
















Chapter 4: 5-HT1B RECEPTOR MODULATION OF 
TRPM8 CHANNEL ACTIVITY 
 
4.1 Introduction 
4.1.1 Serotonin and serotonin receptors 
Serotonin (5-hydroxytryptamine; 5-HT) is a monoamine neurotransmitter that 
is primarily found in the gastrointestinal tract, platelets and the nervous system. 
About 80% of the human body’s serotonin is found in enterochromaffin cells in 
the intestinal wall, where it regulates intestinal movements. Serotonin is also 
involved, for example, in the modulation of cardiovascular function, ejaculatory 
latency, and bladder control (Berger et al., 2009). In the CNS, serotonin is almost 
exclusively produced in neurons from the raphe nuclei, located in the midline of 
the brainstem, that send ascending projections to higher brain structures and 
descending projections to the spinal cord. Serotonin receptors are differentially 
expressed in all areas of the CNS, and thus serotonin is involved in the 
modulation of practically all its functions (Berger et al., 2009). Importantly, 
individual neurons might express multiple serotonin receptors, sometimes with 
opposing functions (Araneda and Andrade, 1991). Dysregulation of the 
serotonergic system has been implicated in the pathogenesis of many psychiatric 
and neurological disorders (Roth, 1994). 
In neurons, serotonin is synthesized from tryptophan by conversion to 5-
hydroxytryptophan by the enzyme tryptophan hydroxylase, followed by 
decarboxylation to 5-HT by a nonspecific amino acid decarboxylase. 5-HT is 
transported back into nerve terminals via a specific serotonin transporter (SERT), 
which effectively ends the synaptic action of 5-HT and enables its degradation 
by monoamine oxidase. 
Major advances in the understanding of serotonin function have been made 
over the last two decades with the cloning of 15 serotonin receptor subtypes 
(Kroeze et al., 2002). 5-HT receptors have been classified on the basis of 




There are 7 families of 5-HT receptors, classified as 5-HT1-7 with further 
subdivision of 5-HT1 into 5-HT1A-B, 5-HT1D/F and 5-ht1E; 5-HT2 into 5-HT2A-C; 5-
HT3 into 5-HT3A-B and 5-ht5 into 5-ht5A/B (Hannon and Hoyer, 2008). In terms of 
nomenclature, uppercase represents those receptors for which functional data is 
available in native tissue and lowercase, e.g. 5-ht5A-B, indicates that no clear 
functional role has been yet established. The 5-ht5B receptor is not expressed in 
man  (Hannon and Hoyer, 2008). 
Like glutamate, serotonin acts through both metabotropic and ligand-gated 
channels. Of the 7 families of 5-HT receptor only the 5-HT3 receptor is a ligand-
gated ion channel; its activation triggers rapid depolarisation by opening a non-
selective cation-permeable pore, causing influx of Na+ and Ca2+ and efflux of K+ 
(Hannon and Hoyer, 2008; Hoyer et al., 2002). The remainder are type A G 
protein-coupled receptors (GPCRs), which show a seven-transmembrane-
structure (Findlay and Eliopoulos, 1990; Trumpp-Kallmeyer et al., 1992). 5-HT1 
receptors are linked to Gi/o and therefore exert an inhibitory effect on adenylate 
cyclase, inhibiting cAMP formation; whereas 5-HT2 receptors preferentially 
couple to Gq/11 and thus promote PLC activation increasing inositol phosphates 
and cytosolic Ca2+ concentrations. 5-HT4, 5-HT6 and 5-HT7 receptors 
preferentially couple to Gs and activate adenylate cyclase resulting in cAMP 
production (Hannon and Hoyer, 2008; Hoyer et al., 2002). 
4.1.2 Serotonin and pain 
Serotonin is involved in the modulation of nociceptive processing and pain 
perception at multiple levels of both the peripheral and the central nervous 
systems. During inflammation, the release of serotonin sensitises primary 
afferent neurons that carry nociceptive information to the CNS (Sommer, 2004). 
Serotonergic neurons in the brainstem send descending projections to the spinal 
cord, thus modulating incoming nociceptive inputs (Braz et al., 2009). 
Additionally, serotonergic neurons from the midbrain send ascending projections 
to limbic and cortical areas that may be involved in the affective-motivational 
component of pain (Li et al., 1993). 
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4.1.3 Serotonin receptors in nociceptive processing in spinal cord 
Although a subset of 5-HT-immunopositive cells has been identified in the 
spinal cord of primates, ventral to the central canal (LaMotte, 1988), practically 
the entire serotonergic innervation of the spinal cord originates from supraspinal 
structures  (reviewed by Millan, 2002). 5-HT-immunopositive nerve fibres, 
observed as immunoreactive varicosities and nerve terminals, have been 
identified in the spinal cord, with highest immunoreactivity in lamina I and IIo 
although they are also present in deeper laminae (Marlier et al., 1991; Maxwell et 
al., 1996; Mizukawa et al., 1986). The main descending serotonergic pathways 
originate from the nucleus raphe magnus (NRM), a medullary structure 
innervated by the periaqueductal grey (PAG) (Bowker et al., 1983; Kwiat and 
Basbaum, 1992; Mason, 1999). Acute and chronic noxious stimulation results in 
the activation of descending serotonergic pathways and increased serotonin 
levels in the dorsal horn of the spinal cord (Mason, 1999; Taguchi and Suzuki, 
1992; Weil-Fugazza et al., 1979; Weil-Fugazza et al., 1984). Descending 
serotonergic pathways are involved in the modulation of spinal cord nociceptive 
processing, exerting either inhibitory or facilitatory influences. Spinal cord 5-HT 
receptors are located on primary afferent terminals, projection neurons and 
inhibitory and excitatory interneurons (Millan, 2002). The location and possible 
functional role of the most relevant 5-HT receptor subtypes found in the spinal 




5-HT1 receptors play largely an inhibitory role in nociceptive transmission in 
the spinal cord. Whereas the 5-HT1A receptor is localised post-synaptically, 
mainly in the superficial dorsal horn, 5-HT1B, 5-HT1D and 5-HT1F receptors are 
predominantly pre-synaptic (Chen et al., 1998; el-Yassir and Fleetwood-Walker, 
1990; el-Yassir et al., 1988; Zemlan and Schwab, 1991). Spinal administration of 
selective 5-HT1A receptor agonists has been shown to attenuate hypersensitivity 
and nocifensive behaviours in rodent models of inflammatory and neuropathic 
pain (Bardin et al., 2003; Deseure et al., 2007).  Triptan drugs, which act on 5-
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HT receptor subtypes 1B, 1D and 1F are widely used for the treatment of 
migraine pain (Johnston and Rapoport, 2010). Moreover, intrathecal sumatriptan 
has been shown to reduce pain hypersensitivity in mice models of persistent 
inflammatory and visceral pain but not in the SNI model of neuropathic pain 
(Nikai et al., 2008). Sumatriptan appears to act on pre-synaptic 5-HT1D receptors 
and the lack of efficacy of this drug to alleviate neuropathic pain has been 
suggested to be related to the down-regulation of 5-HT1D in the central terminals 
of primary afferents identified following nerve injury (Ahn and Basbaum, 2006; 
Jennings et al., 2004; Nikai et al., 2008). Effects of other 5-HT1B agonists and 
antagonists (el-Yassir et al., 1988; Gjerstad et al., 1997; Liu et al., 2007) are also 
consistent with an antinociceptive role of 5-HT1B receptors, although one report 
suggested a pro-nociceptive role (Zhang et al., 2001). Data from knock-out mice 
has confirmed the inhibitory role of 5-HT1 receptors subtypes in nociception. 
Mice lacking 5-HT1A receptors showed higher sensitivity to the hot-plate test 
than their wild-type counterparts, whereas 5-HT1B receptor knock-out mice 





5-HT2A receptors are largely expressed pre-synaptically in the dorsal horn but 
also in moderate levels post-synaptically and in inhibitory neurons where their 
activation has been suggested to mediate antinociceptive responses (Fonseca et 
al., 2001; Li et al., 2000; Maeshima et al., 1998; Sasaki et al., 2003). Data from 
knock-out mice however appears to suggest that 5-HT2A receptors are 
pronociceptive as 5-HT2A receptor null mice exhibited a decrease in the 










5-HT3 receptors are located in the central terminals of small primary afferents 
and axons from excitatory interneurons in the superficial dorsal horn where they 
exert pronociceptive influences (Conte et al., 2005; Zeitz et al., 2002). Intrathecal 
administration of the selective 5-HT3 receptor antagonist ondansetron has been 
shown to attenuate pain hypersensitivity in models of neuropathic and 
inflammatory pain (Green et al., 2000; Rahman et al., 2009; Suzuki et al., 2004). 
Indeed, it has been suggested that descending facilitatory influences originating 
at NK1 receptor-positive neurons in the dorsal horn and relaying through the 
RVM are enhanced following nerve injury or formalin-induced inflammation, 
and that these act on facilitatory spinal 5-HT3 receptors that increase neuronal 
excitability (Suzuki et al., 2002). However, some reports have suggested that the 
facilitatory actions of 5-HT3 receptors might be exerted on GABAergic 
inhibitory neurons in the superficial dorsal horn, resulting in antinociception 
(Fukushima et al., 2009). 
  
5-HT4, 5-HT6 and 5-HT7 receptors 
 
5-HT4, 5-HT6 and 5-HT7 receptors are positively coupled to adenylate cyclase 
and thereby have a facilitatory effect on neuronal excitability (Hoyer et al., 
2002). Antagonism of 5-HT4 receptors has been reported to mediate 
antinociception, especially inputs from enteric viscera and in relation to 
formalin-induced inflammation (Doak and Sawynok, 1997; Espejo and Gil, 
1998). Spinal 5-HT7 receptors have also been suggested to play a pronociceptive 
role in formalin-induced inflammatory pain (Rocha-Gonzalez et al., 2005). 
4.1.4 Peripheral serotonin receptors 
Serotonin receptors have been implicated in the modulation of spinal 
nociceptive transmission through actions both on the central terminals of primary 
afferents and in spinal cord neurons, as described above. Additionally, recent 
studies have investigated the role of peripheral 5-HT receptors in pain 
processing. 5-HT is released by platelets and mast cells following tissue injury 
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and is thus considered an inflammatory mediator (Dray, 1995). Similarly, nerve 
injury following sciatic nerve transection and CCI also results in increased levels 
of serotonin in the injured nerve (Anden and Olsson, 1967; Vogel et al., 2003).  
Intraplantar 5-HT administration results in concentration-dependent increased 
nociceptive behaviour (i.e. paw lifting and licking) in rats, and these effects are 
blocked with pre-treatment using specific 5-HT receptor antagonists (Sufka et 
al., 1992).  
Serotonin receptors have been suggested to be present in primary afferents. A 
study using in situ immunohybridization in rat DRG neurons identified mRNAs 
for 5-HT1B, 5-HT1D, 5-HT2A, 5-HT2B, 5-HT3B and 5-HT4 receptors. However, 
mRNAs for 5-HT1A, 5-HT1E, 5-HT2C, 5-HT5A, 5-HT5B, 5-HT6 and 5-HT7 
receptors were not detected in these neurons (Nicholson et al., 2003). 
Immunohistochemical localisation of 5-HT2A receptors in peripheral sensory 
axons of rat glabrous skin has provided anatomical evidence that 5-HT can have 
a direct effect on primary afferents (Carlton and Coggeshall, 1997). However, 
the functional role of peripheral 5-HT receptors has not yet been fully elucidated 
(Sommer, 2004). Different receptors appear to mediate different, sometimes even 
antagonistic effects. Intradermal injection of a 5-HT1A receptor agonist in rats 
resulted in a rapid development of hyperalgesia whereas 5-HT1B, 2-HT2C and 5-
HT3 receptor agonists did not have that effect (Taiwo and Levine, 1992). 
Administration of 5-HT2 receptor agonists can also result in nociceptive 
sensitisation or evoke nociceptive behaviours, particularly when co-administered 
with 5-HT or other inflammatory mediators (Abbott et al., 1996; Okamoto et al., 
2002; Tokunaga et al., 1998). The 5-HT2A receptor has been further implicated in 
inflammatory pain. Administration of a 5-HT2A receptor antagonist reduced 
thermal hyperalgesia caused by CFA but did not have analgesic effects in CCI 
rats (Okamoto et al., 2002). Furthermore, it was found that levels of 5-HT2A 
receptor mRNA in DRG neurons were increased following CFA, but not after 
axotomy or CCI (Okamoto et al., 2002). 5-HT2A receptor antagonists have also 
been found to attenuate pain behaviours in response to the formalin test in rats 
(Abbott et al., 1997; Obata et al., 2000). Interestingly, 5-HT receptors can also 
mediate direct analgesic effects. Peripheral administration of 5-HT1 receptor 
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specific agonists for the 1A, 1B, 1D, 1F subtypes resulted in decreased 
nocifensive behaviours in the formalin model of pain in rats and this effect was 
abolished by co-administration of specific 5-HT1 receptor antagonists (Granados-
Soto et al., 2010). Systemic administration of the 5-HT1B/D receptor agonist 
sumatriptan reduced thermal hyperalgesia in an inflammatory pain model 
(carrageenan) in mice but not in a sciatic nerve ligation model of neuropathic 
pain in rats through an apparently 5-HT1D receptor-mediated mechanism 
(Bingham et al., 2001), although efficacy was reported in a model of trigeminal 
neuropathic pain (Kayser et al., 2002). Interestingly, it has been recently 
suggested that the analgesic effect of Heterotheca inuloides, a plant used in 
traditional Mexican medicine for its anti-inflammatory properties is mediated by 
5-HT1 receptors (Rocha-Gonzalez et al., 2010). 
4.1.5 5-HT1B receptors 
 
Distribution and function 
5-HT1B receptors are widely distributed within the nervous system. In the CNS 
they are highly expressed in the basal ganglia and cerebellum but are also 
moderately expressed in other brain areas like the hippocampus, periaqueductal 
gray and frontal cortex (for a review see Sari, 2004). 5-HT1B receptors have been 
shown to play a functional role in locomotion and to be involved in psychiatric 
disorders such as anxiety, depression, alcoholism and aggressive behaviour 
(Boulenguez et al., 1995; Brunner et al., 1999; Huang et al., 2003; Kaiyala et al., 
2003; Saudou et al., 1994). 5-HT1B receptors are expressed both in serotonergic 
and non-serotonergic neurons, where they act as autoreceptors (regulating 
serotonin release) and pre-synaptic heteroreceptors (inhibiting neurotransmitter 
release), respectively (Engel et al., 1986; Maura and Raiteri, 1986; Sarhan et al., 
2000).  5-HT1B receptors, which are of particular interest here are expressed in a 
subpopulation of afferents, mainly TrkA positive, SP-negative IB4-negative Aδ 






Molecular structure and signalling 
 
The 5-HT1B receptor in rat and mouse is composed of 386 amino-acids 
whereas its human homologue, formerly known as 5-HT1Dβ and recently 
renamed as h-5-HT1B, is composed of 390 amino-acids (Sari, 2004). It appears 
that structural differences between rodent and human 5-HT1B receptor are 
reflected by some differences in their pharmacological properties. For example, 
rodent 5-HT1B receptors bind to β-adrenergic antagonists with higher affinity 
than the h-5-HT1B receptor and this has been shown to be due to a single amino 
acid difference (Metcalf et al., 1992). 5-HT1B receptors carry out their signal 
transduction mechanisms through their coupling to guanine-nucleotide binding 
proteins (G-proteins), especially those in the Gi/Go family.  Thus their activation 
results in inhibition of adenylate cyclase activity, decreasing the production of 
cAMP from ATP (Hamblin and Metcalf, 1991; Maroteaux et al., 1992; Seuwen 
et al., 1988). Additionally, activation of 5-HT1B receptors has been shown to 
activate p70 S6 kinase and the mitogen-activated protein kinase (MAP kinase) 
ERK-2 (Pullarkat et al., 1998). Moreover, studies on smooth muscle contraction 
have shown that serotonin can stimulate phospholipase D (PLD) via the 5-HT1B 
receptor (Hinton et al., 1999).   
4.1.6 TRPM8 channel and chronic pain states 
As fully described in Chapter 1, activation of the TRPM8 channel has been 
shown to produce a reversal of the behavioural reflex sensitisation to noxious 
stimuli associated with chronic pain states (Proudfoot et al., 2006). Interestingly, 
TRPM8 channel activation did not result in modification of nociceptive reflexes 
in uninjured contralateral limbs or in normal animals (Proudfoot et al., 2006). 
This suggests that TRPM8 channel activity must be somehow modulated in 
chronic pain states.  
TRPM8 channels are expressed by particular subsets of afferent neurons. 
TRPM8-expressing neurons comprise both A-fibre and C-fibre neurons also 
expressing TrkA, and are generally distinct from IB4-positive and SP-positive 
neurons. (Dhaka et al., 2007; Kobayashi et al., 2005; Nealen et al., 2003; Story et 
al., 2003).  
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4.1.7 Aim and Hypotheses 
The programme of work detailed below was carried out to investigate 
modulatory effects at the TRPM8 channel that could potentially influence its 
observed analgesic effect in chronic pain states. Since, in broad terms, the profile 
of afferents expressing TRPM8 channels correlates with the profile expressing 5-
HT1B receptors and serotonin plays a role in both inflammatory and neuropathic 
pain we aimed to explore the possibility that 5-HT1B receptors could potentially 
influence TRPM8 channel function.  
We hypothesised that activation of 5-HT1B receptors would result in a 
facilitatory effect on chemically-mediated TRPM8 channel activity and that this 
effect is mediated through PLD1, possibly leading to an increased production of 
PIP2.  We also hypothesised that co-administration of a 5-HT1B receptor agonist 
and a TRPM8 channel agonist would result in increased analgesia in a rodent 
model of neuropathic pain. 
 
4.2 Results 
4.2.1 Characterisation of responses to icilin in TRPM8-channel-expressing 
HEK293 cells 
HEK293 cells stably transfected with the human form of the TRPM8 channel 
show a concentration-dependent increase in intracellular calcium concentration, 
apparent as an increased calcium fluorescence over baseline values, following 
administration of the TRMP8 channel-selective agonist icilin to cells loaded with 
the Ca2+fluorophore Calcium 4 (Figure 4.1). This effect of icilin is highly likely 
to be TRPM8-mediated as it was reversed in a concentration-dependent manner 
(Figure 4.2) by the TRPM8 channel-selective blocker AMTB (Lashinger et al., 





































Figure 4.1: Concentration-response curve for icilin showing intracellular Ca2+ 
concentration (expressed in relative fluorescence units as fold of basal) in stable 






























Figure 4.2: Concentration-response curve showing a decrease in intracellular 
Ca2+  concentration  (expressed in relative fluorescence units) in stable TRPM8 
channel-expressing HEK293 cells, following administration of increasing 
concentrations of the TRPM8 channel blocker AMTB (dark blue) co-




4.2.2 In vitro cell model studies showing that activation of the 5-HT1B 
receptor results in enhancement of icilin-induced TRPM8 channel responses 
In order to ascertain whether 5-HT1B receptor activation modulates TRPM8 
channel function, calcium fluorometry studies were carried out on HEK293 cells 
stably expressing the human TRPM8 channel and transiently transfected with the 
5-HT1B receptor. Application of the TRPM8 channel agonist icilin resulted in 
concentration-dependent increased levels of intracellular Ca2+ as assessed by 
calcium fluorometry (Figure 4.3). When the selective 5-HT1B receptor agonist CP 
94253 (5-propoxy-3-(1,2,3,6-tetrahydro-4-pyridinyl)-1H-pyrrolo[3,2-b]pyridine; 
3μM) was co-administered with icilin, intracellular Ca2+ levels were significantly 
higher than with icilin alone at 1.25μM, 2.5μM and 5μM (p<0.05; Student’s 
paired t-test) (Figure 4.3.).  CP 94253 on its own (at both 1.5μM and 3μM) did 
not result in a significant increase of intracellular Ca2+ over baseline levels 
(Figure 4.3). It has been shown that CP 94253 is a potent and selective 5-HT1B 
receptor agonist and its functional activity has been demonstrated in both in vivo 
and in vitro experiments (Fish et al., 1999; Koe et al., 1992; Lee et al., 2002).  
Significantly increased intracellular Ca2+ levels were also observed within 
seconds following co-administration of icilin plus CP 94253 using a real time 
fluorometry protocol (Figure 4.4). Importantly, this increment in intracellular 
Ca2+ was abolished in the presence of the selective 5-HT1B receptor antagonist 
SB 224289 in addition to icilin and CP 94253 (Figure 4.4). SB 224289 has been 
shown to be a high affinity, selective antagonist/inverse agonist at 5-HT1B 




































Figure 4.3: Concentration-response curve showing intracellular Ca2+ 
concentration (expressed in relative fluorescence units) in stable TRPM8 
channel-expressing HEK293 cells transfected with the 5-HT1B receptor, 
following icilin application alone (1.25μM, 2.5μM, 5μM and 10 μM; dark blue) 
or co-administration of icilin (1.25μM, 2.5μM, 5μM and 10 μM) and the 5-HT1B 
receptor agonist CP 94253 (3μM; pink). CP 94253 alone (1.5μM or 3μM; green) 
did not result in an increase of fluorescence over baseline values. These 
experiments were carried out in late passage TRPM8-HEK293 cells, where the 
absolute potency of TRPM8 agonists was reduced compared to that in early 
passage cells, but the relative facilitation by 5-HT1B receptor activation was 









































































Figure 4.4: Real-time calcium fluorometry (expressed in relative fluorescence 
units) indicating intracellular Ca2+ concentration in stable TRPM8-channel-
expressing HEK293 cells, transfected with the 5-HT1B receptor, following 
application of icilin (0.7μM; blue), the 5-HT1B receptor agonist CP 94253 
(2.5μM; brown), simultaneous application of icilin plus CP 94253 (red)   and 
simultaneous application of icilin, CP 94253 and the selective 5-HT1B receptor 
antagonist SB224289 (5μM; green). Co-administration of icilin and CP 94253 
resulted in a significant increase in fluorescence compared to icilin alone 
(p<0.05; Student’s paired t-test) and this effect was abolished when icilin and 
CP 94253 were administered in conjuction with SB224289 (p<0.05; Student’s 
paired t-test). Administration of CP 94253 alone did not result in increased 
fluorescence over baseline values. Values are means ± SEM from 5 separate 
determinations.  
 
4.2.3 TRPM8 channels and 5-HT1B receptors physically interact in an in 
vitro cell model 
In order to investigate whether the functional interaction between the 5-HT1B 
receptor and the TRPM8 channel might be mediated by way of a physical 
association between the channel and the receptor, co-immunoprecipitation 
studies were carried out using TRPM8 channel-expressing HEK293 cells 
transfected with FLAG-tagged 5-HT1B receptor.  Figure 4.5 shows representative 
immunoblots from TRPM8 channel immunoprecipitation on the left and anti-
FLAG immunoprecipitation (the reciprocal strategy, used to isolate FLAG-
tagged 5-HT1B receptor) on the right. Top panels confirm specific isolation of 
TRPM8 channel (left) and 5-HT1B receptor (identified as protein bands of 
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appropriate molecular weight) captured by immunoprecipitation antibodies, 
compared to same-species non-immune IgG controls. The bottom-left panel 
represents FLAG-5-HT1B receptor co-immunoprecipitated by specific antibody 
against the TRPM8 channel, with no FLAG-5-HT1B receptor co-
immunoprecipition evident in control non-immune IgG pull-downs, indicating 
that the 5-HT1B receptor specifically interacts with the TRPM8 channel. This was 
further confirmed by using monoclonal anti-FLAG antibody to pull down the 5-
HT1B receptor and probing of immunoprecipitates with anti-TRPM8 channel 
antibody. The bottom-right panel represents TRPM8 channel co-
immunoprecipitating with anti-FLAG (5-HT1B receptor) antibody. The greater 
density of the band isolated with anti-FLAG antibody, compared to non-immune 













































Figure 4.5: Investigation of co-immunoprecipitation of the TRPM8 channel and 
the 5-HT1B. receptor. Stable TRPM8 channel-expressing HEK293cells were 
transfected with FLAG-tagged 5-HT1B receptors. Immunoprecipitation with a 
TRPM8 antibody (left) or with anti-FLAG antibody (right) pulled down levels of 
5HT1B receptor and TRPM8 channel (Co-IP), respectively, which were not 





As the 5-HT1B receptor appears to form a complex with the TRPM8 channel, 
we investigated whether 5-HT1B receptor-mediated signalling might influence 
the channel. The TRPM8 channel is negatively modulated by PKC and PKA 
phosphorylation (Abe et al., 2006; De Petrocellis et al., 2007; Premkumar et al., 
2005) but positively modulated by phosphatidylinositol 4,5-bisphosphate; PIP2 
(Liu and Qin, 2005; Rohacs et al., 2005). The 5-HT1B receptor signals 
predominantly through pathways that do not cause cleavage of PIP2. Indeed, one 
pathway from this receptor is activation of PLD (unpublished work from the lab) 
and the PLD product, phosphatidic acid, can activate phosphatidyl inositol 5-
kinase to increase PIP2 levels (Cockcroft, 2009). Thus one possibility is that PLD 
and increased PIP2 levels may be involved in the 5-HT1B receptor facilitation of 
TRPM8 channel function.  
4.2.4 Evidence suggesting that 5-HT1B receptor-mediated enhancement of 
TRPM8 channel activation may be due to enhancement of PIP2 levels by a 
PLD1-dependent mechanism 
Calcium fluorometry studies were carried out to investigate the signalling 
involved in the 5-HT1B receptor-mediated enhancement of TRPM8 activation by 
icilin, observed as increased intracellular Ca2+ levels. The possible role of PLD1 
in mediating this effect was investigated using a range of inhibitors of PLD1 and 
modulators of other relevant signalling events in stable TRPM8 channel-
expressing HEK293 cells transiently transfected with the 5-HT1B receptor. 
Experiments were designed so that the effect of specific drugs when co-
administered with icilin and the 5-HT1B receptor agonist CP 94253 (2μM), was 
tested against three controls within each experiment: application of icilin 
(0.25μM), co-administration of icilin (0.25μM) plus the 5-HT1B receptor agonist 
CP 94253 (2μM) and co-administration of icilin (0.25μM) and the specific drug 
tested. This experimental design allowed for the identification of any specific 
effects of the drugs tested on the 5-HT1B receptor–mediated enhancement of 
intracellular Ca2+ levels through TRPM8 channel activation by icilin. 
Figure 4.6 summarises the results from this set of experiments. Co-
administration of the PLD1 inhibitors CAY10593 (VU0155069) 0.5 μM (Scott et 
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al., 2009) halopemide 4 μM (Scott et al., 2009) raloxifene 25 μM (Eisen and 
Brown, 2002) and calphostin C  2.5 μM (Sciorra et al., 2001) with icilin plus CP 
94253 resulted in a statistically significant reduction of the enhancement in 
intracellular Ca2+ levels observed when co-administration of icilin plus CP 94253 
was compared to application of icilin alone (Mann-Whitney U Test, p<0.05). 
Application of icilin plus PLD1 inhibitors did not result in significantly different 
intracellular Ca2+ levels compared to icilin alone.  
Calphostin C acts as a potent PLD1 inhibitor (Sciorra et al., 2001), but 
following UV exposure this drug acts as a PKC inhibitor (Bruns et al., 1991). 
Although care was to taken to avoid UV exposure, a control using the PKC 
inhibitor, bisindolylmaleimide 1, BIM1 (Toullec et al., 1991) was carried out. 
Co-administration of BIM1 (2.5 μM) with icilin plus CP 94253 resulted in 
significantly increased intracellular Ca2+ levels compared to icilin alone (Mann-
Whitney U Test, p<0.05) and these levels were not significantly different to 
those obtained with icilin plus CP 94253 (Figure 4.6). Application of icilin and 
BIM1 did not result in significantly different levels of intracellular Ca2+ than 
application of icilin alone (Figure 4.6). These results suggest that the 
enhancement in intracellular Ca2+ levels observed following the concurrent 
activation of the 5-HT1B receptor and the TRPM8 channel is not mediated by 
PKC. This is consistent with evidence that PKC is a negative modulator of the 
channel (Abe et al., 2006; Premkumar et al., 2005).  
 Both phosphatidylinositol 4 and 5- kinases are required for PIP2 synthesis, 
and the latter are activated by the PLD product, phosphatidic acid (Cockcroft, 
2009; Liu and Qin, 2005; Rohacs et al., 2005). In order to assess the role of PI 
kinases in the downstream events following concurrent activation of the 5-HT1B 
receptor and the TRPM8 channel, the effects of wortmannin were investigated. 
Wortmannin is a potent inhibitor of PI 3-kinases, but also with somewhat lower 
potency, of PI 4-kinases (Arcaro and Wymann, 1993). Co-administration of 
wortmannin with icilin plus CP 94253 to stable TRPM8-expressing HEK293 
cells transfected with the 5-HT1B receptor resulted in statistically significant 
lower levels of intracellular Ca2+ levels compared to those obtained when 
administering icilin and CP 94253 (Mann-Whitney U Test, p<0.05) (Figure 4.6). 
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Co-administration of wortmannin with icilin did not result in significantly 
different levels of intracellular calcium levels compared to administration of 
icilin alone (Figue 4.6).  These results suggest that the increase in fluorescence 
observed when the 5-HT1B receptor and the TRPM8 channel are simultaneously 
activated may be dependent on the activity of PI 4-kinase and which is consistent 
with a role for PIP2 here.  
In order to further assess the role of PIP2 on this signalling pathway, we 
investigated the effects of drugs that modulate the activity of phospholipase C 
(PLC) which cleaves PIP2 into diacylglycerol (DAG) and inositol 1, 4, 5 -
trisphosphate (IP3). Co-administration of the PLC activator, 2,4,6-trimethyl-N-
[3-(trifluoromethyl)phenyl]benzenesulfonamide (m-3M3FBS) (Bae et al., 2003) 
(2.5 μM)  with icilin plus CP 94253 to stable  TRPM8 channel-expressing 
HEK293 cells transiently transfected with the 5-HT1B receptor resulted in 
statistically significant lowered levels of intracellular Ca2+ , compared to 
administration of icilin plus CP  94253 (Mann-Whitney U Test, p<0.05) (Figure 
4.6). These results suggest that the increase in fluorescence observed when the 5-
HT1B receptor and the TRPM8 channel are simultaneously chemically activated 
is abolished if PIP2 is cleaved by PLC. Co-administration of m-3M3FBS (2.5 
μM) with icilin also resulted in a significantly lower level of intracellular calcium 
following compared to administration of icilin alone (Mann-Whitney U Test, 
p<0.05) suggesting that PIP2 is partially required ordinarily for the full extent of 
icilin-mediated activation of the TRPM8 channel (Figure 4.6).  
Co-administration of the PLC inhibitor U-73122, ((1-[6-[[17-beta-3-
methoxyestra-1,3,5(10)-trien-17-yl]amino]hexyl]-1H-pyrrole-2,5-dione) 
(Bleasdale et al., 1990) (10 μM) with icilin and CP resulted in a significant 
increase of intracellular Ca2+ levels compared to administration of icilin and CP 
(Mann-Whitney U Test, p<0.05) (Figure 4.6). Co-administration of the PLC 
inhibitor U-73122 (10 μM) with icilin did not result in significantly different 
levels of intracellular calcium compared to administration of icilin alone (Figure 
4.6). This is consistent with the idea that inhibition of ongoing PIP2 cleavage 
would increase PIP2 levels and promote any role in modulating the TRPM8 






























































Figure 4.6: Intracellular Ca2+ levels, as assessed by calcium fluorometry 
(expressed as percentage increase over basal control) following application of 
icilin 0.25μM (dark blue), icilin 0.25μM and CP 94253 2μM (dark red), drug 
treatment plus icilin (yellow) and drug treatment plus icilin and CP 94253 (light 
blue). The enhancement in Ca2+ levels over application of icilin alone observed 
when icilin is co-administered with CP 94253 was significantly reduced by 
concurrent application of PLD1 inhibitors CAY10593 (CAY), halopemide (Hal), 
raloxifene (Ral) and calphostin C (Cal) (but not the PKC inhibitor, 
bisindolymaleimide (BIM1). Similar significant reductions in icilin plus 
CP94253 responses (* p<0.05, Mann-Whitney U-Test) were seen with the PI 
kinase inhibitor, wortmannin (Wor) and the PLC activator, m-3M3FBS (m3M), 
which also attenuated responses to icilin alone († p<0.05). The PLC inhibitor U-
73122 (U73) caused significant facilitation of responses to icilin plus CP94253 
(‡ p<0.05, Mann-Whitney U-Test). Values are means ± SEM from 5 











In order to obtain additional molecular evidence for a role of PLD and 
identify which isoform might be responsible,  stable TRPM8 channel-expressing 
HEK293 cells were co-transfected with the 5-HT1B receptor and either the empty 
vector pcDNA3.1, dominant negative (catalytically inactive) PLD1 or dominant 
negative  (catalytically inactive) PLD2. The constructs [K898R] PLD1 and 
[K758R] PLD2 were kindly provided by Mike Frohman. Calcium fluorometry 
experiments were carried out in these cells to investigate levels of intracellular 
Ca2+ following administration of icilin (0.25 μM) and icilin (0.25 μM) plus CP 
94253 (2 μM). Figure 4.7 illustrates the results from this set of experiments. Co-
administration of icilin and CP94253 resulted in a highly statistically significant 
increase in intracellular calcium levels compared to icilin alone in cells 
transfected with pcDNA3.1 or with dominant negative-PLD2 (p<0.01, Mann-
Whitney U-Test) (Figure 4.7). In cells transfected with dominant negative-PLD1, 
co-administration of icilin and CP94253 still resulted in a statistically significant 
increase in intracellular Ca2+ levels compared to icilin alone (p<0.05, Mann-
Whitney U-Test) but this increase was significantly lower than the response 
observed in cells transfected with pcDNA3.1 (p<0.05, Mann-Whitney U-Test) 
(Figure 4.7). These observations specifically implicate PLD1 rather than PLD2 

































   

























Figure 4.7: Intracellular Ca2+ levels, as assessed by calcium fluorometry 
(expressed as percentage increase over basal control) following application of 
icilin 0.25μM (dark blue) or icilin 0.25μM plus CP 94253 2μM (red). Stable 
TRPM8 channel-expressing HEK293 cells were transiently transfected with the 
5-HT1B receptor and also transfected with either an empty vector (pcDNA3.1), 
dominant negative PLD1 or dominant negative PLD2. CP94253 caused 
significant facilitation of responses to icilin in cells transfected with pcDNA3.1 
or dominant negative PLD2 (** p<0.001, Mann-Whitney U-Test and also to a 
lesser extent in cells with dominant negative PLD1 (* p<0.05). The enhancement 
of icilin-induced increases in intracellular Ca2+ levels due to CP94253 was 
significantly attenuated († p<0.05, Mann-Whitney U-Test) in cells transfected 
with the dominant negative PLD1 compared to pcDNA3.1 controls. Values are 














4.2.5 TRPM8 channels and the 5-HT1B receptor physically interact with 
PLD1 in an in vitro cell model 
Further co-immunoprecipitation studies were then carried out to investigate 
whether PLD1 physically interacts with the TRPM8 channel and/or the 5-HT1B 
receptor in vitro. Stable TRPM8 channel-expressing HEK293 cells were 
transiently transfected with HA-tagged PLD1 and FLAG-tagged 5-HT1B 
receptor.  
Figure 4.8 shows representative blots from this set of co-immunoprecipitation 
studies. Immunoblots from anti-FLAG immunoprecipitation (used to isolate 
FLAG-tagged 5-HT1B receptor) are shown in the left panels, immunoblots from 
TRPM8 channel immunoprecipitation are shown in the third from left panels and 
immunoblots from anti-HA immunoprecipitation (used to isolate HA-tagged 
PLD1) are shown in the second and fourth from left panels. Top panels confirm 
specific isolation of the primary pull down targets FLAG 5-HT1B receptor, 
TRPM8 channel and HA-PLD1 in each case compared to same-species non-
immune IgG controls. 
The lower panels display blots for co-immunoprecipitated proteins. The high 
density band in the bottom-left panel represents HA-PLD1 co-immunoprecipitate 
pulled down with anti-FLAG, with only a faint corresponding band pulled down 
with control non-immune IgG, indicating that PLD1 specifically interacts with 
the 5-HT1B receptor. In order to confirm this result, HA-PLD1 was isolated by 
using anti-HA antibody. Although immunoblotting of anti-HA 
immunoprecipitates with anti-FLAG identified a band of appropriate molecular 
weight suggesting 5-HT1B receptor binding to HA-PLD1 pulldowns, IgG 
controls probed with anti-FLAG also produced a faint band.  
The high density band in third-from-left bottom panel represents HA-PLD1 
co-immunoprecipitate pulled down with the TRPM8 channel, with only a much 
lower density corresponding band pulled down with control non-immune IgG, 
indicating that PLD1 specifically interacts with the TRPM8 channel. In order to 
confirm this result, HA-PLD1 was isolated by using anti-HA antibody. 
Immunoblotting of anti-HA co-immunoprecipitates with anti-TRPM8 channel 
antibody identified a band of appropriate molecular weight suggesting TRPM8 
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binding to HA-PLD1 pulldowns, IgG control pulldowns probed with anti-
TRPM8 channel antibody produced only a faint band of roughly the same 
molecular weight.  
Taken together these co-immunoprecipitation studies suggest that both the 
TRPM8 channel and the 5-HT1B receptor physically interact with PLD1 in an in 






























































































Figure 4.8: Investigation of co-immunoprecipitation of PLD1 with FLAG-tagged 
5-HT1B receptor and TRPM8 channel. Stable TRPM8 channel-expressing 
HEK293cells were transfected with FLAG-tagged 5-HT1B receptor and HA-
tagged PLD1. Immunoprecipitation was carried out with anti-FLAG antibody, 
anti-TRPM8 channel antibody or anti-HA antibody: (labels above each column 
of panels). The upper panels in each case show blots carried out for the primary 
pulldown target to show the success of the specific pulldown procedures. The 
lower panels in each case show probing of these pulldowns for associated (co-
immunoprecipitated) proteins, HA-PLD1, FLAG-5-HT1B receptor and TRPM8 
channel. Taken together these results suggest that both the 5-HT1B receptor and 
the TRPM8 channel interact with PLD1, presumably in some form of regulatory 




4.2.6 Expression of 5-HT1B receptor protein in rat (naïve and CCI) DRG 
and spinal cord 
In order to investigate the patterns of expression of the 5-HT1B receptor in 
chronic neuropathic pain states, Western immunoblotting was carried out in 
whole lysates obtained from DRGs and spinal cord ipsilateral to injury in CCI 
rats at peak sensitivity compared to contralateral and naïve samples (n=3 per 
group).  A 5-HT1B receptor-immunoreactive band was found at an appropriate 
molecular weight but no statistically significant difference was observed between 
treatments (expressed in relative intensity expressed as a proportion of GAPDH 
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Figure 4.9: Western immunoblots of dorsal root ganglia (DRG) and spinal cord 
whole lysates from CCI neuropathic pain model rats (ipsilateral and 
contralateral to injury) and naïve rats (n=3 per group) incubated with a 5-HT1B 
receptor antibody (upper panels). Lower panels represent incubation with 
antibody for the housekeeping enzyme GAPDH. No statistically significant 
differences between treatments (calculated from data expressed as relative grey 





4.2.7 Calcium imaging of 5-HT1B receptor modulation of TRPM8 channel 
responses in cultured DRG cells 
Calcium imaging studies prepared with the assistance of Andrew Allchorne 
(in collaboration with Dr John Curtis) were carried out on DRG neuron cultures 
in order to investigate 5-HT1B-receptor mediated modulation of TRPM8 channel 
activation by icilin in native systems. Experiments were designed to compare a 
drug treatment with an initial application of icilin alone. The first icilin 
application was used both to identify icilin-responsive cells (only a small 
fraction, 5-10% of the cultured DRG cells) and also to provide a response against 
which the effects of the treatment were compared. Figure 4.10 provides an 
illustration of a typical icilin response. The two treatments within each 
experiment were separated by a wash in order to return fluorescence levels to 
baseline. Areas under the curve were calculated for each of the two treatments 
and compared using a Wilcoxon Signed Rank Test (GraphPad Prism 4). 
Simultaneous application of icilin and the 5-HT1B receptor agonist CP 94253 
resulted in significantly higher intracellular Ca2+ levels compared to application 
of icilin alone (p<0.05, n = 19) (Figures 4.10, 4.11 and 4.13). In order to 
elucidate whether a second icilin application resulted in increased fluorescence, 
areas under the curve produced from two consecutive icilin applications 
separated by a wash were compared. No significant difference was observed 
between two successive icilin applications (Figure 4.12 and 4.13, n = 12).   
In order to investigate if the CP 94253-mediated enhancement of TRPM8 
channel activation by icilin was mediated by PLD1, the PLD1 inhibitor 
calphostin C was co-administered with icilin and CP 94253. No significant 
difference was observed between areas under the curve obtained following co-
administration of icilin, CP 94253 and calphostin C (n = 14) compared to those 
obtained for icilin alone, i.e. no enhancement of the TRPM8 channel activation 
caused by icilin was observed (Figure 4.13). Co-administration of BIM1 (in 
order to control for PKC inhibition, as described above) with icilin and CP 94253 
resulted in a significantly increased response compared to that of icilin alone 
(p<0.05, n = 17), although the absolute magnitude of the responses did appear 
less than those due to icilin plus CP 94253 alone (Figure 4.13). 
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Single administration of CP 94253, calphostin C or BIM1 to icilin-responsive 
cells did not result in any discernible effects, defined as a 10% variation over the 
baseline.  
icilin






































Figure 4.10: Trace from a calcium imaging recording from a single DRG cell 
showing a typical response to application of icilin (2.5 μM). Each recording 
period represented 5 sec. Similar responses to the selective TRPM8 channel 










































Figure 4.11: Trace from a calcium imaging recording from a single DRG cell 
showing a typical response to application of icilin (2.5 μM) followed by a 











































Figure 4.12: Trace from a calcium imaging recording from a single DRG cell 


































































































Figure 4.13: Mean stimulus-induced increase in intracellular Ca2+ fluorescence 
resulting from various treatments expressed as fold increase in area under the 
curve (AUC) of excess response expressed as mean ratio ± SEM compared to 
initial icilin response. Experiments were carried out in 3 coverslips/treatment, 
with an average number of icilin responsive DRG cells of 15.5 (±1.6) per 
treatment. Treatments were: icilin (2.5 μM) plus CP 94523 (3 μM), icilin (2.5 
μM) plus CP 94253 (3 μM) and calphostin C (3 μM), icilin (2.5 μM) plus CP 
94253 (3 μM) and BIM1 (2.5 μM) or straightforward repeat of icilin (2.5 μM).  
115 
 
4.2.8 TRPM8 channels and 5-HT1B receptors physically interact in vivo 
In order to investigate whether the functional interaction between the 5-HT1B 
receptor and the TRPM8 channel observed in calcium imaging experiments 
carried out in DRG neuron cultures is correlated with a direct physiological 
association between the channel and the receptor, co-immunoprecipation studies 
were carried out on spinal cord lysates from naive rats. This was carried out in 
spinal cord rather than DRG tissue because inordinately high numbers of animals 
would be required for immunoprecipitation experiments on DRG.   
 
Figure 4.14 illustrates the results from this study. Immunoprecipitation with a 
TRPM8 channel antibody pulled down 5-HT1B receptor immunoreactivity (co-
IP), identified as a dense band around 50kDa, which was not present in non-
immune IgG controls. Following incubation of the 5-HT1B receptor primary 
antibody with a specific blocking peptide (the antigen to which it was raised; 
right panels), Western blotting immunodetection of 5-HT1B receptor was 



































Figure 4.14: Investigation of co-immunoprecipitation of the TRPM8 channel and 
the 5-HT1B receptor in spinal cord homogenates obtained from naïve rats. 
Results are typical of three separate experiments. Immunoprecipitation with an 
anti-TRPM8 channel antibody pulled down levels of 5HT1B receptor (co-IP), 
identified as a dense band between the 51kDa and 39 kDa markers, which was 
not observed in non-immune IgG controls. When a blocking peptide against the 
epitope recognised by the 5-HT1B receptor primary antibody (right panels) was 
preincubated with the antibody (pre-absorbtion control), Western blotting 
immunodetection of the 5-HT1B receptor was abolished, showing specificity of 
the antibody. 
 
4.2.9 Behavioural reflex investigation of 5-HT1B receptor-mediated 
modulation of TRPM8 channel mediated analgesia in the CCI model of 
neuropathic pain 
The 5-HT1B receptor agonist, CP 94253 (2.5 nmol) was injected intrathecally 
together with the TRPM8 channel agonist icilin (2.5 nmol) in CCI rats at peak 
behavioural sensitivity in order to investigate whether the previously reported 
analgesic effect of intrathecally administered icilin was modulated by 5-HT1B 
receptor activation. The effect of A) icilin (2.5 nmol) alone, B) icilin (2.5 nmol) 
plus CP 94253 (2.5 nmol) or C) CP 94253 (2.5 nmol) alone on the mechanical 
and thermal hyperalgesia exhibited by CCI rats at baseline is shown in Figures 
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4.15 and 4.16 respectively and expressed as mean paw withdrawal thresholds (in 
mN/mm2, assessed by von Frey filaments) and mean paw withdrawal latency (in 
seconds, assessed by Hargreaves’ thermal test).  
Intrathecal administration of icilin (at a submaximal dose) resulted in a 
statistically significant difference between ipsilateral baseline mechanical 
withdrawal threshold values and ipsilateral post-injection values (Friedman test, 
p<0.05; followed by post-hoc Dunnett’s test which indicated a significant 
difference at 15 mins post-injection). Additionally ipsilateral and contralateral 
values were not significantly different at 25 mins post-injection (Wilcoxon test, 
p>0.05) (Figure 4.15 A). However, thermal withdrawal latency did not reach 
statistically significant difference between ipsilateral baseline and post-injection 
values (One-way repeated measures ANOVA, p>0.05) and ipsilateral and 
contralateral values remained significantly different at all time points (Wilcoxon 
test, p<0.05) (Figure 4. 16 A). 
Intrathecal administration of icilin and CP 94253 together did not result in a 
statistically significant difference between ipsilateral baseline and post-injection 
mechanical withdrawal thresholds (Figure 4.15 B). However, there was a 
statistically significant difference between baseline and post-injection thermal 
withdrawal latency (One-way repeated measures ANOVA, p<0.05, with post-hoc 
Dunnett’s test showing a significant difference at 15 mins post, injection). 
Additionally, ipsilateral and contralateral values were not significantly different 
at 15 and 25 mins post-injection (Figure 4.16 B).  
Intrathecal administration of CP 94253 alone did not show statistically 
significant differences between baseline and post-injection values either on 
mechanical withdrawal thresholds or on thermal withdrawal latency (Figure 4.15 
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Figure 4.15: Effects of intrathecal administration of A) icilin (2.5 nmol); B) the 
selective 5-HT1B receptor agonist CP 94253 (2.5 nmol) co-administered with 
icilin (2.5 nmol) and C) CP 94253 (2.5 nmol) alone on the mechanical 
hypersensitivity developed in the ipsilateral paw (red) compared to the 
contralateral paw (blue) in rats at peak behavioural sensitisation following CCI 
surgery (n=6). Data show mean paw withdrawal thresholds (in mN/mm2) ± 
SEM. (*) denotes statistically significant difference between ipsilateral and 
contralateral values at individual time points (Wilcoxon signed rank test). (†) 
denotes statistically significant difference between ipsilateral baseline values 
and post-injection values (Friedman test).  The inset graphs show the percentage 
of mean baseline difference between ipsilateral and contralateral values 























































































































































B) icilin + CP 94253

















































b/l 15 25 35 45 55 65
*





Figure 4.16: Effects of intrathecal administration of A) icilin (2.5 nmol); B) the 
selective 5-HT1B receptor agonist CP 94253 (2.5 nmol) co-administered with 
icilin (2.5 nmol) and C) CP 94253 (2.5 nmol) alone on thermal hyperalgesia 
developed in the ipsilateral paw (red) compared to the contralateral paw (blue) 
in rats at peak behavioural sensitisation following CCI surgery (n=6). Data 
show mean paw withdrawal latency (in seconds) ± SEM. (*) denotes statistically 
significant difference between ipsilateral and contralateral values at individual 
time points (Paired t-test). (†) denotes statistical significant difference between 
ipsilateral baseline values and post-injection values (One-way repeated 
measures ANOVA test). The inset graphs show the percentage of mean baseline 




Figures 4.17 and 4.18 show mechanical withdrawal thresholds and thermal 
withdrawal latencies in CCI rats at peak behavioural sensitivity following 
administration of A) icilin alone (2.5 nmol) B) icilin (2.5 nmol), plus CP 94253 
(2.5 nmol) and the PLD1 inhibitor, calphostin C (0.65 nmol) and C) calphostin C 
(0.65 nmol) alone.  
Intrathecal administration of icilin and CP 94253 in the presence of calphostin 
C did not result in a statistically significant difference between ipsilateral 
baseline and post-injection mechanical withdrawal thresholds (Friedman test, 
p>0.05) (Figure 4.17 B). Additionally, there was no statistically significant 
difference between baseline and post-injection thermal withdrawal latency (One-
way repeated measures ANOVA, p>0.05) (Figure 4.18 B, contrasting with the 
significant differences previously observed in the case of icilin plus CP 94253 
(Figure 4.16B)).  
Intrathecal administration of calphostin C alone did not show statistically 
significant differences between baseline and post-injection values either on 
mechanical withdrawal thresholds or on thermal withdrawal latency (Figure 4.17 
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Figure 4.17: Effects of intrathecal administration of A) icilin (2.5 nmol); B) the 
selective PLD1 inhibitor Calphostin C (0.65 nmol) co-administered with icilin 
(2.5 nmol) and CP 94253 (2.5 nmol) and C) Calphostin C (0.65 nmol) alone on 
the mechanical hypersensitivity developed in the ipsilateral paw (red) compared 
to the contralateral paw (blue) in rats at peak behavioural sensitisation 
following CCI surgery (n=6). Data shows mean paw withdrawal threshold (in 
mN/mm2) ± SEM. (*) denotes statistically significant difference between 
ipsilateral and contralateral values at individual time points (Wilcoxon signed 
rank test). (†) denotes statistically significant difference between ipsilateral 
baseline values and post-injection values (Friedman test). The inset graphs show 
the percentage of mean baseline difference between ipsilateral and contralateral 
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Figure 4.18: Effects of intrathecal administration of A) icilin (2.5 nmol); B) the 
selective PLD1  inhibitor Calphostin C (0.65 nmol) co-administered with icilin 
(2.5 nmol) and CP 94253 (2.5 nmol) and C) Calphostin C (0.65 nmol) alone on 
thermal hyperalgesia developed in the ipsilateral paw (red) compared to the 
contralateral paw (blue) in rats at peak behavioural sensitisation following CCI 
surgery (n=6). (*) denotes statistically significant difference between ipsilateral 
and contralateral values at individual time points (Paired t-test). (†) denotes 
statistical significant difference between ipsilateral baseline values and post-
injection values (One-way repeated measures ANOVA test). Data shows mean 
paw withdrawal latency (in seconds) ± SEM. The inset graphs show the 
percentage of mean baseline difference between ipsilateral and contralateral 





Cooling and topical menthol have been historically used as analgesics. Recent 
advances in molecular cloning have made possible the identification of a member 
of the transient receptor potential family of channels, TRPM8, as a transducer in 
cool temperature detection and also as the mediator involved in cooling analgesia 
in pathophysiological (sensitised) pain states (Proudfoot et al., 2006). However, 
activation of the TRPM8 channel under normal, unchallenged physiological 
conditions does not result in alteration of nociceptive thresholds. This suggests 
that the TRPM8 channel must be subject to a mechanism of facilitatory 
modulation in chronic pain states that enables its analgesic effect upon 
activation. TRPM8 channel expression has been noted to increase in DRG 
neurons ipsilateral to injury in the CCI model of neuropathic pain (Frederick et 
al., 2007; Proudfoot et al., 2006). However, no alterations in TRPM8 channel 
expression were reported in the SNL model of nerve injury or in a model of 
inflammation (Katsura et al., 2006; Obata et al., 2005). Thus, increased 
expression of the TRPM8 channel in sensory neurons does not appear a 
sufficient mechanism to explain the reversal of nociceptive sensitisation 
observed following TRPM8 channel activation in chronic pain states. 
Serotonin (5-HT) has been suggested to play an important role in pain 
processing following injury. 5-HT is released by platelets and mast cells 
following tissue injury, inflammation and also after nerve injury (Anden and 
Olsson, 1967; Dray, 1995; Vogel et al., 2003). Several 5-HT receptors have been 
identified in sensory neurons, with different, even antagonistic effects in pain 
processing (see section 4.1.4.). 5-HT1B receptors appear to mediate 
antinociceptive effects and their pattern of expression in peripheral afferents is 
very similar to that of TRPM8 channels. Thus, 5-HT1B appeared like a good 
candidate to investigate as a potential mediator in the facilitation of TRPM8 
channel activation in sensitised pain states.  
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4.3.1 Chemically mediated TRPM8 channel opening is facilitated by 
activation of the 5-HT1B receptor 
In order to investigate our hypothesis that TRPM8 channel activity is 
modulated by 5-HT1B receptor activation a number of in vitro studies were 
carried out. Administration of the TRPM8 channel selective agonist icilin to 
HEK293 cells stably transfected with the human form of the TRPM8 channel 
showed a concentration-dependent increase in intracellular calcium concentration 
and this effect was reversed by the selective TRPM8 channel-selective blocker 
AMTB and was absent in untransfected HEK293 cells, confirming specificity of 
this action through the TRPM8 channel. Co-administration of icilin and the 5-
HT1B receptor-selective agonist CP 94253 to HEK293 cells stably transfected 
with TRPM8 and transiently transfected with the 5-HT1B receptor, resulted in 
intracellular Ca2+ levels that were significantly higher than with icilin alone. 
Administration of CP 94253 without icilin did not result in an increase in 
intracellular Ca2+. Moreover, the increment in intracellular Ca2+ associated with 
co-administration of icilin and CP 94253 was abolished in the presence of the 
selective 5-HT1B receptor antagonist SB 224289, confirming the specificity of 
this action through the 5-HT1B receptor.  
Our results from the calcium imaging experiments carried out in dissociated 
adult rat DRG neurons also suggested a facilitatory action of the 5-HT1B receptor 
on TRPM8 function in native systems, as the increase in calcium fluorescence 
associated with icilin was potentiated when icilin was co-administered with CP 
94253. Further calcium imaging studies should aim to confirm the specificity of 
this action using 5-HT1B antagonists. Additionally, since we propose that this 
mechanism might operate in chronic pain states through the mediation of 
serotonin, calcium imaging studies in DRG cultured neurons investigating the 
role of serotonin on TRPM8-mediated calcium entry, using 5-HT1B receptor 
agonists and antagonists, would also be valuable. 
Recent studies have suggested a modulatory role of serotonin receptors on 
TRPV1 channel activity. Activation of spinal 5-HT2A/2C receptors with the 
selective agonist DOI ((6)-2,5-dimethoxy-4-iodoamphetamine) resulted in an 
increase in capsaicin-evoked  release of SP-like immunoreactivity in the rat 
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dorsal horn, which was partially reversed by the 5-HT2A receptor antagonist 
ketanserin (Kjorsvik et al., 2003). The 5-HT2A receptor has been recently shown 
to be expressed in TRPV1-positive primary sensory neurons (Van et al., 2009). 
Additionally, calcium imaging and whole-cell patch-clamp studies on cultured 
DRG neurons from newborn rats showed that 5-HT potentiated the increases of 
[Ca2+]i, current and depolarizing responses induced by capsaicin, protons and 
noxious heat (Ohta et al., 2006). TRPV1 function is also potentiated by 5-HT in 
colon sensory neurons from rats and mice and this has been suggested as a 
mechanism mediating visceral hypersensitivity (Qin et al., 2010; Sugiuar et al., 
2004). The 5-HT2A receptor has been shown to be involved in pro-nociceptive 
actions and to be implicated in inflammatory pain (its expression being 
upregulated in inflammation), whereas 5-HT1B has been associated with anti-
nociception (Abbott et al., 1997; el-Yassir et al., 1988; Gjerstad et al., 1997; 
Kayser et al., 2007; Obata et al., 2000; Okamoto et al., 2002). These divergent 
actions appear to be furthered through the functional association of 5-HT2A and 
5-HT1B with a typically nociceptive (TRPV1) and analgesic (TRPM8) system, 
respectively. 
   
Western immunoblotting was carried out in whole lysates obtained from 
DRGs and spinal cord ipsilateral to injury in CCI rats at peak sensitivity 
compared to contralateral and naïve samples, but no statistically significant 
difference in the expression of the 5-HT1B receptor was observed between 
treatments. Upregulation of the 5-HT1B receptor has been described in 
inflammatory pain models (Liu et al., 2005; Wu et al., 2001) but to our 
knowledge no changes in the expression patterns of this receptor have been 
reported in models of neuropathic pain. 
Extensive trials were carried out with a variety of commercially available 5-
HT1B receptor antibodies in order to try and identify the subpopulation of DRG 
cells in which the receptor is expressed (and to investigate possible co-
localisation with the TRPM8 channel) using double-label immunofluorescence 
histochemistry. Despite lengthy evaluation of different fixation, signal 
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amplification and incubation techniques it was not possible to identify an 
adequate reagent and protocol.  
The functional interaction between the 5-HT1B receptor and the TRPM8 
channel described above might be mediated by a physical association between 
the channel and the receptor, as suggested by the results from co-
immunoprecipitation studies on HEK293 cells transfected with the TRPM8 
channel and the 5-HT1B receptor. Physical interaction of the TRPM8 channel and 
the 5-HT1B receptor was also observed in spinal cord homogenates from naïve 
rats, suggesting that this might be relevant in vivo. No previous reports have 
identified a physical interaction between a GPCR and a TRP channel. 
4.3.2 5-HT1B receptor-mediated facilitation of TRPM8 channel activation 
may be due to a PLD1-dependent mechanism 
Recent studies have unravelled mechanisms of TRPM8 modulation, both 
inhibitory and facilitatory. The TRPM8 channel appears to be negatively 
modulated by PKC and PKA phosphorylation (Abe et al., 2006; Bavencoffe et 
al., 2010; De Petrocellis et al., 2007; Premkumar et al., 2005). On the other hand, 
TRPM8 activity is positively modulated by phosphatidylinositol 4, 5-
bisphosphate, PIP2 (Liu and Qin, 2005; Rohacs et al., 2005).  
As our study suggested that the 5-HT1B receptor appears to form a complex 
with the TRPM8 channel, we investigated whether 5-HT1B receptor-mediated 
signalling might influence the channel. The 5-HT1B receptor signals 
predominantly through pathways that do not cause cleavage of PIP2. Indeed, one 
pathway from this receptor is activation of PLD (unpublished work from the lab) 
and PLD can activate phosphatidylinositol 5-kinase to increase PIP2 levels 
(Cockcroft, 2009).  
Co-administration of the PLD1 inhibitors CAY10593 (VU0155069), 
halopemide, raloxifene or calphostin C with icilin and the 5-HT1B receptor 
agonist, CP 94253 resulted in the abolition of the enhancement in intracellular 
Ca2+ levels observed when co-administration of icilin plus CP 94253 was 
compared to application of icilin alone. These results were further confirmed in 
calcium imaging studies carried out in DRG cultured neurons where calphostin 
C, but not BIM-1 resulted in intracellular calcium responses to icilin plus CP 
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95243 that were not significantly different from those obtained by application of 
icilin alone. 
Recent studies have identified a regulatory role of histamine receptors and 
metabotropic glutamate receptors on TRPC3 channel activity that is mediated by 
PLD (Glitsch, 2010; Kwan et al., 2009). 
 
There are two mammalian specific PLD isoforms, PLD1 and PLD2, encoded 
by two PLD genes, each one with two splice-variants and each isoform appears 
to be involved in specific cellular processes (Hammond et al., 1997; Liscovitch 
et al., 2000). In order to identify which PLD isoform might be responsible for the 
observed 5-HT1B receptor-mediated enhancement of TRPM8 channel activity,  
fluorometry studies were carried out in stable TRPM8 channel-expressing 
HEK293 cells co-transfected with the 5-HT1B receptor and either the empty 
vector pcDNA3.1, dominant negative (catalytically inactive) PLD1 or dominant 
negative  (catalytically inactive) PLD2. In cells transfected with the dominant 
negative PLD1 (but not the dominant negative construct), the icilin-induced 
increase in calcium fluorescence was significantly lower than the response 
observed in cells transfected with pcDNA3.1, suggesting that PLD1 rather than 
PLD2 is involved in the effect of the 5-HT1B receptor on TRPM8 channel 
responses.  
 
Further co-immunoprecipitation studies were carried out to investigate 
whether PLD1 physically interacts with the TRPM8 channel and/or the 5-HT1B 
receptor in vitro. Our results suggest that PLD1 might bind to both the channel 
and the receptor. Previous studies have provided evidence for physical 
interactions of PLD with several GPCRs (Barclay, 2010; Bhattacharya et al., 
2004; Koch et al., 2003). However, to our knowledge this is the first time that a 
regulatory signalling complex between a GPCR, a TRP channel and PLD has 
been described. PLD hydrolyses phosphatidylcholine to produce phosphatidic 
acid and choline (Liscovitch et al., 2000). PLD can result in activation of PIP 5-
kinase which, in turn, is involved in PIP2 synthesis (Cockcroft, 2009). Since PIP2 
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is known to have a positive modulatory action in TRPM8 activity we carried out 
a number of in vitro experiments to investigate this pathway (Figure 4.19). 
 














Figure 4.19: Diagram illustrating the mechanism of interaction between the 5-
HT1B receptor and the TRPM8 channel, through PLD activation and increased 
PIP2 levels. All processes relating to lipids will occur within the plasma 
membrane but the diagram has been expanded to aid clarity.   
 
In order to assess the role of PI kinases in the downstream events following 
concurrent activation of the 5-HT1B receptor and the TRPM8 channel, the effects 
of wortmannin, an inhibitor of PI 3-kinases and PI 4-kinases were investigated 
using calcium fluorometry on stable TRPM8 channel-expressing HEK293 cells 
transiently transfected with the 5-HT1B receptor. Wortmannin reversed the 
enhancement of intracellular Ca2+ levels obtained when administering icilin and 
CP 94253. Although wortmannin inhibits both PI 3-kinases and PI 4-kinases, 
studies using a low dose of wortmannin, which inhibits PI 3-kinases but not PI 4-
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kinases, suggested that the inhibition of PIP2 synthesis is mainly dependent on 
the activity of PI 4-kinase (Liu and Qin, 2005). 
The role of PIP2 in this signalling pathway was investigated using drugs that 
modulate the activity of phospholipase C (PLC) which cleaves PIP2 into 
diacylglycerol (DAG) and inositol 1,4,5-trisphosphate (IP3). Co-administration 
of the PLC activator, m-3M3FBS with icilin plus CP 94253 to stable  TRPM8 
channel-expressing HEK293 cells transiently transfected with the 5-HT1B 
receptor resulted in abolition of the increase in levels of intracellular calcium 
levels observed with administration of icilin plus CP  94253 compared to icilin 
alone. These results suggest that the increase in fluorescence observed when the 
5-HT1B receptor and the TRPM8 channel are simultaneously chemically 
activated is abolished if PIP2 is cleaved by PLC. Interestingly, co-administration 
of m-3M3FBS with icilin also resulted in a significantly lower level of 
intracellular calcium compared to administration of icilin alone, suggesting that 
PIP2 is partially required ordinarily for the full extent of icilin-mediated 
activation of the TRPM8 channel. Indeed, previous reports have suggested that 
PIP2 acts constitutively as a positive regulator of TRPM8 channel activity (Liu 
and Qin, 2005; Rohacs et al., 2005). 
Co-administration of the PLC inhibitor U-73122 with icilin and CP resulted in 
a significant increase of intracellular Ca2+ levels compared to administration of 
icilin and CP. This is consistent with the idea that inhibition of ongoing PIP2 
cleavage would increase PIP2 levels and promote any role of PIP2 in modulating 
the TRPM8 channel.   
4.3.3 The role of 5-HT1B receptor activation on TRPM8 channel-mediated 
analgesia in the CCI model of neuropathic pain  
TRPM8 channel activation, using peripherally (topically) or centrally 
(intrathecally) applied TRPM8 channel agonists menthol and icilin in the CCI 
model of chronic neuropathic pain, results in a reduction of sensitised reflex pain 
behaviours (Proudfoot et al., 2006). In order to assess any modulatory influences 
of concurrent 5-HT1B receptor activation on TRPM8 channel-mediated analgesia, 
we assessed effect of intrathecal co-administration of the 5-HT1B receptor 
agonist, CP 94253 and the TRPM8 channel agonist icilin (compared to 
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administration of either icilin or CP 94253 alone) in CCI rats at peak behavioural 
sensitivity.  
Although intrathecal administration of icilin (at a submaximal dose) resulted 
in a statistically significant difference between ipsilateral baseline mechanical 
withdrawal threshold values and ipsilateral post-injection values, thermal 
withdrawal latency did not reach statistically significant difference between 
ipsilateral baseline and post-injection values. This is probably a reflection of a 
sub-optimal dose of icilin being deliberately used in these experiments 
(Proudfoot et al., 2006).  
Intrathecal administration of icilin and CP 94253 resulted in no significant 
difference between baseline and post-injection thermal withdrawal latency and 
between ipsilateral and contralateral values at particular time points post-
injection. Intrathecal administration of CP 94253 alone did not show statistically 
significant differences between baseline and post-injection values either on 
mechanical withdrawal thresholds or on thermal withdrawal latency. This 
suggests that the reversal of sensory sensitisation observed with co-
administration of icilin and CP 94253 is not solely the result of 5-HT1B 
activation. Although previous studies have suggested an antinociceptive role for 
spinal 5-HT1B receptors (el-Yassir et al., 1988; Gjerstad et al., 1997; Liu et al., 
2007) this effect was not obvious at the dose required here to apparently facilitate 
TRPM8 channel activation.  
In order to assess the role of PLD1 in the possible modulation of 5-HT1B 
receptor activation on TRPM8 channel-mediated analgesia we assessed 
mechanical withdrawal thresholds and thermal withdrawal latencies in CCI rats 
at peak behavioural sensitivity following intrathecal co-administration of icilin, 
CP 94253 and the PLD1 inhibitor, calphostin C, compared to administration of 
icilin or calphostin C alone. Intrathecal administration of icilin and CP 94253 in 
the presence of calphostin C did not result in a statistically significant difference 
between ipsilateral baseline and post-injection mechanical withdrawal thresholds 
and there was no statistically significant difference between baseline and post-
injection thermal withdrawal latency. This suggests the involvement of PLD1 in 
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the reversal of thermal behavioural sensitisation in CCI rats observed when there 
is concurrent activation of the 5-HT1B receptor and the TRPM8 channel.  
Taken together, these observations on nociceptive behavioural reflex 
assessments following intrathecal drug administration are consistent with the 
idea that activation of 5-HT1B receptors can facilitate TRPM8 channel responses 
in vivo through a route involving PLD. However, further studies using a range of 
icilin doses and the administration of 5-HT1B antagonist drugs would be required 
to confirm and fully develop these findings. 
4.3.4 Conclusion 
The results arising from this chapter provide evidence for a positive 
modulatory role of the 5-HT1B receptor on TRPM8 channel activity, involving 
the actions of PLD1 and PIP2 together with demonstration of a physical complex 
in both in vitro systems that brings the TRPM8 channel, the 5-HT1B receptor 
(and PLD1) into direct contact. This could provide a therapeutic target for the 



















Chapter 5: SUMMARY AND CONCLUSION 
 
Chronic neuropathic pain represents a major clinical concern for both human 
and animal patients. The mechanisms underlying chronic neuropathic pain states 
have not been fully elucidated and treatment remains problematic, reflecting a 
need for novel therapeutic targets to enable development of new improved 
analgesics. In animals, these issues are further complicated by the lack of 
objective pain assessment tools for both the rigorous characterisation of pain 
states and evaluation of the efficacy of current and novel therapeutic strategies.  
Quantitative Sensory Testing (QST) has recently emerged as a preferred tool 
for monitoring pain in a clinical setting, as it provides a standardised, objective 
methodology, which does not rely on the clinician’s experience. Quantification 
of nociceptive thresholds provides a measure of pain hypersensitivity 
(hyperalgesia and allodynia), which develops after surgery or is associated with 
chronic pain states (e.g. chronic lameness) (references reviewed by Vinuela-
Fernandez et al., 2007). Moreover, QST has been shown to be reliable in 
measuring analgesic efficacy in a variety of pain models, validating the 
sensitivity of the method sensitivity and thus paving the way or its use in 
assessing the efficacy of novel analgesic drugs (e.g. KuKanich et al., 2005; 
Slingsby et al., 2001).  One of the aims of this study was to develop a novel 
method for the assessment of hoof compression thresholds in horses suffering 
from equine laminitis, a disease associated with severe pain and debilitation. For 
that purpose, we used a novel hydraulically-powered feedback-controlled hoof 
tester. The results have shown that hoof compression thresholds (for limb 
withdrawal) of laminitic horses are consistently in the order of 50% lower than 
those of normal horses (a statistically significant alteration). This is consistent 
with previous studies reporting increased mechanical sensitivity on the hooves of 
laminitic horses. Moreover, the reliability of the method suggests that the new 
hoof tester could be used for the measurement of pain thresholds in both research 
and clinical contexts. Further studies should aim at establishing the method’s 




Laminitic horses often respond poorly to standard anti-inflammatory therapy. 
Although extensive research has been carried out to elucidate the pathogenesis of 
this disease, little is known about the neurobiology of the pain state associated 
with laminitis. Therefore, we aimed to characterise peripheral nerve damage that 
might have occurred as a consequence of the pathological changes associated 
with the disease. The results from this part of the study demonstrate for the first 
time that equine laminitis pain has a neuropathic component, evidenced by 
morphological changes in digital nerves innervating the hoof, including a 
significant reduction in the number of myelinated and unmyelinated fibres, and 
an increased expression of the nerve injury marker ATF3 and neuropeptide Y in 
DRG cells involved in hoof innervation. Our study was limited to the peripheral 
nervous system. Further studies should aim to uncover spinal cord mechanisms, 
for example investigating NMDA receptors and associated proteins, which might 
be involved in the maintenance of chronic laminitis pain.  
Our findings are relevant to clinical strategies for the management of equine 
laminitis, as they suggest that the administration of anti-neuropathic analgesic 
agents may result in improved pain relief in horses suffering from refractory 
laminitis. Indeed, since the publication of our findings in the journal Pain (Jones 
et al., 2007), there have been reports in the veterinary literature advocating a 
modification in the approach to pain therapy in laminitic horses in order to 
address the neuropathic component of the disease (e.g. Driessen et al., 2010; 
Muir, 2010). Current pharmacological treatment for human patients suffering 
from neuropathic pain is still limited, either due to poor drug efficacy (with high 
numbers-needed-to-treat) or due to the associated adverse side effects (Collins et 
al., 2000). Although there is a lack of published clinical studies regarding the 
treatment of neuropathic pain in veterinary patients, the same limiting factors are 
likely to be relevant in this context (Grubb, 2010). Thus, there is a need for the 
identification of new targets and mechanisms that could lead the way to the 
development of more efficacious agents. The TRPM8 channel, which has been 
shown to exert an analgesic effect in laboratory models of chronic pain and 
human patients following its activation, appeared to be a prime candidate for 
further investigation.     
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Thus, the second component of the study reported the discovery and the 
investigation of a mechanism of TRPM8 channel modulation involving 5-HT1B 
receptors. Using in vitro techniques we identified an increase in chemically-
mediated TRPM8 channel activity when 5-HT1B receptors were concurrently 
activated. Moreover, our results suggest that this facilitatory modulation might 
be mediated through a signalling complex formed between the TRPM8 channel, 
the 5-HT1B receptor and PLD1, possibly involving downstream PIP2 actions on 
TRPM8 channels. The uncovering of macromolecular signalling complexes 
formed between GPCRs, ion channels and enzymes generating second 
messengers  has been described as a candidate mechanism for enhanced control 
achieved by spatial micro-organisation of key mediators (Laporte et al., 2001). 
An example of such a signalling complex involves the direct association between 
β2 adrenergic receptors and the class C L-type calcium channel Cav1.2, in which, 
β2 adrenergic receptor stimulation could increase neighbouring L-type channel 
activity (Davare et al., 2001). As the understanding of the regulatory role of these 
complexes expands, novel technologies to investigate protein:protein interactions 
have been and continue to be developed. Further studies should be carried out to 
validate the interaction between the TRPM8 channel and the 5-HT1B receptor 
reported here. For example, the use of fluorescence resonance energy transfer 
(FRET) in cell lines (where the channel and the receptor carry distinct 
fluorescent-protein-tags), would allow an independent confirmation of the 
interaction.    
In vivo results carried out in CCI rats at peak sensitivity suggest an 
enhancement of analgesic influence on thermal sensitivity associated with 
intrathecal co-administration of icilin and a 5-HT1B receptor agonist, compared to 
administration of icilin alone. Further studies should aim to confirm these in vivo 
influences by investigating whether co-administration of a 5-HT1B receptor 
antagonist with icilin and a 5-HT1B receptor agonist reverses the enhancement in 
icilin-mediated analgesia. Since in our study, a suboptimal dose of icilin was 
used deliberately in order to maximise any observable effects of 5-HT1B receptor 
activation on icilin-mediated analgesia, further dose finding studies should aim to 
135 
 
establish optimal doses of icilin and 5-HT1B receptor agonist, in order to achieve 
a maximal analgesic effect.   
Studies carried out using TRPM8-GFP mice have identified TRPM8 channel 
expression in distinct nerve terminal endings in the superficial layers of the 
epidermis (Dhaka et al., 2008). To our knowledge such anatomical 
characterisation has not been carried out for the 5-HT1B receptor and it is not 
currently known if this receptor is expressed in peripheral nerve terminals. 
Further studies should also investigate the co-localisation of the TRPM8 channel 
and the 5-HT1B receptor both in skin terminals and DRG, (a target attempted but 
not achieved here because of the inadequacy of currently available reagents).  
Since a 5-HT1B receptor agonist exerted an analgesic effect when administered 
subcutaneously in a rodent model of inflammatory pain and icilin has been 
reported to be effective as an analgesic through topical administration 
(Granados-Soto et al., 2010; Proudfoot et al., 2006) peripheral routes conjoint of 
administration of TRPM8 channel and 5-HT1B receptor agonists should be 
explored in a range of laboratory models of chronic pain to further validate the 
mechanism suggested by our results.    
 
In conclusion, we have validated a novel QST technique for the measurement 
of mechanical nociceptive thresholds in laminitic horses, which holds potential 
for clinical assessment of the disease and for the assessment of analgesic 
efficacy. We have further shown that the pain state associated with equine 
laminitis might have a neuropathic component, which provides a basis for the 
incorporation of anti-neuropathic drugs in pain management protocols. We have 
also identified a novel modulatory mechanism of TRPM8 channel activity, which 
is mediated through 5-HT1B receptors, which form a physical complex with these 
channels. This finding represents an important example of the newly developing 
concept of functional receptor/channel signalling complexes and potentially 
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Laminitis is a common debilitating disease in horses that involves painful disruption of the lamellar dermo-epidermal junction
within the hoof. This condition is often refractory to conventional anti-inflammatory analgesia and results in unremitting pain,
which in severe cases requires euthanasia. The mechanisms underlying pain in laminitis were investigated using quantification of
behavioural pain indicators in conjunction with histological studies of peripheral nerves innervating the hoof. Laminitic horses dis-
played consistently altered or abnormal behaviours such as increased forelimb lifting and an increased proportion of time spent at
the back of the box compared to normal horses. Electron micrographic analysis of the digital nerve of laminitic horses showed
peripheral nerve morphology to be abnormal, as well as having reduced numbers of unmyelinated (43.2%) and myelinated fibers
(34.6%) compared to normal horses. Sensory nerve cell bodies innervating the hoof, in cervical, C8 dorsal root ganglia (DRG),
showed an upregulated expression of the neuronal injury marker, activating transcription factor-3 (ATF3) in both large NF-200-
immunopositive neurons and small neurons that were either peripherin- or IB4-positive. A significantly increased expression of neu-
ropeptide Y (NPY) was also observed in myelinated afferent neurons. These changes are similar to those reported in other neuro-
pathic pain states and were not observed in the C4 DRG of laminitic horses, which is not associated with innervation of the
forelimb. This study provides novel evidence for a neuropathic component to the chronic pain state associated with equine laminitis,
indicating that anti-neuropathic analgesic treatment may well have a role in the management of this condition.
 2007 International Association for the Study of Pain. Published by Elsevier B.V. All rights reserved.
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Laminitis is a common cause of equine lameness
involving one or more feet [11]. It is characterised by dis-0304-3959/$32.00  2007 International Association for the Study of Pain. P
doi:10.1016/j.pain.2007.08.035
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Walker).
1 These authors contributed equally to this work.ruption of the dermo-epidermal laminar bond within the
hoof (Fig. 1b and c) and subsequent structural weakness
that can result in displacement of the pedal bone within
the hoof capsule [41]. The pathogenesis of this disease is
poorly understood but it is generally thought that vascu-
lar disturbances leading to ischemia-reperfusion injury
of the lamellar structures are involved in the pathophys-
iology of laminitis [23]. Currently, no therapeutic regime
is able to arrest or prevent its onset [42]. Moreover, lam-
initic pain can be difficult to control using traditionalublished by Elsevier B.V. All rights reserved.
Fig. 1. (a) Latero-medial radiograph of laminitic equine digit showing
rotation and vertical displacement (‘‘sinking’’) of the third phalanx
relative to normal anatomy. Lines represent the standardised methods
for measuring displacement (D) which is the distance (mm) between
the proximal limit of the dorsal hoof wall and the extensor process of
the distal phalanx, and the rotation angle (a) which is the angle
between the dorsal surface of the distal phalanx and the dorsal surface
of hoof wall [9]. (b) Haematoxylin/Eosin (H&E) stained histological
section of the intact lamellar distal phalangeal apparatus in a normal
horse showing the normal appearance of dermal (arrowhead) and
epidermal (arrow) laminae 10·. (c) H&E stained histological section
showing disruption and separation of the secondary epidermal (arrow)
and secondary dermal (arrowhead) laminae in acute laminitis 10·. (d)
Chronic laminitis. Mild inflammation in the laminar dermis, with small
foci of lymphocytes in a perivascular location (arrows). H&E, original
magnification 20·. (e) Chronic laminitis. Blood accumulation in the
inner stratum medium. H&E, original magnification 4·. Scale bars (b–
e) = 100 lm.
322 E. Jones et al. / Pain 132 (2007) 321–331anti-inflammatory agents and euthanasia on welfare
grounds is not uncommon [20,42,51]. Therefore,
improved understanding of laminitis is much needed.
We hypothesized that the pathological inflammatory
processes affecting the hoof laminae during laminitis also
damage the sensory neurons innervating this region.
Peripheral nerve injury can be associated with the gener-
ation of a neuropathic pain state characterised by allo-
dynia (the perception of normally innocuous stimuli as
painful), hyperalgesia (a heightened response to painful
stimuli), spontaneous pain and a lack of response to con-ventional analgesics. A key factor in the neural plasticity
underlying neuropathic (compared to inflammatory)
pain is altered gene expression in sensory DRG neurons
[10,21,58,59]. This can be demonstrated by an increase in
expression of the neuronal injury marker ATF3, a mem-
ber of the activating transcription factor/cAMP-respon-
sive element binding protein (ATF/CREB) family, in
sensory DRG cells [19,53]. Furthermore, phenotypic
changes occur in primary afferent DRG neurons after
peripheral nerve damage, resulting in altered expression
of neuropeptides, including neuropeptide Y (NPY), the
expression of which is induced from normally low levels
in large diameter, neurofilament-200 (NF-200)-positive
neurons following axotomy [21,54], nerve injury
[31,36], demyelination [56] and streptozotocin-induced
diabetes [46].
Injury to sensory nerves induces neurochemical, phys-
iological and anatomical modifications to afferent and
central neurons that are likely to contribute to chronic,
sensitised neuropathic pain responses [58]. Such changes
to the sensory neurons innervating the equine foot could
lead to a clinically relevant component of chronic pain as
it would explain the limited effectiveness of conventional
analgesics in the treatment of laminitic pain [20].
Therefore, the aims of this study were to identify and
quantify equine laminitic pain using objective behav-
ioural assessment, characterise peripheral nerve damage
in the lateral digital nerve and demonstrate potential
nerve injury-associated alterations in protein expression
in DRG sensory neurons innervating the feet of horses
with laminitis.2. Methods
2.1. Behavioural observations in laminitic and clinically normal
horses
In order to define and quantify the behavioural characteris-
tics of equine laminitis, we carried out continuous video mon-
itoring over 3 days to compare behaviours in laminitic and
normal horses.
Seven horses admitted for management of refractory lami-
nitis were selected using the following clinical criteria: animals
must have displayed clinical signs consistent with this disease
including multi-limb lameness, increased amplitude of the dig-
ital pulses, warmth across the dorsal hoof wall and a laminitic
gait [50]. For details of all laminitic horses used in this study
see Table 1.
Latero-medial radiographs of the fore limb digits were
obtained from each of these horses [7]. The position of the
pedal bone within the hoof capsule was evaluated both subjec-
tively and objectively by an experienced equine clinician using
standard measures (Fig. 1a).
Informed client consent was obtained in writing prior to
the onset of data collection. Laminitic horses received phe-
nylbutazone (PBZ) twice daily at 08:00 and 20:00 h (Equipa-
lazone Arnolds, UK; 2.2–4.0 mg kg1) and intramuscular
Table 1
Details of horses used in the study
Horse group/No. Sex Time from onset Possible precipitating/concurrent conditions Prior treatments
Laminitic 1 MN 1 month Obese, increased liver enzymes PBZ, ACP, NG, SS, RF, A, T
Laminitic 2 F 2 months Obese PBZ, ACP, RF, FT, SS
Laminitic 3 F Recurrent >1 year Obese PBZ
Laminitic 4 F 2 days None known ACP, SS, F, A
Laminitic 5 MN Recurrent >1 year Grain overload PBZ, F, SS, R, P
Laminitic 6 M Recurrent >1 year Obese PBZ, RF, SS, NG, FT
Laminitic 7 MN Recurrent >1 year Access to rich pasture PBZ, SS
Laminitic 8 MN 1 month None known: prior history unknown PBZ, FT, ACP, NG, SS, RF, A
Laminitic 9 MN Recurrent >1 year Euthanasia requested for chronic condition PBZ, FT, RF
Laminitic 10 MN Recurrent >1 year None known: prior history unknown PBZ, FT
Laminitic 11 MN Recurrent >1 year None known: prior history unknown PBZ, RF
Laminitic 12 MN Recurrent >1 year None known: prior history unknown PBZ, RF
Sex abbreviations: MN, male neutered; M, male intact; F, female.
Treatment abbreviations: PBZ, phenylbutazone; F, flunixin; A, aspirin; ACP, acepromazine; SS, solar supports; RF, remedial farriery; FT, foot
trimming; NG, nitroglycerin (vasodilatory therapy); R, rehydration therapy; T, Trilostane (modifier of steroidogenesis); P, procaine penicil-
lin + neomycin sulphate.
Estimated weight range for laminitic horses: 250–550 kg; age range: 6–21 years. Control horses used were 3 females, 3 neutered males and an intact
male. Estimated weight range for control horses: 350–600 kg; age range: 8–19 years.
E. Jones et al. / Pain 132 (2007) 321–331 323acepromazine three times daily at 08:00, 16:00 and 24:00 h
(ACP Novartis, UK; 0.02–0.04 mg kg1).On the day of
admission to hospital the timing of drug administration var-
ied between individuals. Pedal bone support (Styrofoam
Solar Support System/Lilypads) was provided at the cli-
nician’s discretion. Subjects participated in the study for a
maximum of 3 days. Seven age, type and sex-matched
horses, which were considered ‘pain free’ (control group),
were stabled directly opposite the laminitic horses and
recorded simultaneously in order to account for extraneous
effects on behaviour. All horses were maintained on shavings
and had free access to water. Laminitic animals were fed
restricted rations of soaked hay, as is standard procedure,
whereas control animals received haylage ad libitum.
Twenty-four-hour time-lapse video equipment (AG-6124,
Panasonic) was used to record undisturbed behaviour in each
stable. Point samples of 1 h duration were taken at 8-h inter-
vals, at 06:00, 14:00 and 22:00 h, for 3 days starting at
14:00 h on Day 1. Samples were analysed continuously for
duration of state and frequency of event behaviour (The
Observer vs. 4.1, Noldus Information Technology, The
Netherlands).
Two behaviours were selected for statistical analysis as
being representative of the behaviours where changes were
most likely to be observed [43,44]. Frequency of ‘forelimb lift-
ing’ (as lifts min1) was defined as the raising and lowering of a
forelimb, without locomotion and was adjusted for total time
spent standing. ‘Proportion of time spent at the back of the
box’ was defined as time spent positioned in the furthest 50%
of the box, away from the entrance to the stable.
On a repeated dose regime, peak PBZ concentrations occur
between 2 and 6 h following administration, although individ-
ual variation is high [17]. In the present study a 12-h dosing
regime was used, minimising variation and increasing the
probability of the maintenance of a ‘steady state’. For sample
point analysis of behaviours, data were collected at three dif-
ferent time points to reflect an expected minimum plasma
PBZ concentration (06:00 h) and shortest (2 h post-administra-
tion – 22:00 h) and longest (6 h post-administration – 14:00 h)
times for peak PBZ concentrations were chosen. In addition,to evaluate some of the possible effects of drug accumulation,
analyses were repeated just using data from day 1, days 1 and 2
and days 1, 2 and 3.
2.2. Morphological investigations
Lateral digital nerves were obtained from five horses
euthanised on clinical grounds due to laminitis which was
either recurrent or refractory to therapy and also from four
horses which had no history of forelimb lameness that were
euthanised for clinical reasons other than forelimb pathology
(control group). The lateral digital nerves were removed from
the forelimb (3 cm long segments) at the level of the proximal
sesamoid bone and fixed for 4 h in 2.5% glutaraldehyde and
2% paraformaldehyde in 0.1 M sodium cacodylate buffer, pH
7.3, post-fixed in OsO4, and embedded in Araldite. For light
microscopy, 1 lm resin sections of the nerve were stained with
Toluidine blue and three fascicles were chosen at random by
bright-field microscopy. Ultra-thin (80 nm) sections were
stained with uranyl acetate and lead citrate and examined on
Phillips BioTwin electron microscope (FEI, UK Ltd, Cam-
bridge, UK). Electron microscope (EM) images of cross-sec-
tions of fascicles within each nerve (areas ranging between
6732 and 47,215 lm2) were analysed by eye by a trained,
blinded observer using Image Tool 3.0 (UTHSCSA, USA).
The total area of the nerve sections and the percentage of
the nerve area occupied by nerve fascicles were calculated in
order to investigate any differences between normal and lamin-
itic digital nerves that might reflect oedema and therefore affect
the quantification of axon density. The number and axon
diameter of intact myelinated fibers was calculated as well as
the percentage of damaged myelinated fibers, defined as those
with a severe disruption of the myelin sheath and/or axonal
degeneration. Myelin sheath thickness was measured and G-
ratio of axons was calculated by dividing the axonal diameter
by the total diameter of axon plus myelin sheath. The propor-
tion of A-fibers with continuous Schwann cell cytoplasm (an
abnormal morphological feature previously described by [8])
was also determined. C-fibers were identified as small-diameter
unmyelinated fibers, surrounded by Schwann cell cytoplasm.
324 E. Jones et al. / Pain 132 (2007) 321–331The total number of C-fibers was calculated as well as the per-
centage of solitary unmyelinated fibers and the number of
unmyelinated fibers per Remak bundle. All analysis was car-
ried out on identity-concealed samples.2.3. Immunohistochemistry
DRG from cervical segments eight (forelimb innervation)
and four (non-forelimb innervation) from the same horse were
obtained post-mortem from the five laminitic horses and four
control horses. The tissue was snap frozen and embedded in
OCT embedding matrix (CellPath plc., Powys, Wales, UK).
Cryostat sections of C8 DRGs (15 lm) were thaw-mounted
on poly-L-lysine slides (Merck-BDH).
DRG sections were pre-incubated for 1 h at room tempera-
ture in 0.1 M PBS, pH 7.4, buffer containing 0.2% Triton X-
100, 2% fish skin gelatin and 10% normal goat serum; and then
incubated overnight at 4 C with primary antibodies diluted in
the same buffer. For co-localisation of the peptide NPY or
ATF3 with the myelinated cell marker neurofilament 200 kDa
(NF-200) [27,32], or either of the unmyelinated cell markers, per-
ipherin or isolectin B4 (IB4) [18,33], antisera/lectin were used at
the following concentrations: rabbit anti-NPY (1:250; Peninsula
Laboratories Inc, Belmont, CA, USA); rabbit anti-ATF3
(1:300; Santa Cruz Biotechnology, Santa Cruz, CA, USA);
mouse monoclonal anti-NF-200 (1:400; clone N52; Sigma);
mouse monoclonal anti-peripherin (1:250; Chemicon Interna-
tional, Harlow, UK); IB4 from Bandeiraea simplicifolia (1:400;
Sigma). Sections were then washed in buffer and incubated at
room temperature for 2 h with Alexafluor 488-labelled goat
anti-mouse IgG (1:500; Molecular Probes Europe BV, The
Netherlands), Alexafluor 568-labelled goat anti-rabbit IgG
(1:1000; Molecular Probes Europe BV, The Netherlands) or
Alexa Fluor 488-labelled streptavidin (1:200). Three washes in
0.1M PBS were performed before the addition of To-Pro3 cya-
nine nucleic acid stain (Molecular Probes Europe BV, The Neth-
erlands). Three final washes in 0.1 M PBS were conducted before
cover-slipping with Vecta-Shield (Vector Laboratories, Burlin-
game, CA, USA). Control sections were processed as above
omitting the primary reagents.
Observations were made and sections photographed on an
Olympus microscope equipped for epifluorescence. All counts
of profiles labelled for immunopositive cells were performed by
the same observer (who was blinded to sample treatment) on
randomly selected, 15 lm sections of DRG from each of the
animals in each group. Every sixth section was selected to
ensure that measurements were taken only once for each cell.
Results were expressed as the proportion of labelled profiles
per total number of single or double-labelled profiles from
all sections, 95% confidence intervals (CI) are indicated.2.4. Western blots
C4 and C8 DRG were taken from laminitic horses (n = 3).
Whole lysate preparations were prepared by homogenising tis-
sue in 20 volumes of Laemmli lysis buffer (Tris (tris-hydrox-
ymethylaminoethane, 50 mM, pH 7.4), 5% mercaptoethanol
and 2% sodium dodecyl sulphate (SDS)), boiled for 5 min
and frozen. Western blotting was carried out as described pre-
viously [15]. Blots were incubated with rabbit polyclonal pri-mary antibodies to ATF3 (1:200, Santa Cruz Biotechnology,
Santa Cruz, CA, USA) and detected by peroxidase-linked sec-
ondary antibody and enhanced chemiluminescence. The ubiq-
uitous housekeeping enzyme glyceraldehyde-3-phosphate
dehydrogenase (GAPDH, 1:750, Chemicon) was monitored
as a control for protein level normalisation. Quantitative den-
sitometry analysis of protein bands was performed using the
ScanAnalysis (Elsevier) program.
2.5. Statistical analyses
Linear mixed-effect models were used to determine any dif-
ferences between laminitic and control horses in the frequency
of lifting the forelimb and time spent at the back of the box, in
order to account for the repeated sampling of the same horses
[40]. The ID of the horse that the samples came from was
entered as a random effect. Laminitic/control, time point in
experiment and time of day were entered as fixed effects. Prior
to analysis of the forelimb lifting results, the data were square
root-transformed to achieve normalisation of the residuals.
For the analysis of percentages of damaged A-fibers, A-
fibers with Schwann cell cytoplasm and solitary unmyelinated
fibers, only one meaned value per horse was obtained, and
therefore repeated sampling has not taken place. Repeated
measures of mean axon diameters in myelinated and unmyeli-
nated fibers and thickness of myelin sheath were taken in both
control and laminitic horses. Therefore, linear-mixed effect
models were also used to determine any differences between
(i) mean axon diameters in myelinated and unmyelinated
fibers; (ii) thickness of myelin sheath from laminitic and con-
trol horses. Multiple measurements per horse were also taken
of the number of fibers per Remak bundle but as the data were
integers, differences in the number of fibers per Remak bundle
were analysed using generalised linear mixed-effect models
with Poisson errors. Only a single measurement per horse of
the percentage of damaged A fibers; A fibers with continuous
Schwann cell cytoplasm and solitary unmyelinated fibers was
taken, therefore simple logistic regressions were employed to
determine the differences between control and laminitic horses.
Differences in total nerve area occupied by fascicles between
normal and laminitic horses were investigated using a Student’s
t-test, and differences in the percentage of nerve area occupied by
fascicles between normal and laminitic horses by general linear
models with binomial errors. Any differences in the proportion
of labelled profiles were assessed by v2 analysis. Mann–Whitney
non-parametric tests were used to analyse fiber density. Immu-
noblot data were analysed using a matched pair t-test. All anal-
yses were carried out in S-PLUS 6.0 (Insightful, Seattle, USA)
and SigmaStat 2.03 (SPSS Inc., USA). In all cases p < 0.05 was
taken to indicate statistical significance, and degrees of freedom
associated with any tests are denoted by subscripts.
3. Results
3.1. Radiographic abnormalities associated with laminitis
were seen in all the laminitic horses
The horses clinically diagnosed with laminitis dis-
played radiographic evidence of this disease when the
radiographs were evaluated objectively [7]. The angle
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the distal phalanx was increased when compared to nor-
mal values (Fig. 1a). Means (±SD) values from the lam-
initic group were 8.2 ± 3.0 (normal values 0.86 ±
2.4) [9]. Assessment of the D distance between the
extensor process of the distal phalanx and the coronary
band also showed a marked increase in the laminitic
group (D = 16.4 ± 4.9 mm) when compared to normal
values (4.1 ± 2.17 mm) [9]. Histological sections of lam-
initic tissue also indicated inflammatory changes
(Fig. 1d).
3.2. Laminitic horses display quantifiable abnormal
behaviours
3.2.1. Data analysis: Forelimb lifting
When considering overall data, laminitic horses show
a statistically significant increase in the mean square
root frequency of forelimb lifting (F1,12 = 11.5,
p = 0.005; Fig. 2a) adjusted for time spent standing
compared to control horses recorded in the same envi-
ronment over the same time period. Fluctuations in
the frequency of this behaviour occurred in both groups
over the period of observation, but the pattern of such
changes did not differ significantly between control
and laminitic horses (F1,140 = 3.6, p = 0.059).
3.2.2. Data analysis: Proportion of time spent at the back
of the box
Laminitic horses spent significantly more time at the
back of the box than control horses (F1,12 = 6.1,
p = 0.03). There was no difference between the two
groups in how behaviour altered throughout the study
(F1,148 = 0.2, p = 0.683) (Fig. 2b). Time spent at the
back of the box was markedly higher in laminitics than
in controls at both 06:00 and 22:00 h but not at 14:00 h
(days 2 and 3), when assessing individual sample point
data. This effect is not seen at 14:00 h on day one, prob-
ably because drug administration regimes were not well-
established at this time.
3.3. Distinct morphological abnormalities in both
myelinated and unmyelinated peripheral nerve fibers
innervating the hoof, in the lateral digital nerve of
laminitic horses
The lateral digital nerves at the level of the proximal
sesamoid bone were examined from both normal and
laminitic horses. A mean of 11.65% (range 8.75–14.35)
of the total fascicle area from each nerve section was
analysed. EM analysis of three randomly selected fasci-
cles per lateral digital nerve revealed morphological dif-
ferences in both the myelinated and unmyelinated fiber
populations in laminitic compared to non-laminitic
horses (Table 2). Abnormalities in the shape of surviving
axons and disruption of the myelin sheath, with accu-mulation of lipid droplets and myelin debris, were
observed. The most obvious quantitative feature
appeared to be a significant reduction in the number
of both unmyelinated (43.2%) and myelinated fibers
(34.6%) per unit area in laminitic compared to control
horses (p = 0.016). In order to eliminate the possibility
that any nerve oedema could artefactually lead to the
appearance of reduced fiber density, morphometric
analyses were carried out to measure the percentage area
of nerve sections occupied by fascicles and total nerve
area in normal compared to laminitic horses. No signif-
icant differences in the mean percentages were identified
(t4 =  0.91, p = 0.414) between normals 37% (95% CI:
35.7–38.1) and laminitics 41% (39.5–42.0). No signifi-
cant differences in total nerve area were identified
between normal and laminitic horses (t4 =  0.43,
p = 0.692). Further abnormalities were a significant
decrease in the number of unmyelinated nerve fibers
per Remak bundle (F1,7 = 20.7, p = 0.003) together with
an increase in the percentage of solitary unmyelinated
fibers in laminitics compared to normal horses
(v21 ¼ 35:7; p < 0:001, Fig. 3 and Table 2b). The per-
centage of morphologically damaged myelinated fibers
was significantly higher in laminitic horses when com-
pared to normal horses (v21 ¼ 31:5; p < 0:001, Fig. 3
and Table 2a). Finally, the proportion of myelinated
fibers with continuous Schwann cell cytoplasm was sig-
nificantly higher in the laminitic horses (v2 = 338.4,
p < 0.001). No significant differences in myelin thickness
or G-ratios were identified in laminitic compared to nor-
mal horses (F1,7 < 0.5, p > 0.311).
3.4. The neuronal injury marker ATF3 is selectively
expressed in sensory neurons innervating the forelimb in
laminitic horses
Using immunohistochemical analysis of the DRG
cell population, we assessed the presence of ATF3 in
comparison with the expression of NF-200 and either
IB4 or peripherin. ATF3 expression was significantly
increased in NF-200-positive C8 DRG cells from lam-
initic horses (n = 3), where 67% (15 sections, 304 cells,
CI 58.8–69.9) of NF-200-positive DRG cells co-
expressed ATF3, while only 10% (15 sections, 345
cells, CI 6.9–13.5) of NF-200-positive DRG cells in
control horses (n = 3) co-localised ATF3 (v21 ¼ 208;
p < 0:001) (Fig. 4). There was a significantly increased
expression of ATF3 in IB4-positive C8 DRG cells in
laminitic horses (n = 3), where 54% (five sections, 53
cells, CI 41.5–67.3) of IB4-positive C8 DRG cells
co-localised ATF3 compared with 9% (five sections,
56 cells, CI 3.9–19.3) in control horses (n = 3)
(v21 ¼ 24:5; p < 0:001). There was also a significantly
increased proportion of peripherin-positive DRG
cells that were positive for ATF3 in C8 DRG cells
from laminitic horses, (n = 3), where 57% (nine
Fig. 2. Quantifiable pain behaviours in laminitic horses compared to control horses. Behavioural indices were recorded in laminitic horses (m, solid
line) (n = 7) and clinically normal (h, dashed line) horses (n = 7) over a period of 3 days, with 1-h observations at 06:00, 14:00 and 22:00 h.
Phenylbutazone was administered each day at 08:00 and 20:00 h with supplementary acepromazine at 08:00, 16:00 and 24:00 h. (a) Forelimb lifting
frequency adjusted for total time standing, expressed as lifts/min. When considering overall data, laminitic horses show a statistically significant
increase in the mean square root frequency of forelimb lifting (±SE) adjusted for time spent standing compared to control horses recorded in the
same environment over the same time period. (b) Proportion of time spent at the back of the box (away from the entrance), expressed as a percentage
of time (±SE). Laminitic horses show a marked increase in the overall proportion of time spent at the back of the box, with marked differences from
control horses at 06:00 and 22:00 h.
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cells co-expressed ATF3 compared with 21% (nine
sections, 127 cells, CI 13.8–29.4) showing double-label-
ling in control horses (n = 3) (v21 ¼ 30:9; p ¼ 0:001;
Fig. 4).Accordingly, immunoblot analysis revealed a sig-
nificant increase (p < 0.05) in ATF3 expression
(expressed as mean percentage of GAPDH expres-
sion) in C8 DRG (38.9% (28.7–49.1)) in comparison
to low levels in the control C4 DRG (4.6% (0.5–
Table 2
Summary of myelinated and unmyelinated nerve fiber characteristics in normal and laminitic horses
Nerve fiber characteristics Normal horses n = 4 Laminitic horses n = 5
(a) Myelinated fibers
Mean number of fibers per 100 lm2 0.52(±0.04) 0.34(±0.02)*
Mean percentage of damaged A fibers 16.40(±2.75) 30.08(±5.67)***
Mean percentage of A fibers with continuous (>40%) Schwann cell cytoplasm 17.45(±1.63) 72.46(±5.85)***
Mean axon diameter (lm) 5.38(±0.1) 5.08(±0.1)
Mean thickness of myelin sheath (lm) 1.06(±0.03) 1.09(±0.04)
(b) Unmyelinated fibers
Mean number of fibers per l00 lm2 5.77(±0.53) 3.28(±0.31)*
Mean number of fibers per Remak bundle 2.75(±0.07) 2.09(±0.03)**
Mean percentage of solitary unmyelinated fibers 30.14(±2.33) 38.06(±5.15)***
Mean axon diameter (lm) 1.36(±0.01) 1.28(±0.01)
Statistical significances are indicated by asterisks (*p value of <0.05, **p < 0.01, ***p < 0.001; linear mixed effects models, Mann–Whitney test – mean
number of fibers per 100 lm2). Values are expressed as means ± SEM.
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ing NF-200, IB4 or peripherin were unaltered in
laminitic DRG compared to normal horses (696
compared to 575 NF-200-IR cells, n = 32 sections,Fig. 3. Reduced myelinated and unmyelinated fiber density associated
with laminitis. (a) Electron microscopy images of digital nerve from a
normal horse. Arrows indicate intact, normal myelinated fibers.
Arrowheads indicate clustered unmyelinated fibers in Remak bundles.
(b) Electron microscopic images of digital nerve from a laminitic horse
displaying reduced myelinated fiber density (arrows), lower numbers of
C-fibers per Remak bundle, as well as increased numbers of solitary
fibers (arrowheads) and increased collagen-filled space, compared to
normal horse. Scale bars, 5 lm.115 compared to 127 peripherin-IR cells, n = nine
sections, 56 compared to 53 IB4-IR cells, n = five
sections, in normal compared to laminitic horses,
respectively).Fig. 4. (a–e) Immunohistochemical co-localisation of DRG neuronal
subtype markers (NF-200 and peripherin, green) with neuronal injury
marker, ATF3 or neuropeptide Y (NPY) (red) in C8 DRG (which
receives forelimb innervation) of laminitic (a,d,e), or control horses (b)
and co-localisation of NF-200 (green) with ATF3 (red) in C4 DRG
(not associated with forelimb innervation) from the same horse (c). (a)
In laminitic horses, there was an increased expression of ATF3 (red) in
NF-200-positive DRG cells (green) compared to C8 DRG control
(non-laminitic) horse (b) and C4 DRG from laminitic horse (c).
Laminitic horses show expression of ATF-3 (red) in peripherin-positive
(green) in DRG cells (d), while control horses do not (data not shown).
Additionally, there was increased co-localisation of NPY (red) and
NF-200 (green) in C8 DRG cells of laminitic horses (e) compared to
control horses, where there was normally only sparse NPY expression
(data not shown). Scale bars, 100 lm. White arrows show co-localised
immunopositive cells. Open arrows show cell marker (NF-200 or
peripherin)-positive cells lacking co-localisation. (f) Typical immuno-
blots of whole DRG lysates of laminitic horses (n = 3) show clear
ATF3 expression in C8 but not C4 DRG. Levels of the housekeeping
enzyme, GAPDH (lower blots), were unchanged.
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expression of Neuropeptide Y (NPY) in sensory neurons
A significant increase in NPY immunoreactivity
(NPY-IR) was observed in the C8 DRG of laminitic
horses, where 77% (17 sections, 271 cells, CI 72.0–
82.3) of NF-200-positive cells showed NPY-IR co-local-
isation, compared to only 10% (17 sections, 351 cells, CI
15.7–24.7) in control horses (v21 ¼ 193; p < 0:001;
Fig. 4).
4. Discussion
Damage to sensory nerves has been linked to abnor-
mal pain and heightened sensitivity to touch in a variety
of clinical and experimental studies. In this study, we
have quantified for the first time abnormal behaviours
associated with equine laminitis which are indicative of
a hypersensitive sensory state. Additionally, we provide
novel evidence for changes associated with nerve dam-
age in the sensory nerves innnervating the forelimb in
laminitic horses, which are consistent with those
reported in previously characterised neuropathic pain
states.
4.1. The laminitic horses included in this study have digital
pathology
Assessment of the radiographs from the laminitic
horses identified pedal bone displacement (rotation or
distal displacement) associated with laminar tearing. It
was not possible to perform radiographic assessment
of the control horses due to ethical and health and safety
limitations, therefore data were compared to well-estab-
lished normal data [9]. Chronic inflammatory changes
were also observed (Fig. 1d) which have been previously
shown to associate with sensory nerve losses in the skin
[28,52].
4.2. Laminitic horses display chronically altered behaviour
We have quantified two behavioural changes associ-
ated with laminitis, which are suggestive of a chronic
hypersensitive neuropathic pain state, characterised by
the development of allodynia, hyperalgesia and sponta-
neous pain. Forelimb lifting represents an abnormal, de
novo behaviour associated with laminitis, being at low
levels or absent in the clinically normal horse. The over-
all scores for frequency of forelimb lifting were signifi-
cantly greater in laminitic than control horses.
Additionally, laminitic horses spent more time posi-
tioned towards the back of the box, a retiring behaviour
that has also been associated with acute post-surgical
limb pain [43]. This behaviour may represent a reluc-
tance to engage in the external environment and prefer-
ence to remain withdrawn from surroundings. Thedifferences in retiring behaviour (percentage of time
spent at the back of the box) showed the appearance
of a marked cyclical pattern, although this was not seen
with forelimb lifting, weight bearing when walking or
general demeanour. The pattern apparent in time at
the back of the box observations may correspond to
NSAID dosing times, external environmental stimuli
or possibly an intrinsic diurnal rhythm. This emphasises
the need for behavioural testing at a number of regular
intervals in order to correctly reveal specific changes.
Moreover, the consistent deviations from normal behav-
iour over the three-day period confirmed that the
NSAID analgesic regime was not consistently effective.
When individual time points were evaluated, marked
differences from control horses were consistently seen
at 06:00 and 22:00 h observations.
4.3. Abnormal hoof sensory nerve morphology in laminitic
horses is consistent with that reported in damaged
peripheral nerves in neuropathic pain states
Two types of sensory receptors have been identified in
the equine foot. Lamellated corpuscles, similar to Pacin-
ian corpuscles, found primarily in the solar dermis of the
heel, are low-threshold mechanoreceptors, which trans-
mit their input via rapidly conducting, myelinated A-
fibers [5]. Additionally, numerous naked nerve endings
containing the neuropeptide, calcitonin gene related
peptide (CGRP)-like immunoreactivity and other sen-
sory neuropeptides such as substance P, neurokinin A
and PHI (peptide histidine–isoleucine) were detected in
the dermis of the dorsal hoof wall and sole [6]. Those
containing CGRP are associated with nociception [48]
and transmit via slowly conducting C-fibers. Axons
from the hoof nociceptors and low-threshold mechano-
receptors as well as sympathetic fibers innervating the
vasculature contribute to the sensory digital nerve.
Changes in any of these could potentially contribute
to the etiology of the chronic laminitic pain state. To
understand the mechanisms underlying laminitis pain
and the incomplete response to anti-inflammatory anal-
gesics, it is important to establish whether axonopathic
changes may contribute. In laminitic horses, EM analy-
sis identified marked decreases in myelinated and unmy-
elinated fiber numbers per unit area of digital nerve.
This is unlikely to be due to nerve oedema as there were
no significant differences between nerve section areas
and fascicle areas in normal and laminitic horses. The
marked increase in the number of solitary, unmyelinated
fibers, may reflect demyelinated A-fibers or an absence
of guiding pathways for regenerating C-fibers [4]. These
morphological changes are consistent with those in lab-
oratory neuropathic pain models, such as chronic con-
striction injury [2,14,16,34], crush injury [30],
photochemically-induced ischemia [60] and diabetic neu-
ropathy [12,25,29,49], thereby supporting our hypothe-
E. Jones et al. / Pain 132 (2007) 321–331 329sis that peripheral nerve damage may contribute to lam-
initis pain.
Functional changes in the injured peripheral nerve
have also been described in neuropathic pain models.
The loss of large fibers in nerves from laminitic horses
is important as part of the behavioural changes in neu-
ropathic pain states may result from the loss of spinal
inhibitory controls exerted indirectly by these afferents
[2]. On the other hand, damage to both A and C-fibers
appears to be necessary for the establishment of hyper-
algesia and allodynia [14,60]. Electrophysiological stud-
ies further suggest that ectopic discharges in both spared
C- and A-fibers may be important in maintaining neuro-
pathic pain [1,14,24].
4.4. Sensory neurons of the forelimb in laminitic horses
show characteristic changes associated with peripheral
nerve injury
Following peripheral nerve damage, phenotypic
changes occur in primary sensory neurons that may con-
tribute to mediating central sensitisation [21,53]. We
assessed whether key neurochemical changes in sensory
neurons of laminitic horses are similar to those in rodent
neuropathic pain models. The numbers of DRG cells
expressing anatomical markers NF-200, peripherin or
IB4 were unaltered. Following nerve crush injury, peri-
pherin increases transiently in large DRG cells [57].
However, that model is associated with sensory loss [4]
rather than the hypersensitivity seen here, as in other
neuropathic and inflammatory pain states, where indeed
peripherin expression is not upregulated [13,45,47].
Neuronal expression of ATF3, which is normally
minimal, is upregulated after peripheral nerve injury
and so acts as a marker of nerve injury [53]. The clear
expression of ATF3 in NF-200, peripherin or IB4-posi-
tive sensory neurons of laminitic horses indicates neuro-
nal damage to both A and C-fibers matching our
observations of abnormal nerve morphology. These
findings suggest that primary afferent injury associated
with laminitis arises locally from the damage caused
by hoof pathology, rather than from systemic disease,
since ATF3 expression is low in neurons of unaffected
limbs. Ischemia and ischemia/reperfusion are estab-
lished causes of ATF-3 expression [19], so the ische-
mia-reperfusion injury of the digit thought to underlie
acute laminitis [22] may also be involved in neuronal
damage. We also found upregulated expression of
NPY in large NF-200-positive DRG cells from laminitic
horses, paralleling observations in other neuropathic
pain models [26,31,36–38,46,55,56].
The novel findings reported here suggest that patho-
logical changes occurring during laminitis bring about
a chronic pain state with a neuropathic component.
Although the mechanisms underlying the pathogenesis
of laminitis remain to be fully elucidated, it is apparentthat the early stages of laminitis are associated with
vasoconstriction of the digital microvasculature [39]
and inflammation [3]. Indeed, such pathological events
can result in nerve damage (e.g. [35,60,61] and may
thereby play a part in laminitis pain through the transi-
tion from acute inflammatory pain to a chronic syn-
drome with a neuropathic pain component.
Future studies will address the cellular and molecular
mechanisms involved in the chronic laminitic pain state.
These changes may be responsible, at least in part, for
the limited efficacy of currently used anti-inflammatory
therapy. The administration of anti-neuropathic agents
may therefore achieve better pain management and
improved quality of life in horses suffering from refrac-
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Summary
Reasons for performing study: To evaluate quantitative sensory
testing (QST) of the feet of laminitic horses using a power-
assisted hoof tester.
Hypothesis: Hoof Compression Thresholds (HCTs) can be
measured reliably and are consistently lower in horses with
chronic laminitis than in normal horses.
Methods: HCTs of chronic laminitic (n = 7) and normal horses
(n = 7) were repeatedly measured using a hydraulically
powered and feedback controlled hoof tester. Data from 2
tests, at 3 sites in both forefeet, during 3 sessions
were collected and statistically analysed using linear mixed
models.
Results: The mean  s.e. HCT for the laminitic horses was 29.6
 3.5 kg/cm2 and for horses in the normal group was 59.8 
4.3 kg/cm2. Residual variance was the largest of the error
components and was greater (P<0.001) for the normal horses;
none of the other components significantly differed between
the 2 groups. Averaging of HCTs from each foot could produce
a test with intraclass correlation coefficients of 0.83 for the
normal group and 0.87 for the laminitic group, with an
estimated sensitivity of 0.94 and a specificity of 0.93. This test
would permit detection with 80% power and 95% confidence
of a reduction of over 40% in the difference in mean HCTs
between laminitic and normal horses following effective
treatment provided that the experimental groups are of 9 or
more horses.
Conclusions: HCTs can be safely and reliably measured
experimentally using this hoof tester. The level of variability
found indicates that, under these conditions, treatments may
need to produce at least a 40% improvement to be detected.
Simplification of the hoof tester, training of the horse and
repeated testing may permit the method to be used clinically
to detect changes in the HCTs of individual laminitic horses
but these potential improvements will require further
investigation.
Potential relevance: Measurement of HCTs can provide an
additional means for assessing the effectiveness of treatments
for alleviation of chronic equine laminitis.
Introduction
Accurate evaluation of pain in horses is of fundamental importance
to equine welfare and for effective veterinary management of the
equine patient. Clinical assessment of pain in the feet continues to
be largely subjective and relies heavily upon the expertise and skills
of the clinician. In attempts to improve assessment, quantitative
sensory testing (QST) has been used in horses (e.g. Pippi and Lumb
1979; Kamerling et al. 1988; Chambers et al. 1990; Redua et al.
2002; Haussler and Erb 2006a,b; Haussler et al. 2007). QST
methods involve the controlled application of standard noxious
stimuli (mechanical or thermal) that evoke an easily recognised and
consistent response, usually the start of a withdrawal response,
which is used as the ‘end-point’ and defines the QST threshold. For
a QST method to become established for clinical use it needs to be
valid, sufficiently sensitive, reproducible and easily applied
(Viñuela-Fernandez et al. 2007).
Equine laminitis is a common cause of lameness. The high
prevalence and severe pain that can be caused by this condition
means that laminitis is a serious welfare concern for the equine
industry. Moreover, the pain experienced by horses suffering from
laminitis can be chronically persistent and difficult to control using
traditional analgesic/anti-inflammatory agents (Herthel and Hood
1999). Recent work suggests that the hypersensitive state
associated with laminitis might be due not only to inflammation but
also to damaged sensory nerves resulting in neuropathic pain
(Jones et al. 2007).
Effective pain control is a prime and urgent target in treating
laminitis and the development of new treatments relies on the
ability to reliably and sensitively assess changes in the sensitivity of
the feet to painful stimulation. Conventional, hand-operated, hoof
testers are routinely used to assess the general sensitivity of the foot
and to localise more sensitive sites within the foot. The
application and interpretation of this test is heavily dependent upon
the skill and experience of the operator. Attempts to improve the
reliability of assessments in laminitic horses, by using a calibrated
electronic hoof tester, have previously been made by Kamerling
et al. (1988); in their studies, force was applied manually with
potential for variability in its rate of application and in the
maximum pressure applied by the hoof tester probe. Their
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approach to quantitative hoof compression testing was used
successfully to measure hoof compression thresholds at 21
different points across the sole in 6 horses with a variety of painful
foot conditions including laminitis. This research group also used
this quantitative approach to determine the effectiveness of
analgesic treatments for chronic laminitis (Owens et al. 1995,
1996) but quantitative assessment has not yet become established
for routine clinical assessment of laminitis.
This study aimed to: 1) evaluate the reliability and ease of use
of a hydraulically-driven, feedback controlled, hoof tester for the
quantification of mechanically evoked responses to noxious hoof
stimulation in groups of normal and laminitic horses; and 2) record
the range of thresholds and describe sources of their variation to
help understand the difficulties involved in establishing




Seven horses suffering from refractory (chronic) laminitis
for more than 2 months were selected, with their owners’ consent,
from patients of one of the authors (E.J.), at the Royal
(Dick) School of Veterinary Studies and from horses under the
care of the International League for the Protection of Horses
(now World Horse Welfare), Belwade Farm, Aboyne,
Aberdeenshire. As the laminitic cases were drawn from a clinical
caseload it was not acceptable to stop therapy during the
measurement period. Both forefeet were usually affected,
although the results showed that the severity was generally not
the same in each forefoot.
Seven normal (control) horses, each one matched as far as
possible for size, age, breed and sex with one of the laminitic horses
were selected, with their owners’ consent, from amongst horses in
local riding schools or belonging to members of staff of the Royal
(Dick) School of Veterinary Studies.
Hoof tester
This instrument (see Fig 1) was designed and constructed by
Robert Clark (Consultant Engineer, Roslin, Midlothian), and is
powered by high-pressure fluid from a hydraulic pump through
flexible hydraulic lines to a piston and a stimulating probe with a
load cell in series. For stimulation, the flat surface (14.0 mm
diameter) of the probe was applied to the sole of the hoof with the
fixed, nonslip ‘anvil’ of the hoof tester applied opposite to it, on the
more rigid dorsal wall of the hoof. A process controller (Eurotherm
3508, Eurotherm, UK) used the output of the load-cell to set a
maximum (safety cut-off) and permitted the output of the load cell
to be recorded to an Excel file (Microsoft Corporation, USA). The
hoof tester was calibrated and adjusted to reliably produce a
convenient and safe pressure vs. time output; an example of one test
from one horse is shown in Figure 2.
Ethical considerations
It was agreed with the UK Home Office Inspectorate that any pain
inflicted by these studies was of limited severity and of short
duration, that the results were of potential benefit to the horses
being tested and that the studies did not need to be licensed as
scientific procedures under the Animals (SP) Act (1986). The limits
to the intensity and duration of testing were based on those used by
Kamerling et al. (1988) and on results from preliminary testing
carried out with the approval of the ethical research committees of
the Royal (Dick) School of Veterinary Studies and the University of
Edinburgh.
Testing protocol
Testing was carried out in a quiet environment and the horses were
allowed about 10 min to become accustomed to the environment.
Horses were also habituated to the noise produced when switching
the hoof tester on and off. None of the horses responded to this

























Fig 1: Hydraulically-powered and feedback controlled hoof tester: The diagram shows the hand piece, its connections to the control system and to a laptop
computer. A hoof with surface marks on the sole is shown to indicate the location of the 3 sites (toe, medial and lateral) used for testing.
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The horses were tested while standing squarely on a firm level
surface and were restrained, using a head collar, by an experienced
horse handler. All testing was performed by the same veterinarian
(I.V.-F.) after lifting the horse’s forelimb and holding it as is
standard practice in farriery. After cleaning the sole with a wire
brush or hoof knife, the flat, circular, surface of the probe was
applied to 3 sites, labelled ‘toe’ (half way between the apex of the
frog and the white line), ‘medial’ (to the apex of the frog) and
‘lateral’ (to the apex of the frog) (Fig 1).
Application of gradually increasing pressure was started and
stopped by a single ‘on-off’ thumb-switch on the handle of the
instrument. The test threshold (HCT) was detected and pressure on
the probe was immediately released by the operator at the onset of
a withdrawal response of the limb. This response was generally
detected by the operator as a sudden change in tone of the flexor
muscles of the limb being held for testing. If the horse did not
respond, pressure was automatically released through a relief valve,
set by the process controller to open at 85 kg/cm2 (maximum) to
avoid lasting damage. The rate of application and the setting for the
pressure relief valve (maximum) were chosen after preliminary
studies (not reported here) in which the rate, duration and
maximum pressure applied to normal horses were gradually
increased. Pre- and post test lameness assessments, at a walk and
trot, carried out by an experienced equine veterinary clinician (E.J.)
did not detect any adverse effects.
The pressure exerted by the probe (kg/cm2) was calculated from
the force measured by the in-line, calibrated load cell and the
contact area of the probe (1.54 cm2). Pressure during each test was
monitored graphically and recorded to an Excel file on a laptop
computer.
Horses were tested in 3 test sessions separated by one week.
Within each session, the forefeet of horses were tested twice at the
3 sites (toe, medial and lateral) with 10–15 s between tests and
2–3 min to change feet. Thus, 12 tests were obtained per horse on
each session and a total of 36 tests/horse. Eight readings were not
successfully recorded due either to operator error or failure to get
the horse to cooperate. In total there were 250 measurements from
the laminitic group and 246 from normal animals.
Statistical analysis
Graphical analysis demonstrated that results could be treated as
normally distributed in the statistical analyses (Fig 3).
Preliminary statistical analysis to investigate differences in
hoof compression thresholds between normal and laminitic horses
were carried out using a linear mixed model (Brown and Prescott
1999), treating Pressure as the response variable; Group (laminitic
or control) and the other variates: Session (1, 2 or 3), Leg (left or
right), Site (toe, medial, or lateral) and Test (1st or 2nd) and all
interactions nested within Group, fitted as fixed effects and a factor
encoding the sample matching (Matching), its interaction with
Group (which is statistically equivalent to fitting an individual
horse effect) and all possible interactions of the latter term with the
other fixed effects, included as random effects. The fixed effects
were progressively removed in a stepwise-type process until only
statistically significant factors remained.
In order to appreciate the sources of variation better, data for
the 2 groups were separately analysed using linear mixed models,
which treated all relevant factors and their interactions as random
effects. The estimated variance components are used to summarise
the sources of variability in the data. The 16 estimated random
effects can be found in the Table 2. Parsimonious models were also
produced, by excluding components that were not associated with
a statistically significant improvement in model fit, as quantified by





























Fig 2: Hoof tester output: The graph shows the record of pressure vs. time
for a single (typical) HCT; each change in force was logged from the load
cell and data points for each second were averaged to produce the graph.
The rate of increase in pressure for the last 4.0 s before reaching the HCT
threshold was 9.8 kg/s/cm2. The repeatability of this rate of increase is
indicated by the standard deviation of the mean of 7 HCTs selected from 4
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Fig 3: Histograms of the frequency of occurrence of hoof compression
thresholds (pressure in kg/cm2) obtained from testing of (a) normal (n = 7)
and (b) laminitic (n = 7) horses.
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variance components for each group of horses were used, in
statistical models, to allow prediction of the benefits of reducing
different sources of variability (errors) and prediction of the
numbers of animals and tests that would be required to show
treatment effects of various sizes.
To assess the repeatability of the method, intraclass correlation
coefficients were determined by calculating the ratio of population
variability to the total variability estimated from the final fitted
model. All mixed modelling was carried out using Genstat 10th
edition (VSNi, UK). Intraclass correlation coefficients, the
sensitivity, specificity and area under the receiver-operating
characteristic (ROC) curve were estimated parametrically using
these variance components; calculations were carried out in
Excel 2003.
Results
Differences between normal and laminitic horses
Histograms, presented in Figure 3, indicate that the threshold
responses obtained from both normal (control) and laminitic horses
can be described by a normal distribution.
A not unexpected and highly statistically significant (P<0.001)
difference was found between the mean  s.e. HCTs of normal (59.8
 4.3 kg/cm2) and laminitic horses (29.6  3.5 kg/cm2) (Table 1).
None of the fixed effects were found to be statistically
significant, except for the 3 way interaction Group.Site.Test (P =
0.03) where the effect was centred on a difference of less than
3 kg/cm2 between the first and second HCTs of normal horses at the
Lateral site.
Variance components analysis
Variance components, estimated separately for the HCTs of both
normal and laminitic horses, are summarised in Table 2.
In both groups, variance components associated with Session,
Leg and Site were consistently small. Subsequent refitting of the
model without these terms showed that the properties of the model
were not affected, showing that these models are consistent with
the fixed effects model described earlier. However, these terms
were statistically significant when they were estimated in
interaction with the term ‘animal’, i.e. individual horses showed
significant variability associated with these components.
For both normal and laminitic horses, the residual variance,
estimated from the pairs of observations (‘Tests’ 1 and 2), was the
largest of the variance components. This residual variance was
significantly greater in the normal group than in the laminitic group
(P<0.01 by z test). No statistically significant differences were
found between normal and laminitic horses for the other variance
components.
In normal horses the interaction providing the largest
contribution to the total variance was that of ‘animal by session’,
whereas for laminitic horses it was that of ‘animal by leg’
(Table 2).
Statistical test evaluation: variability between animals
Further statistical analysis was carried out by calculating the
intraclass correlation coefficients (ICCs), i.e. the ratio of the
population variability to the total variability in the data. The ICCs
were 0.50 (normal group) and 0.57 (laminitic group). Therefore, for
TABLE 1: Summary of measurements for normal and laminitic horses. The values are the mean hoof compression test thresholds  s.e. for Group,




Toe Medial Lateral Left Right
Normal 59.8  4.3 60.7  4.5 57.8  4.5 61.0  4.5 61.7  4.4 57.9  4.4
Laminitic 29.6  3.5 28.2  3.6 28.5  3.6 32.0  3.6 28.7  3.8 30.5  3.8
TABLE 2: Estimated variance components and s.e. for HCTs of normal and laminitic horses. Values in brackets were obtained after re-fitting of the
REML model. Nonstatistically significant random effects are presented as either - or (-)
Random term
Normal horses Laminitic horses
Component s.e. Component s.e.
Animal 19.4 (19.1) 29.5 (29.6) 39.8 (37.8) 35.1 (35.0)
Session 0.0 (-) - (-) 0.9 (-) 4.5 (-)
Leg 1.3 (-) 10.8 (-) 0.0 (-) - (-)
Site 0.0 (-) - (-) 3.0 (-) 4.6 (-)
Animal: Session 44.6 (38.7) 23.6 (23.4) 8.3 (10.5) 7.0 (6.9)
Animal : Leg 9.9 (10.3) 11.7 (13.6) 26.0 (26.1) 16.7 (16.4)
Session : Leg 9.1 (-) 11.2 (-) 1.7 (-) 3.3 (-)
Animal : Site 12.6 (12.9) 8.2 (8.2) 1.5 (6.5) 5.2 (5.0)
Session : Site 1.0 (-) 3.2 (-) 0.1 (-) 2.3 (-)
Leg : Site 0.0 (-) - (-) 0.0 (-) - (-)
Animal : Session : Leg 10.0 (22.0) 11.4 (15.1) 0.4 (0.5) 4.8 (5.4)
Animal : Session : Site 0.0 (-) - (-) 4.5 (-) 6.3 (-)
Animal : Leg : Site 0.0 (-) - (-) 2.7 (-) 5.3 (-)
Session : Leg : Site 0.0 (-) - (-) 0.0 (-) - (-)
Animal : Session : Leg : Site 0.0 (0.0) - (-) 0.0 (5.1) - (7.6)
Residual variance 102.6 (103.0) 10.6 (10.6) 65.1 (65.2) 7.5 (8.3)
© 2010 EVJ Ltd
I. Viñuela-Fernandez et al. 65
both groups, around half of the observed variability was associated
with interanimal variability.
The statistical sensitivity, specificity and area under the
receiver-operating characteristic (ROC) curves were estimated as
0.89, 0.86 and 0.94, respectively.
The values of the mean and variance components for each
group of horses were used to determine the benefits of averaging
the pairs of tests (Tests 1 and 2); this showed that the ICCs were
0.67 (normal group) and 0.73 (laminitic group), with an estimated
sensitivity of 0.91, a specificity of 0.89 and an area under the ROC
curve of 0.96.
Statistical test evaluation: within animals and between sessions
To assess the repeatability of testing between sessions, ICCs were
determined by estimating the ratio of variability associated with
session to the total variability, while excluding variance
components associated with interanimal variability. The estimated
ICCs were 0.32 (normal group) and 0.14 (laminitic group). This
indicates that, for both groups, when focusing on a single animal,
little of the variability was between sessions.
Since most of the variability is between individual tests, total
variability could be reduced by averaging the 2 HCTs for each site;
the ICCs would then be 0.45 (normal group) and 0.20 (laminitic
group).
The estimated variance components were also used to model a
linear increase in the HCTs of laminitic horses over 3 sessions, until
they become typical of those of normal animals, as would occur in
clinical situations in response to effective treatment and healing.
This hypothetical model was used to estimate the numbers of
horses and/or test repeats (replicates) required to detect an increase
(using a 2-sided t test) in the mean HCT of laminitic horses. The
increase in HCTs between sessions was modelled and quantified as
the percentage reduction in the initial difference between the mean
HCTs of normal and laminitic horses; this difference disappears as
laminitic horses reach normality. Assuming 80% power and 95%
confidence for the statistical test, examples of the numbers of
horses required are shown in Table 3 and it can be seen that if 5
HCTs were obtained from a laminitic foot (from a randomly
selected site) in each session for a group of 9 horses, there would be
an 80% chance of detecting a change in mean HCT of 40% towards
the mean HCT of normal horses.
Discussion
This study confirms and extends measurements of thresholds, to
noxious mechanical stimulation of the forefeet of lame horses,
presented by Kamerling et al. (1988). They reported HCTs and the
number of loci that were pain sensitive for 6 horses with lameness
from various foot problems (they did not test normal horses). The
range of HCTs found when converted to kg/cm2 was from 18.9 
3.4 to 46.4  12.0 with a mean  s.e. of 24.9  3.2 kg/cm2, which
is consistent with the mean reported here for laminitic horses (29.6
 3.5 kg/cm2). The highest HCTs in their range are quite close to
the mean reported here for normal horses (59.8  4.3 kg/cm2).
Kamerling et al. (1988) found decreases in HCTs
(hyperalgesia) after an undefined number of repeated tests.
Hyperalgesia was also found as a result of repeated hoof testing by
Owens et al. (1995, 1996) when using the same calibrated hoof
tester to measure the effectiveness of detomidine, ketoprofen and
phenylbutazone as analgesics for chronic hoof pain. Owens et al.
(1995, 1996) measured proportional changes in the HCTs of
laminitic horses following treatment and expressed the
effectiveness of treatments as the percentage increase in HCTs with
reference to the baseline. They did not present absolute HCT values
for either normal or laminitic horses.
Kamerling et al.’s (1988) calibrated hoof tester was applied
manually over a period of about 2 s and the maximum pressure
applied was often determined by the grip strength of the examiner.
Results from the present study suggest that increasing probe
pressure at the slower rate of about 10 kg/s/cm2 (Fig 2) and
prevention of overstimulation by automatic control of the
maximum pressure, avoids excessive stimulation and prevents
development of hyperalgesia. No damage was detected by clinical
examination for lameness and no evidence was found, from
decrease in the HCTs, that hyperalgesia developed as a result of
repeated testing.
Hoof testing with this prototype instrument was only a little
more difficult to achieve than with a standard manually-applied
hoof tester. However, this hoof tester would be easier to use if the
handpiece could be made free of connections by including both the
power and recording systems without becoming more bulky.
The HCT thresholds for the group of chronically laminitic
horses were generally <50% of those obtained for ‘normal’ control
horses and this can be related to a widely accepted view of the
severity of foot pain suffered by horses with chronic laminitis.
Because of the severity of this pain, the study suggests that great
care should be taken and independent ethical justification agreed if
horses, found to have HCTs below 20 kg/cm2, are to be re-tested.
In order for a new QST method to be established for routine
assessment its reliability needs to be evaluated. This study
approached this by analysing the sources of variation and
calculating intracorrelation coefficients.
In both normal and laminitic horses, the ‘residual variance’
component, which reflects variability between Tests 1 and 2 in
individual horses, was the largest element of the error and it was
significantly greater in normal than laminitic horses (Tables 1 and
2). This finding may be attributed to the lower HCTs of laminitic
horses and their increased reluctance to move voluntarily because
of increased pain. The shorter time taken for each test in laminitic
horses reduces opportunities for interfering variables to produce
measurement errors and includes a reduced number of coincident
voluntary movements of the horse, which obscure detection of the
threshold. No published quantitative evidence has been found with
TABLE 3: Power calculations: The table shows the numbers of repeated
tests and horses in each group required to detect hypothetical
improvements of 10, 20, 40 and 80% in the HCTs of laminitic horses
towards normal values. A 100% improvement constitutes return to
normality. Estimates were obtained from the results by modelling and a
power of 80% with a confidence of 95% was assumed for the statistical
testing. The table illustrates that, to detect an improvement of 40%, a
group of at least 9 horses would be required and that each hoof would
need to be tested at least 5 times before and after treatment
Percentage change, towards normal
values, in the HCTs of a group of
laminitic horses.
Number of tests
2 3 4 5 6
Number of horses required
10% 40 36 34 32 32
20% 21 19 18 17 16
40% 11 10 10 9 9
80% 6 6 6 5 5
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which to compare these differences in the variability of HCTs
between normal and laminitic horses.
Variability between different horses was a large source of
variability in the data, particularly for the group of laminitic horses.
This is likely to be due to these horses being at different stages of
progression of their laminitis and to differences in their responses
to therapy.
In normal horses, one of the largest contributions to variability
was a result of ‘animal by session’ interaction (i.e. the variability in
HCTs of a horse, from one session to another). This was confirmed
by calculation of intraclass correlation coefficients, which showed
that, in normal horses, about one-third of the total variability is
associated with between session variability. Such high variability in
normal horses over time is a limiting factor in studies using HCTs
for the measurement of treatment effects but suggestions as to how
this may be overcome are included below.
The benefits of averaging of various sampling factors were
modelled and averaging of HCTs from different sites in the same
leg (foot) seems likely to be a useful strategy for improving the
effectiveness of the test. The magnitude of the variance associated
with an ‘animal by leg’ interaction in laminitic horses, might
correspond to differences in the sensitivity of the left vs. right foot
of individual animals. It is a common clinical finding that one of the
feet is generally more severely affected than the other and this was
also reported by Kamerling et al. (1988). Therefore averaging of
HCTs from both forefeet together, would not be beneficial, for
assessment of changes in the severity of laminitis.
In neither normal nor laminitic horses was there any strong
evidence of differences in the statistical properties of HCTs
measured at the 3 different sites. A single site, the toe (half-way
between the apex of the frog and the white line), would be easier to
use as a consistent anatomical location for testing and might
provide less variable HCT measurements.
Differences between the first and second HCT in normal horses
at the lateral site were statistically significant, although relatively
small (<3 kg/cm2) and it was not dependent on the right or left foot
(leg). We believe this unexpected finding should be taken
cautiously and it needs to be confirmed before further investigation
of or speculation on its origin is pursued.
Owens et al. (1995, 1996) concluded that, because of
underlying variability, relatively large and consistent changes in
HCTs are required to show statistically significant improvements in
response to treatment. The results presented here are consistent
with this and provide further insight into the sources of the
variability. No direct evidence was obtained here to support their
proposal that quantitative measurement of HCTs provides a better
means for detecting analgesic effects than subjective assessment of
changes in lameness obtained using the Obel scoring method. More
studies, in which both methods of assessment are used on the same
horses at the same time, are required to test this proposal.
Results reported here indicate that when using HCTs for
assessment of the efficacy of treatments for laminitis, measurement
of normal horses should be included to help assess the
completeness of their recovery.
In conclusion, this study shows that HCTs can be safely and
reliably measured, under experimental conditions, using this hoof
tester. The variability found in the HCTs indicates that treatments
need to produce at least a 40% improvement in order to be detected
in a group of 9 laminitic horses. Clinical application of the method,
which requires measurement of meaningful changes in the HCTs of
individual laminitic horses, may be achieved after successful
investigation and implementation of one or more of the following
potential improvements: 1) Decreasing the variability between
measurements on the same foot of an individual horse by rigorous
attention (including training) to: the horse’s ‘mental state’, its
behavioural responses to hoof testing, precise location of the
instrument and improvements in the ability of the operator to
reliably detect the HCT threshold (end-point) for a particular horse.
2) Finding well-defined and easily applied criteria for the rejection
of HCT threshold measurements affected by coincident variables
such as environmental disturbances or failure of the horse to
cooperate. Criteria might include; rejection of all measurements at
or exceeding the maximum (cut-off) pressure, and rejection of
measurements greater or less than twice the s.d. of the ‘running
mean’ HCT for the particular horse. 3) Accommodation of
variability by averaging out some of the errors. Most variability
occurs at the test stratum and we suggest that the averaging of 5
well-controlled HCTs, performed at one site (toe) on the sole of
each foot, might be safely achieved without cumulative deleterious
effects. 4) Because of the complexity and high cost of this hoof
tester, development and testing of simpler and cheaper calibrated
hoof testers, would help clinical exploitation of HCTs. We suggest
that, in order to help ensure the welfare of horses being tested,
specifications for and use of calibrated hoof testers should be
consistent with the protocols and safe ‘limits’ described here.
5) After this study, to avoid the need to convert measurements to
meet the kg/cm2 standard, the contact area of the probe was reduced
to 1.0 cm2. The hoof tester, with this smaller probe, has been used
on >20 laminitic horses without finding evidence of hyperalgesia
(decreasing HCTs) or increases in the severity of lameness (clinical
scoring) as a result of the testing.
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